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Abstract
Photonic discrimination and specific targeting of vascular stem cells.
Claire Molony
Cardiovascular disease remains the leading cause of death and disability 
world-wide. The current treatment options include balloon angioplasty 
and the deployment of drug-eluting stents (DES) coated with anti-mitotic 
drugs to prevent intimal-medial thickening (IMT). Despite this, an 
unacceptably high failure rate remains due to non-specific targeting of 
cells and drug-depletion over time. The source of the cells contributing to 
IMT remains controversial; one theory suggests a reprogramming of 
native differentiated vascular smooth muscle cells (SMC) while the other 
proposes myogenic differentiation of resident vascular and/or circulating 
stem cells. Resolution of this controversy through identification of the 
source of the contributing cells would greatly assist in the development of 
future drug targeting strategies using novel DES platforms.
The use of photonics and vibrational spectroscopy is gaining popularity 
for disease diagnosis. Both platforms have the ability to yield cellular and 
molecular information about cells and tissues label-free, making them 
attractive technologies for analysing biological specimen. The first main 
objective of this work was to analyse individual cells from normal 
(healthy) and arteriosclerotic (diseased) vessels ex vivo using 
autofluorescence (AF) in response to broadband light and to compare 
their AF signatures to undifferentiated stem cells and their myogenic 
progeny in vitro. The second aim was to use vibrational spectroscopy 
(Raman and FTIR) to examine undifferentiated stem cells, their myogenic 
and osteogenic progeny and and further compare their spectra to re-
programmed differentiated SMC.
Finally, a novel therapeutic platform for targeting stem cell-derived 
myogenic progeny using magnetic nanoparticles was developed. Using 
pharmacological inhibitors of glycogen synthase 3 beta (GSK3β), the 
effects on Notch, a well known mediator of myogenic differentiation were 
first evaluated in vitro. Further to this, a prototype GSK3β inhibitor was 
incorporated into a novel drug delivery system consisting of polymer 
coated Fe304 magnetic nanoparticles which can be systemically 
administered and specifically targeted to bare-metal stents by an external 
magnetic field. 
Chapter 1 
General Introduction
1.1.1 Cardiovascular Disease Statistics
According to the World Health Organisation (WHO), cardiovascular 
disease (CVD) is the leading cause of death globally (WHO., 2017). One 
CVD related death is reported every 40 seconds in America. (Benjamin et 
al., 2017). In Europe, CVD accounts for 47% of all deaths (Nichols et al., 
2014). CVD is not only detrimental to the health of the world’s 
populations, it also has a significant societal impact on national 
healthcare budgets. The total number of cardiovascular related 
operations in the U.S. increased by 28% from 2000 to 2010 with the total 
cost of CVD related treatments increasing to $321.6 billion (Go et al., 
2013). The incidence of CVD diagnosis and mortality is set to rise 
significantly and it is estimated that by 2030, 23.6 million people will die a 
year from CVD (WHO, 2017). Faced with statistics such as these, it is 
imperative solutions are found for this global dilemma. 
1.1.2 The Vasculature
The cardiovascular system is a complex system consisting of the heart i.e 
the pump and an array of connected tubes with various functions. The 
efferent tubes (vessels) consist of the arteries and arterioles that deliver 
nutrients and oxygen to the capillaries that can transport the materials to 
surrounding tissue. The afferent vessels consist of the veins and venules 
that transport the waste products from the surrounding tissue back to the 
heart. 
The average adult artery consists of three general layers, the intimal 
layer, the medial layer and the adventitia (Lilly et al., 2012). 
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Figure 1.1 Basic Arterial Structure. The structure of a regular healthy 
artery with the three forming layers. The innermost endothelial layer 
(blue), the middle 'medial layer' containing SMC/stem cells (red) and the 
outermost adventitial layer containing fibroblasts/stem cells (purple). The 
lumen space inside the arterial layers is wide for regular blood flow.
The intimal layer, which is the innermost layer of the artery, consists of a 
wall of endothelial cells one cell thick in most rodents (Alberts et al. 
2002). The endothelial layer is the initial layer formed during development 
(Grittenberger-De-Groot et al. 1998). In humans, the endothelial or intimal 
layer thickens normally with age and is composed of extracellular matrix 
proteins, α-actin+ smooth muscle-like cells and proteoglycans. Excessive 
intimal thickening in human coronary arteries before intimal lipid 
depositions is now considered the initiation of coronary atherosclerosis 
(Subbotin et al., 2016). Nakashima et al., performed the most detailed 
analysis of normal human vessels and demonstrated that (i) the normal 
adult coronary tunica intima is thicker than the tunica media; and (ii) the 
tunica intima comprises numerous cell layers of α-actin+ smooth muscle-
like cells which are arranged in dense manner and comprise two-thirds of 
the intimal thickness. The cell layer density progressively increases 
toward the internal elastic lamina (Nakashima et al., 2002).
The primary function of the intimal endothelial cell lining the internal 
elastic lamina is to regulate vascular tone through modulation of the 
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underlying medial vascular smooth muscle layer and the expansion and 
contraction of the blood vessel to accommodate blood flow. The 
endothelial cells in response to various factors such as shear stress or 
metabolic conditions produce a host of vasoactive molecules, including 
nitric oxide, endothelin, prostacyclin and other prostanoids which act as a 
relaxation/contraction factors to control vascular one and maintain 
homeostasis. Nitric oxide diffuses onto the vascular smooth muscle cells 
(vSMCs) in the medial layer stimulating the production of guanylate 
cyclase to generate cyclic GMP which decreases the intracellular 
calcium, relaxing the vSMCs and subsequently widening the artery (Lilly 
et al., 2012).
 
The medial layer, which as the name suggests is the middle layer, is 
composed of a high concentration of vSMCs (Karrer et al., 1961) and a 
small population of resident multipotent vascular stem cells (MVSCs) 
(Tang et al., 2012). During development, the mesoderm begins to acquire 
vascular smooth muscle cell markers; firstly, α-actin (SMA, ACTA2) and 
later SMC markers such as transgelin (SM-22α), calponin1 (CNN1) and 
smooth muscle myosin heavy chain 11 (Myh11) (Gittenberger-De-Groot, 
1998). A heterogeneous population of vSMCs in the medial layer has 
been widely reported (Gittenberger-De-Groot, 1998; Rensen et al., 2008; 
Shanahan  & Weissberg, 1998). Many of these reports purport that these 
vSMC subpopulations undergo phenotypic switching (or re-
reprogramming) from contractile to synthetic phenotypes in response to 
certain physiological/pathophysiological stimuli where vSMCs go from 
resident vascular tone ‘regulators’ to migratory ‘pro-proliferative’ cells that 
accumulate within the expanding medial and intimal layers (Li et al. 
1999). In addition, a small population of resident vascular stem cells 
(MVSCs) have been identified in the medial layer however the precise 
function of these cells remains controversial (Tang et al., 2012, Huang et 
al., 2015).
Finally, the outer adventitial layer is made up of connective tissue, 
fibroblasts and a small niche of resident vascular stem cells; adventitial 
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Sca1+ progenitor stem cells (APCs). The adventitia has many functions 
including facilitation of crosstalk between endothelial cells and smooth 
muscle cells, controlling the movement of cells in and out of individual 
layers and facilitating microvessel formation that permeate the vessel wall 
(Majesky et al., 2011). 
1.1.3 Vascular Disease
CVD manifests itself as an obstruction within the blood vessel wall that 
restricts normal blood flow. This puts a mechanical strain on the heart and 
causes high blood pressure i.e. hypertension, that can lead to more 
serious conditions such as stroke or heart failure (Hollander et al., 1976). 
Atherosclerosis accounts for 75% of cardiovascular related deaths. The 
initial step in atherosclerosis is intimal medial thickening (IMT) that occurs 
throughout ageing but,  if exaggerated, facilitates the build-up of LDL (low 
density lipoprotein) particles within the intimal layer of the vessel wall 
(Sun et al., 2000, Subbotin et al., 2016). LDL are proteins that transport 
and deposit cholesterol around the body (Insull et al., 2009). High LDL 
concentrations can be attributed to various risk factors such as diet, 
abdominal obesity, metabolic syndromes e.g. hyperglyceredaemia and 
chemical toxins e.g. nicotine all of which are related to each other and 
can be reduced by ceasing smoking, eating more plant based foods and 
exercising regularly (Reddy et al., 2010). The build-up of the LDL-
particles activates the endothelial cells which in turn activate the vSMCs. 
The activated endothelial and vSMCs then recruit inflammatory cells such 
as leukocytes, monocytes and neutrophils to the arterial wall progressing 
the next major step in intimal thickening (Insull et al., 2009). The 
monocytes are subsequently activated in the sub-endothelial space 
where they are encouraged to present receptors on their surface that 
initiate the digestion of oxidised lipids which stimulates the transition from 
activated monocyte cells to macrophage foam cells. 
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The macrophage foam cells undergo apoptosis and their debris forms 
most of the lipid rich plaque which promotes further inflammation, 
therefore more inflammatory cells are recruited to the site and additional 
formation of macrophage foam cells. Vascular SMC-like cells accumulate 
and constitute up to 90% of the neointimal lesion. The vSMCs then 
synthesise a collagen-rich extracellular-matrix that forms the fibrous cap 
of the lipid plaque, providing structure and stability (Hunt et al., 2002). 
The lipid plaque and collagen rich fibrous cap is highly thrombogenic and 
may rupture causing a clotting cascade and further occlusion of the blood 
vessel (Sherif et al., 2010).
In an attempt to lower the incidence of atherosclerosis, high-risk 
individuals are prescribed cholesterol-lowering drugs, Statins. Statins 
inhibit the enzyme HMG-CoA Reductase that is essential in the 
conversion of dietary fatty acids to cholesterol. However, atherosclerosis 
is a silent disease and mostly proceeds un-diagnosed until a cardiac 
event occurs (Yamashita et al., 2010). 
 
The most common treatment of a vessel occlusion is balloon angioplasty 
and stent placement. Balloon angioplasty is minor surgery that involves 
inserting a balloon inside the occluded vessel at the plaque site. The 
balloon is then inflated to crush the plaque against the vessel wall and 
facilitate resumed blood flow through the artery.  However, in 40% of 
patients, this can result in a re-occlusion of the artery due to elastic recoil 
(White et al., 2005). Cardiologists therefore began to insert bare metal 
stents during balloon angioplasty to keep the artery open after the balloon 
angioplasty procedure. However, even after stent placement, 25% of 
patients display renewed intimal medial thickening (IMT) termed ‘in-stent 
restenosis’ (ISR) (Dangas et al., 2002). 
The pathology of ISR differs from atherosclerosis and is a form of more 
symmetrical internal thickening, referred to as arteriosclerosis. 
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Figure 1.2 In-Stent Restenosis. Represents the original occlusion of the 
artery, the mechanism for combating this occlusion with a stent and the 
incidence of re-occlusion at the site of stent placement. 
Figure 1.3 Arteriosclerosis & Atherosclerosis: Cross sections of a healthy 
artery with a wide lumen area with a normal medial size; symmetrical 
thickening of the medial layer and neointima formation leading to a 
luminal reduction of an arteriosclerotic artery; and the asymmetrical 
thickening and subsequent loss of luminal layer due to plaque build up of 
atherosclerotic artery.
There are four main mechanisms reported to be involved in restenosis, 
particularly ISR. The first mechanism is vasoconstriction of the vessel due 
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to endothelial disruption from e.g., a stent placement. This occurs within 
24 hours and results in initial narrowing of the artery. The second step is 
the activation of local platelets and secretion of thrombin, forming a mural 
thrombus. This response occurs 2-3 weeks after stent placement. The 
third mechanism, and possibly the most important, is the formation of a 
neointimal lesion. This occurs from 48 hours to months after the stent 
placement (Kibos et al., 2007). Schiele et al., reported that the number of 
cells representing α-actin in the neointima increased from day 7 to day 30 
to 98% (Schiele et al., 2005) suggesting that the majority of cells forming 
the neointima are vSMCs-like cells and their associated matrix (Schiele et 
al., 2005). The fourth mechanism of restenosis is vascular remodelling. 
This is the change in the arterial wall size due to the first 3 mechanisms. 
1.1.4 The source of neointimal SMCs…the central dogma
As mentioned above, up to 98% of the cells that present in the restenotic 
lesion are primarily vascular smooth muscle-like cells (Schiele et al., 
2005). Originally, it was purported by many investigators that these 
neointimal SMC-like cells originated from differentiated SMCs that 
switched phenotype to become de-differentiated and began proliferating/
migrating to the site of injury to form the neointima. Subsequent lineage 
tracing studies have provided further compelling evidence in support of 
SMC switching and re-programming by demonstrating that neointimal 
SMCs (Nemenoff et al., 2011; Herring et al., 2014; Shankman et al., 
2015) and a considerable number of neointimal macrophage-like cells 
(Shankman et al., 2015) may be derived from ‘marked’ medial 
differentiated SMC in vivo (Cherepanova et al., 2016; Shankman et al., 
2015; Majesky et al., 2016; Chappell et al., 2016). Furthermore, it 
appears not all ‘marked’ differentiated SMCs are responsible but rather 
there exists a discrete subpopulation of ‘plastic’ medial SMCs (Chappell 
et al., 2016). Moreover, epigenetic modifications indicative of SMC 
lineage identity at the Myh11 locus (H3K4me2:histone 3 lysine 4 
dimethylation) are retained in de-differentiated SMCs that are no longer 
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transcriptionally active. These signatures have been used to further 
suggest that neointimal SMCs and macrophage-like cells are derived 
from differentiated SMCs in vivo (Gomez et al., 2015; Shankman et al., 
2015). 
However, several recent reports have challenged this idea of SMC 
phenotypic switching and re-programming by demonstrating the presence 
of stem cell markers within rodent and human vascular lesions, and the 
isolation and characterisation of these cells as multipotent mesenchymal 
stem like cells in vitro (Torsney et al., 2011; Hu et al., 2004).  The putative 
role of the resident vascular stem cells undergoing myogenic 
differentiation and contributing to the neointimal lesion has been 
evaluated by several research groups. Circulating and resident 
mesenchymal stem-like cells have been reviewed for their contribution to 
lesion formation and calcification (Klein, 2016).  MSC-like CD44+, CD90+ 
and CD105+ cells have been isolated from the wall of the thoracic aorta 
raising the possibility of MSCs driving vascular remodelling and triggering 
calcification (Klein et al., 2011). To demonstrate the presence of 
circulating bone marrow MSCs (bm-MSCs) in the neointima, Sata et al., 
transplanted the bone marrow from ROSA26 mice expressing β-
galactosidase (LacZ) to control mice and reported that 63% of the 
neointimal cells were LacZ positive indicating they were derived from the 
bm-MSCs (Sata et al., 2002). Double staining further showed that the 
LacZ+ cells in the neointima were also either α-actin or CD31 positive 
which would suggest that the bm-MSCs differentiated to SMCs or 
endothelial cells following injury (Sata et al., 2002). While the contribution 
of bone-marrow derived stem cells has since been clarified (Hoglund et 
al., 2010), the origin of neointimal SMC-like cells stills remains 
contentious and incompletely understood.
A controversial Nature Communications paper was published by Song 
Li’s group in 2012 wherein they challenged the role of de-differentiated 
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vSMCs and concluded that the data were misinterpreted and an 
overstatement of differentiated vSMC function (Tang et al., 2012). The 
researchers identified a small niche of multipotent resident vascular stem 
cells (MVSCs) within the medial layer of the adult rat, mouse and human 
arteries that were Myh11 and CNN1 negative but positive for stem cell 
markers S100β, Sox17 and Sox10. Parallel lineage tracing analysis 
provided further evidence that neointimal SMC-like cells were derived 
from this Myh11 negative population.  They further argued that previous 
studies provided no direct evidence for de-differentiation/re-programming 
of vSMCs to conclude that the proliferating neointimal vSMCs originated 
from a native SMC source (Tang et al., 2012). 
Subsequent lineage tracing studies here too have provided important 
evidence that a significant subset, if not the majority of neointimal SMC-
like cells may be derived from medial resident stem cells (Tang et al., 
2012; Wan et al., 2012), adventitial stem cells (Shikatani et al., 2016; 
Kramann et al., 2016; Kramann et al.,2015) and mesenchymal stem cells 
(EndMT)(Cooley et al, 2014) following (EndoMT) using various models of 
vascular injury in mice. Indeed,  follow-up lineage tracing studies by Song 
Li’s group that mapped Sox10+ cells following injury clarified the presence 
of neointimal SMC-like cells derived from a parent Sox10+ population in 
addition to cells from a Myh11+ population (Yuan et al., 2017).
Importantly, drivers of myogenic differentiation are commonly found in 
neointimal lesions (Majesky et al. 1991; Kanzaki et al. 1995; Otsuka et al. 
2006; Tsai et al. 2009; Liao et al. 2016; Sakata et al. 2004; Gridley et al. 
2010; Caolo et al. 2011). For example, transforming growth factor beta 
(TGF-β1) has repeatedly been implicated with neo/intimal lesion 
progression (Majesky et al. 1991; Kanzaki et al. 1995; Otsuka et al. 2006; 
Tsai et al. 2009; Liao et al. 2016). In addition, TGF-β1 has been 
associated with various stem cells undergoing myogenic differentiation. 
Specifically,  TGF-β isoforms (TGF-β1, TGF-β2 and TGF-β3) contribute to 
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myogenic differentiation of embryonic stem cells (Wang et al., 2015), C3H 
T10 1/2 cells (Guo & Wang, 2009), mesenchymal stem cells (Kurpinski et 
al. 2010), multipoint vascular stem cells (MVSCs) (Tang et al. 2012) and 
endothelial derived MSCs (EndoMT) (Chen et al. 2015; Evrard et al. 
2016; Zeisberg et al. 2007) in vitro.  Gene expression analysis studies of 
TGF-β1 stimulated stem cells revealed another smooth muscle 
associated molecule commonly found in lesions, Jagged-1 (Jag-1). Jag-1 
is one of many Notch ligands associated with coronary artery disease 
(CAD) models (Sakata et al., 2004; Gridley et al., 2010; Caolo et al., 
2011). Stimulation of Notch in embryonic stem cells (Kurpinski et al., 
2010), mesenchymal stem cells (Doi et al., 2006; Kurpinski et al., 2010, 
Mooney et al., 2015), neural crest stem cells (High et al. 2007), 
endothelial derived MSCs (Chang et al., 2011) and multipotent vascular 
stem cells (Tang et al.,2012) promotes myogenic differentiation. The 
presence of drivers of myogenic differentiation within neointimal lesions 
further supports the evidence of stem cells as the major source of the 
SMC-like cells in injured/arteriosclerotic vessels and provides a new 
therapeutic platform when considering the rate of restenosis after 
vascular ballooning and stenting.  
Overall, excessive intimal hyperplasia in human coronary arteries before 
intimal lipid depositions is considered the initial event leading to coronary 
atherosclerosis (Subbotin et al., 2016). The evidence supporting a role for 
resident vascular stem cell(s) contributing to intimal hyperplasia is 
growing, however the subject still remains controversial (Tang et al.,
2012). Therefore, classification and characterisation of these cells is vital 
before determining the best treatment option to target restenosis after 
vascular ballooning and stenting.
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1.2 Photonics for disease diagnosis
The use of light to assess health and treat disease has become 
increasingly popular over the last number of years. In as early as 1903, 
Niels Finsen won the Nobel Prize in Physiology and Medicine for his use 
of ultraviolet (UV) light to treat lupus vulgars. The direction of photonics in 
medicine has more recently focused on the diagnostic power rather than 
healing power of this technology. To understand how it can be used to 
characterise biological samples and diagnose disease, it is important to 
note the fundamentals of light interactions with a material. The interaction 
of light with matter, such as tissue, can result in a scattering or absorption 
of that light. When a sample interrupts the direct path of light and alters it 
to produce scattered light, the states of scattering can be recored and 
mapped to give discrete information about that sample. On the other 
hand, when light is absorbed by the sample, the energy from the photons 
changes to vibrational or electronic energy and can result in inelastic 
scattering or accoustomechanical waves which can be recorded to yield 
physical, biochemical and molecular information about a sample (Yun & 
Kwok., 2017). In this section, two methods of light scattering, auto-
fluorescence and Raman spectroscopy, and one method of light 
absorption, Fourier-transform infrared spectroscopy, will be described in 
the context of characterising biological samples and disease.
1.2.1 The LiPhos Project
LiPhos (living photonics) is a project involving microfluidic technologies 
and auto-fluorescent signalling. It relies on the principles of elastic light 
scattering, which is also the basis of the well-known flow cytometry 
technique. The elastic scattering of light from a cell depends on the size, 
shape, morphology and refractive index of the cell from the surrounding 
medium. The project utilises microfluidic systems to capture single cells 
before exposure to broadband light to generate auto-fluorescence 
signatures and patterns for individual cell populations. Using this 
technique, the cell is subjected to a single laser beam only, and the 
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measurement of the scattering from that cell is recorded, without the 
interference from any other cell or laser beam. The resulting scattered 
light is interpreted through mathematical models such as the Muller 
matrix, T-matrix or the Finite-Difference Time-Domain (FDTD) method to 
provide information on the characteristics of that cell (Kinunnan et al., 
2015). Several studies have already been carried out utilising the elastic 
light scattering technique (ELS) to characterise cells label-free. ELS has 
been shown to enhance Raman signals (outlined later in this section) and 
the combination of the two techniques have been used to compare and 
characterise lymphocytes and granulocytes (Watson et al., 2004). Red 
blood cells undergoing heamolysis have also been studied and changes 
in refractive index were noted between cell samples (Popescu et al., 
2005).
1.2.2 Autofluorescence Imaging for disease diagnosis
To date, label-free autofluorescence (AF) readings are not a widely used 
method to diagnose disease. In fact, there are only two main applications 
for label-free autofluorescence readings in the area of disease diagnosis 
in the literature. The first is for identifying changes in fluorophores in the 
fundus of the eye to identify ocular diseases or degradation. In this case, 
confocal scanning lasers are used with broadband emission wavelengths 
and alterations in the eye in response to disease can be detected. For 
example, alterations in the retinal pigment epithelium or alterations in the 
blood vessels of the eye have been reported (Fleckenstein et al., 2010). 
The other clinical application of autofluorescence spectra for disease 
diagnosis are skin autofluorescence readings (SAF). SAF exploits the 
accumulation of advanced glycation end products and collagen, which 
are novel risk factors of CVD and chronic kidney disease (CKD), 
particularly in skin biopsies. It has been widely reported that elevated skin 
autofluorescence is associated with atherosclerosis and also to be a 
predictor of a serious cardiac event in diabetic patients (McIntyre et al., 
2011; Noordzig et al., 2012; Dekker et al., 2013; Wong et al., 2014).
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At a cellular level, AF detection has been applied in the areas of cancer, 
neurodegeneration and stem cell differentiation models. Much of the 
autofluorescence cellular studies so far are based on the naturally 
fluorescent nicotinamide adenine dinucleotide (NADH) to study cell state 
metabolism. NADH is commonly known to be involved in many cellular 
processes such as mitochondrial function, calcium homeostasis, 
metabolism, ageing, oxidative stress and apoptosis. Therefore, 
alterations in NADH levels can be indicative of diseases such as cancer 
and Alzheimers disease. Researchers have taken advantage of this 
fluorophore and identified changes in AF readings in different cancer cell 
lines and alterations in AF readings based on NADH of ovarian and 
bladder cancer cells in response to chemotherapy. As NADH is a good 
indicator of mitochondrial function, it is an ideal biomarker for 
neurodegenerative diseases such as Alzheimers disease. Varying AF 
levels in senile plaques ex vivo of mice have been reported compared to 
healthy controls. This pattern of autofluorescence is considered a good 
photonic biomarker for Alzheimers disease (Heikal, 2010). There are 
some reports detecting changes in AF readings for stem cells following 
differentiation. AF readings have been shown to decrease for MSCs 
differentiating to osteocytes and adipocytes, increase for mESCs 
differentiating to embryoid bodies and mESCs to neural stem cells (Quinn 
et al., 2013; Rice et al., 2007; 2010; Thimm et al., 2015). As stem cells 
have been implicated in tumourogenesis (Miranda-Lorenzo et al., 2014) 
and now vascular diseases (Klein, 2016), AF analysis of stem cells and 
their progeny may become novel biomarkers for disease.
1.2.3 Microfluidic Systems for Single Cell Analysis
The concept of optically analysing cells in aqueous solution has been 
around since the 1930’s leading to the development of Flow Cytometry in 
the 1970’s. The first microfluidic device to trap biological particles for 
singular optical analysis was reported by Arthur Askin in the 1970’s (Yun, 
2013). Microfluidics has significantly advanced since then and microfluidic 
devices now have the potential to mix fluids, pump liquids, determine 
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optimal reaction conditions and even culture cells. The microfluidic 
devices have also been miniaturised making them easily portable and 
suitable for point-of-care diagnostics (Godin et al., 2008). Microfluidic 
devices which perform multiple operations on a single platform are known 
as Lab-on-a-chip (LOC) devices and can be used for a range of analytical 
techniques (Greiner et al., 2004). There are five common microfluidic 
platforms which vary mainly on their dominant fluid propulsion principle. 
These techniques are capillary (lateral flow), pressure, electrokinetic, 
acoustic driven flow and finally, the most relevant to this thesis, 
centrifugal microfluidics (Mark et al., 2010). 
1.2.4 Methods of microfluidic transport
• Lateral Flow
Lateral flow devices are typically wettable test strips that contain 
chemicals or antibodies within to react with the sample to give a read-out. 
The liquid is transported via capillary action through the test-strip for 
detection (Mark et al.,2010).
• Pressure Driven Laminar Flow
The flow of liquid through micro-channels is typically laminar. Using 
external or internal pressure pumps, the liquid can be hydrodynamically 
controlled for purposes such as predictable velocity profiles, controllable 
diffusing mixing and stable phase arrangements. However, the necessity 
for internal or external pumps reduces the devices portability and 
automation (Mark et al.,2010). 
• Electrokinetic
Electrokinetic systems are controlled by electric fields acting on the 
electrical charge of the sample which can induce several electrokinetic 
effects such as electroosmosis, electrophoresis and dielectrophoresis. 
The surface of the microchannels can be electrically charged and 
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charged particles in the sample can transport electrostatically to the 
corresponding electrode. Components of a liquid sample can thus be 
separated due to their electrical charge and this technique forms the 
basis of the commonly known capillary electrophoresis (Mark et al. 2010)
• Surface Acoustic Waves
The surface acoustic wave platform uses mechanical waves from 
piezoelectric transducer chips to exert acoustic pressure on liquids places 
on hydrophobic surfaces. The acoustic waves can then manipulate 
droplets of the liquid around the microfluidic device. The device can only 
be used with very small samples, in the nanoLitre range, and the 
chip:sample interaction is not particularly stable (Mark et al., 2010). 
• Centrifugal Microfluidics
Centrifugal microfluidics works on the principle of centrifugal forces 
propelling fluid. The frequency of rotation of the microstructured substrate 
controls the flow of the fluid radially outwards from the inner to outer edge 
of the substrate. The technique of using external centrifugal forces means 
there is no need for pumps or electrodes within the system making the 
devices cheap to make and easily portable (Lindström et al., 2011).  
1.2.5 Approaches for single cell capturing on a microfluidic system
The purpose of utilising microfluidic devices in research is to facilitate 
capture of individual cells in liquid medium on a microfluidic chip for single 
cell analysis. Currently, there are numerous methods for capturing single 
cells within microfluidic devices such as mechanical traps, 
micropatterning, encapsulation, magnetic trapping, optical trapping, and 
hydrodynamic trapping. Briefly, mechanical traps are compartments in the 
device such as microwells that are capable of trapping a cell within for 
analysis. The shape, size and number of microwells can be altered during 
device manufacture depending on the required experimental parameters. 
Micropatterning involves formulating a pattern of extracellular matrices 
such as fibronectin and laminin onto specific regions of the device to 
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promote the adhesion of adherent cells to the surface. The patterns can 
also be arranged in any order to suit the experiment. Encapsulation is the 
capture of cells in small droplets of liquid, however, controlling the amount 
of cells per droplet remains an issue. Magnetic trapping is a popular 
method of trapping cells in microfluidic devices and involves the 
attachment of a superparamagnetic bead with a conjugated anti-body 
specific to the cell within the microfluidic chamber. Passing cells bind to 
the conjugated antibody and are held for analysis. Optical trapping, most 
often optical tweezers, are optical forces generated from laser beams that 
attract the cell towards the focal point of the beam where it can be held or 
moved using the laser beams. Finally, hydrodynamic trapping – the 
method used in this research thesis work – involves obstacles in the 
device that capture cells from the fluid as the liquid transports through the 
chip. Cup shaped traps are most commonly used for this purpose with the 
size of the cup generated to capture one single cell at a time (Lindström 
et al., 2011).
1.2.6 Portable centrifugal microfluidic chip for single cell capture
One widely used portable device for the analysis of single cells in 
aqueous solution is the Lab-on a-Disc (LoaD) platform first described by 
Burger et al., (2015) (Burger et al., 2015). This was an adaptation of a cell 
culture array previously described Carol et al., (2006) (Carlo et al., 2006). 
The system relies on centrifugal force to manipulate cells in suspension 
into a microfluidic chamber which leads to an array of v shaped cups to 
singularly capture cells for photonic analysis. These chips are constructed 
of polydimethylsiloxane (PDMS) containing the pre-moulded cup arrays 
and microfluidic chambers bonded to PDMS coated PMMA discs. 
Microfluidic chips were originally constructed with glass or silicon 
however these substrates are expensive and are therefore unsuitable as 
disposable devices. Currently, PDMS, poly(methyl methacrylate) PMMA, 
high density polyethylene (HDPE), low density polyethylene (LDPE), 
polyamide 6 and SU-8 are the most commonly used polymers for 
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microfluidic chip fabrication. The polymeric chips are typically formulated 
using the ‘soft-lithographic technique’. Soft-lithography is a family of 
fabrication techniques of micro-fluidic devices made from mechanically 
soft material. The soft nature of the materials means patterns, such as 
arrays, and chambers can be developed in the chip structure making 
these types of chips ideal for biomedical applications. PDMS is the most 
commonly used polymer for the chips due to its desirable low cost, safety 
and opaqueness (Friend et al., 2016). 
The centrifugal microfluidic platform is ideal for blood analysis as 
parameters such as glucose, proteins, lipids and electrolytes identified in 
blood can yield information about the body. Kuo et al. (2014) used a 
centrifugal microfluidic platform to separate blood plasma from whole 
blood using inertial force. The sample was then further aliquoted in the 
system for a creatine test (Kuo et al., 2014). Nwankire et al., (2015) used 
a similar technique to separate blood plasma but this time with valves in 
the chip to aliquot plasma into separate chambers to perform a rapid liver 
assay (Nwankire et al., 2015). The technique has also been adapted and 
utilised for the identification of bacteria in urine samples for rapid 
diagnosis of urinary tract infections (UTIs). Schroder et al., loaded the 
chips with urine from patients with known UTI’s and exposed the captured 
single cells to Raman spectroscopy. Raman spectra were recorded for E. 
Coli and E. faecilis and were successfully identified in patient samples. 
With the use of the portable Lab-on-a-Disc, bacterial diagnosis was 
performed within one hour (Shroder et al., 2015). The Burger LoaD 
platform was further adapted using a loaded disc with live rat 
cardiomyocytes and cells interrogated for growth and beat pattern over 
time (Espulgar et al., 2015). Although this particular technique has shown 
great promise over the last numbers of years, the majority of the focus 
has been on photonically characterising biological material (tissue and 
cells) and diagnosing disease using vibrational spectroscopy techniques 
such as Raman spectroscopy and FTIR which are discussed below.
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1.3 Vibrational Spectroscopy as a method for identification of cells 
contributing to vascular remodelling:
Vibrational spectroscopy methods such as Raman spectroscopy and 
FTIR have been utilised to characterise cells through their cellular 
‘footprint’ i.e., a unique light scattering pattern. These methods are 
gaining huge attention as diagnostic tools, particularly in the area of 
cancer and some initial vascular studies. The concept and success of 
these tools will be discussed below with the potential of this tool to 
discriminate vascular stem cells, which may contribute to the 
accumulation of smooth muscle-like cells in the vascular lesion, to be 
kept in mind.
1.3.1 Background to vibrational spectroscopy of cells
The concept of spectroscopy has been reported from as early as the 17th 
century. Sir Isaac Newton introduced the word ‘spectrum’ following the 
observation of spectral dispersion through a glass prism (Newton 1704, 
Rehman et al., 2013). It wasn’t until 1800 that infrared radiation (IR) was 
discovered by William Herschel (Ring et al., 2000), with the first IR 
spectrometer dated 1937 (Gershinowiltz et al., 1978). Raman 
spectroscopy was discovered by Raman himself in 1928 (Smith et al., 
2016). 
One of the first reports of using spectroscopy for the analysis of biological 
samples, was carried out by Elliot and Ambrose (1950) and published in 
Nature. Elliot and Ambrose reported a change in spectra between folded 
and extended polypeptide chains. Although their conclusions were later 
proven to not be entirely correct (Miyazawa and Blout 1961; Krimm et al.,
1962) it heralded the beginning of a new era using methods such as 
vibrational spectroscopy and photonics to study biological molecules.
The most common spectral bands using Raman spectroscopy and IR 
spectroscopy as experimental tools for different components of the plant 
cells such as proteins, amino acids, lipids, fatty acids, carbohydrates, 
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phenols and terpenoids has been reviewed (Schultz and Baranska, 
2007). As the majority of the plant cell components are present in the 
animal cell, the characteristic bands can be translated across and 
contribute to animal cell molecule identification (Rehman  et al., 2013). 
1.4. Raman Spectroscopy for the analysis of biological samples
Raman spectroscopy is a form of vibrational spectroscopy that has been 
employed to extract molecular information from a substance. Vibrational 
spectroscopy relies on the interaction of electromagnetic radiation with 
molecules. The electromagnetic radiation causes a transition in energy 
state of molecules in a sample, giving off energy that can be quantified 
(Sathyanarayana et al., 2004). When an atom of electromagnetic 
radiation (photon) interacts with a molecule and the scattered photon has 
the same frequency as the initial interacting photon (incident photon) it is 
referred to as Rayleigh scattering. When the scattered photon has more 
or less energy than the incident photon due to transfer of energy between 
the photon and the molecule, it is referred to as Raman scattering.  There 
is also phenomena called stokes and anti-stokes Raman scattering where 
stokes scattering is the excitation of a molecule from ground to a higher 
energy state and anti-stokes is the scattering of the molecule from the 
higher energy state to the ground state. Typically, spectra are obtained 
from the Raman scattering in the stokes state only (Rehman et al., 2007). 
Raman spectra are plots of the difference in initial and final vibrational 
energy levels when a sample is hit with a monochromatic laser. Individual 
molecules can be uniquely identified by this method by analysing the 
frequency difference between Raman-scattered and non-Raman 
scattered (incident) light for that molecule. This forms a peak in the 
spectrograph with each band representing a molecule (Rehman et al., 
2007).
Raman spectroscopy has been widely used to characterise cells based 
on their vibrational molecular ‘fingerprint’. The fingerprint region is 
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generally between 400-2000 cm-1 wavenumber with regions in the 
wavenumbers that have been characterised as proteins (1500-1700 
cm-1), nucleic acids (785-788, 1090, 1262, 1319, 1341, 1585, 1662 cm-1) 
carbohydrates (470-1200 cm-1) and lipids (1451, 2855, 2889, 2930 cm-1) 
(Butler et al., 2016, Kiselev et al., 2016). Due to detectable differences in 
the fingerprint regions of biological samples, Raman spectroscopy is 
rapidly evolving as a highly specific diagnostic technique. 
Figure 1.4 Raman Spectroscopy. Simple Raman Spectroscopy 
schematic adapted from Salvas et al. 2010. Diagram of the direction of 
laser light to a sample and the filtration and dispersion of the emitted light 
through filters and spectrometers to a detector (camera) to produce a 
spectrum.
The focus of much of the research with Raman spectroscopy relates to 
various types of cancer models, including breast and prostate cancer 
which are the most common in women and men respectively (Vardaki et 
al., 2016). Indeed there has been significant research carried out for 
breast (Haka et al., 2005; Pichardo-Molina et al., 2007), prostate (Crow et 
al., 2003; 2005; Li  et al., 2014; Patel et al., 2010; 2011), brain (Jermyn et 
al., 2015;2016;  Zhou et al., 2012; Baker et al., 2014; Gajjar et al., 2012;; 
Beljebbar et al., 2010) bladder (Crow et al., 2005; Draga et al., 2010; 
Mourant et al., 1995; Jong et al., 2006; Kerr et al., 2016) cervical (Lyng et 
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al., 2007; Rubina et al., 2013; Kim et al., 2016; Krishna et al., 2006; 
Utzinger et al., 2001) colon (Chen et al., 2006; Molckovsky et al., 2003; 
The et al., 2008, Li et al., 2016) lung (Huang et al., 2003; Mcgregor et al., 
2016) skin (Lieber et al., 2008; Zhao et al., 2008; Lui et al., 2012) and 
leukemia cancers (Gonzales-Solis et al., 2014; Chan et al., 2008; 
Manago et al., 2016; Happillon et al., 2015). Many peaks and 
wavenumbers have been identified in these studies to be associated with 
cancer cells in comparison to their control counterparts (see Table 1.1)
1.3.3 Raman Spectroscopy Peaks for Cancer Cells
Cancer Type Peaks Associated Author(s)
Breast 1445 cm-1 and 1551 cm-1 Pichardo-Molina
Prostate 721, 783, 827, 1096, 1250, 
1305, 1450, 1577, 1568 
cm-1 (Crow) 
1445 cm and 1586 cm-1 (Li) 
781-787 cm-1 (Patel) 
Crow 2005; Li 2014; Patel 
2010.
Brain 1548, 1587-1605, 1732 
cm-1 (Zhou) 
721 cm-1 and 782 cm-1 
(Baker) 
1001 and 1670 cm-1 (Gajjar) 
1063, 1086, 1131, 1300 
and 1739 cm-1 (Koljenovic) 
1005, 1126, 1176, 1548 
and 1578 cm-1 (Beljebbar)
Zhou 2012; Baker 2014; 
Gajjar 2012; Belijebbar 
2010.
Bladder 1003, 1083, 1260, 1310, 
1446, 1665 cm-1 (Crow) 
680, 789, 1003, 1170, 
1180, 1208, 1370, 1386, 
1560 cm-1 (Draga) 
1584 cm-1 (Shapiro) 
Crow 2005; Draga 2010; 
Shapiro 2011.
Cervical 1655 cm-1 (Lyng) 
1450 cm and 1660 cm-1 
(Rubina) 
1448 cm-1 (Kim) 
620, 644, 719, 757, 1004, 
1033, 1270, 1461, 1671, 
1092, 1128, 1300, 780, 
1340, 1492 cm-1 (Krishna) 
1454-1656 cm-1 (Utzinger)
Lyng 2007; Rubina 2013; 
Kim 2016; Krishna 2006; 
Utzinger 2001.
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Table 1.1 Raman spectral peaks associated with various cancer 
types.  Peak wavelengths in bold represent signatures that are common 
in more than one study.
Interestingly, peaks from the 1445-1450 cm-1 range that are attributed to 
proteins and lipids (Kiselev et al., 2016) were identified by at least one 
article per cancer type outlined in Table 1 above to be elevated in 
cancerous samples, except for the brain (Pichardo-Molina et al., 2007; 
Crow et al., 2005; Li et al., 2014; Rubina et al., 2013; Kim et al., 2016; 
Utzinger et al., 2001; Teh et al., 2008; Chen et al., 2006; Huang et al., 
2003; Happillon et al., 2015). Using the differences in these peaks, the 
researchers could employ statistical algorithms to discriminate between 
cancerous and non-cancerous samples with high accuracy.
Raman spectroscopy is not limited to cancer models. It has also been 
implicated in the field of microbiology, particularly for bacterial 
identification (Butler et al. 2016; Jarvis et al., 2004; Maquelin et al., 2002; 
Neugebauer et al., 2006; Pahlow et al., 2015; Ashton et al., 2011) and in 
the diagnosis of infectious microorganisms (Tien et al., 2016; Avci et al., 
2015; Kusters et al., 2016).  As mentioned previously, there has also 
been extensive research of Raman spectroscopy in plants, as reviewed 
by Schultz and Baranska (Schultz and Baranska 2007). Since then, the 
technique has been adopted for many areas in plant science including 
monitoring plant health and development (Butler et al., 2015), early 
detection of plant diseases (Yeturu et al., 2016) and the characterisation 
of plant-associated bacteria (Paret et al., 2010).  
Colon 1265, 1305, 1450 and 1660 
cm-1 (Teh) 
788, 1034, 1446, 1657 
cm-1 (Chen)
Teh 2008; Chen 2006
Lung 752, 1004, 1223, 1336, 
1445-1655 cm-1 (Huang) 
Huang 2003
Leukaemia 917 cm-1 (Gonzales-Solis) 
1126, 1605, 1615 cm-1 (Chan) 
1447 cm-1 (Manago) 
796, 1106, 1380, 1454, 
1498, 1556, 1585 and 2954 
cm-1 (Happillon)
Gonzales-Solis 2014; Chan 
2008; Manago 2016; 
Happillon 2015.
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Raman spectroscopy has been widely used in the pharmaceutical sector 
as a non-invasive tool to, for example, analyse pharmaceutical products 
such as tablets and capsules and also monitor crystallisation of 
pharmaceutical formulations as reviewed by Buckley et al. (Buckley et al., 
2011). Raman microscopy, which involves both Raman spectroscopy and 
high power optical imaging, is more common in the pharmaceutical sector 
(Smith et al., 2015). Raman spectroscopy has been further applied in 
pharmaceutical sciences to distinguish between visually indistinguishable 
pharmaceuticals (Jahme et al., 2016), compound detection in unknown 
pharmaceutical products (Boiret et al., 2016), quality control for 
pharmaceutical compound formulations (Meek et al., 2016) and 
quantifying and evaluating the uniformity of pharmaceutically active 
ingredients in drug products (Li et al., 2016). 
The focus of Raman spectroscopy for this research thesis is the utilisation 
and current trends of Raman spectroscopy in the broad area of heart 
disease and in particular vascular remodelling. 
1.3.4 Raman & Atherosclerosis
Atherosclerosis is responsible for 75% of cardiovascular related deaths 
(Insull et al., 2009). It is characterised by an asymmetrical thickening of 
an artery due to the formation of what is called a ‘plaque’. The plaque is 
an obstruction in the artery composed of cholesterol, lipids, inflammatory 
cells such as macrophages and lymphocytes and a high concentration of 
smooth muscle-like cells. The plaque is usually contained by a fibrous 
cap which can become vulnerable to rupture and cause a thrombus 
formation (Libby & Theroux., 2005). Diagnosing atherosclerosis is a tricky 
business as most patients do not present any symptoms and access to 
the arteries is very limited. The most common method to diagnose 
atherosclerosis is still catheterised coronary angiography. The catheter 
leads the x-ray source to the site of obstruction and records x-ray images 
of the plaque or stenosis. There are various other methods to image 
atherosclerotic plaques such as coronary computed tomographic 
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angiography, magnetic resonance angiography, optical coherence 
tomography, CT scan and PET-CT scans as outlined in the recent review 
by Tarkin et al. (2017) (Tarkin et al., 2017). 
The limitation of all of these techniques is the inability to extract 
biochemical information from the presented plaque or obstruction. The 
techniques can record images of the obstruction and observe the 
phenotype of the disease, but that means the plaque has to be already 
present in the patient before detection. Therefore, methods such as 
optical spectroscopy, which can extract biochemical information from 
biological tissues, are ideal for early detection of subtle changes within 
the vasculature that contribute to disease progression. Many researchers 
have recognised the power of Raman spectroscopy for this purpose.
Wrobel et al., constructed a thorough table outlining the Raman band 
assignments corresponding to atherosclerotic plaques that presented in 
the literature to that date. This table provides a foundation for a Raman 
library for the detection of atherosclerosis biomarkers such as cholesterol, 
smooth muscle cells, collagen fibre/fibrous cap, fat cells, foam cells and 
calcification (Wrobel et al., 2014). Further research to expand the Raman 
library for atherosclerosis biomarkers would be beneficial to the early 
detection of atherosclerosis.
1.3.5 Raman & Vascular Remodelling
Vascular remodelling can occur spontaneously throughout ageing or in 
response to risk factors such as hypertension or vascular injury by 
catheterisation or stenting. In these cases, the resulting obstruction is not 
due to the presence of a fatty plaque, but a build up of primarily 
neointimal smooth muscle-like cells with an additional small population of 
inflammatory cells and endothelial cells. The accumulation of smooth 
muscle-like cells in the vasculature is therefore an early biomarker for 
stenosis (Schiele et al., 2005). Although much work has been done so far 
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with Raman and atherosclerosis, there is scant information available  for 
analysing non-atherosclerotic vascular lesions. However, some work has 
been carried out using Raman analysis of vascular smooth muscle cells 
and associated extracellular matrix proteins, collagen and elastin, which 
could serve as spectral early biomarkers for non-atherosclerotic stenotic 
progression. Table 1.2 outlines the current literature for the biochemical 
peaks for SMCs and extracellular matrix proteins collagen and elastin.
Peak Number Attributed to In Vascular Reference
853/940/1034 
940/1034 
1030; 935; 850 
cm-1 
           853cn-1 + 
936/938 cm-1
C-C or C-H Bending 
C-C and C-H bending 
C-C or C-H bending 
C-C or C-H bending 
+ C-C stretching of protein 
backbones
SMC-like cell 
dSMCs 
dSMCs 
Myosin
Buschman 
2001 
Peres 2011 
Abubaker 2007 
Pascut 2011
855 cm-1 C-C Stretching Mode of 
Proline 
Collagen Buschman 
2001
876 cm-1 Gly-Pro-X and Gly-X-Hyp. Collagen Latterman 
2013
921 cm-1 Gly-Pro-X and Gly-X-Hyp Collagen Latterman 
2013
933 cm-1 C-C Stretching Mode of 
Proline
Collagen Buschman 
2001
938, 1001, 1260, 
1305, 1555, 1657
SMC-like cell Lopes 2011
1004 cm-1 
1004 cm-1 
1004 cm-1 
1004 cm-1 
Phenylalanine 
Phenylalanine 
Phenylalanine 
Phenylalanine
SMC-like cell 
dSMCs 
Remodelled 
Tunica Media 
dSMCs
Buschman 
2001 
Peres 2011 
Marcez 2015 
Abubaker 2007
1104 cm-1 Desmosine/Isodesmosine Elastin Buschman 
2001
1244 cm-1 Amide III Remodelled 
Tunica media
Marcez 2015
1264 cm-1 
1265 cm-1
Amide III Collagen Buschman 
2001 
Abubaker 2007
1255 cm-1 
1256 cm-1
Amide III 
Amide III
Elastin/Collagen 
Aortic Intima 
SMC-like cell
Peres 2011 
Manohoran 
1995 
Lopez 2011
1268 cm-1 
1268 cm-1 
Amide III 
Amide III
SMC-like cell 
dSMCs
Buschman 
2001 
Peres 2011
 1270 cm-1 Amide III dSMCs Abubaker 2007
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Table 1.2. Raman spectroscopy table for SMCs and associated 
extracellular matrix proteins collagen and elastin. differentiated SMC 
(dSMC) represents SMCs analysed directly from a healthy vessel, SMC-
like cells represent the smooth muscle like cells present in hyperplasia or 
diseased models. 
It is interesting to note the spectral similarities for differentiated SMCs 
(dSMCs) analysed straight from healthy tissue and the SMC-like cells 
identified in diseased models as outlined in various Raman spectroscopy 
studies. The similar peaks are often associated with extracellular matrix 
proteins collagen and elastin which is known to be associated in dSMC 
extracellular matrix proteins and also to be produced by stem cell derived 
SMCs (Bank et al. 1996; Naryanan et al. 1976; Wanjare et al. 2015). 
These Raman peaks can be used to identify the presence and 
accumulation of SMC-like cells in the intima of patient arteries, indicating 
the initiation of a neointimal formation that could begin to occlude the 
artery. 
1336 cm-1 
1336 cm-1 
1335 cm-1 
1334 cm-1
Desmosine/Isodesmosine 
C-C and C-H bending 
C-C and C-H bending
Elastin 
dSMCs 
SMC-like cell 
dSMCs
Buschman 
2001 
Peres 
Lopes 2011 
Abubaker 2007
Decrease in 1338 
cm-1
Elastin/Disease Manoharan 
1995
1440; 1100 cm-1 Desmosine/Isodesmosine Elastin Abubaker 2007
1452 cm-1 
1455 cm-1 
1455 cm-1 
1452 cm-1 
1450 cm-1 
1451 cm-1
CH2 Bending 
Amide III 
C-C or C-H bendingSMCs 
CH bending 
C-C or C-H Bending
Elastin/Collagen 
Elastin 
Aorta Intima 
SMC-like cell
Peres 2011 
Abubkaer 2007 
Manoharan 
1995 
Buschman 
2001
1660 cm-1 
1660 cm-1 
1660 cm-1 
1660 cm-1 
1660 cm-1
Amide I 
Amide I 
Amide I 
Amide I 
Amide I
SMC-like cell 
Remodelled 
tunica media 
dSMCs 
Aortic intima 
dSMCs
Buschman 
2001 
Marcez 2015 
Abubaker 2007 
Manoharan 
1995 
Peres 2011
1664 cm-1 
1665 cm-1 
1663 cm-1
Amide I 
Amide I 
Amide I
Elastin  
dSMCs 
Elastin
Buschman 
2001 
Peres 2011 
Abubaker 2007
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Recently, a lot of attention has been focused on the role of stem cells to 
the contribution of vascular remodelling including atherosclerosis and 
arteriosclerotic disease (Yuan et al., 2017; Tang et al., 2012; 2013; 
Majesky et al., 2015). With this in mind, the presence of stem cells and 
their respective progeny within the neointima of an artery is another 
potential early marker for vascular remodelling that can be exploited by 
Raman spectroscopy.
The role of vibrational spectroscopy including Raman spectroscopy for 
identifying stem cells and their differentiated progeny has recently been 
reviewed (Sule-Sulo et al., 2014;  Askoy et al., 2012). Table 1.3 below is a 
summary of the stem cells that have been studied by Raman 
spectroscopy and the peaks that have been identified as important for 
stem cells and their differentiated progeny. Interestingly,  stem cells had 
higher RNA and DNA values at 813 cm-1 and 788 cm-1 than their 
respective differentiated cells (Notingher et al., 2004; Chan et al., 2009; 
Downes et al., 2011; El-Said et al., 2015). These studies were reported 
over a period of ten years and include mESCs, MSCs and neural stem 
cells. Further investigation into the wide range of stem cells, particularly 
at those markers, could provide an identifiable spectral marker for stem 
cells recruited to vascular lesions.
Stem Cell Type Peak Number Attributed to Phenotype Reference
mESC 813 cm-1 
788 cm-1
O–P–O stretch 
vibration  - RNA 
Cytosine ring 
vibration - DNA
Both higher in 
SCs than 
differentiated 
Notingher 
2004
hESC 811 cm-1 
785 cm-1 
1090 cm-1
RNA 
DNA  
DNA
All higher in 
SCs than 
differentiated 
Chan 2009
hESC 1003 cm-1 
1308 cm-1 
1448 cm-1 
1669 cm-1
Phenylalanine 
Lipid CH2 Twist 
CH deformation 
Amide I
Strong hESC 
bands
Chen 2011
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Table 1.3. Collection of Raman studies for various types of stem 
cells. Raman spectroscopy table for stem cells and their myogenic 
progeny.
The current library for Raman spectra for cells involved in vascular 
remodelling is somewhat limited but further research into this area could 
identify specific spectral signatures for this disease.
1.3.6 FTIR of Biological Samples
Fourier Transform Infrared Radiation (FTIR) is another method of 
hESCs to 
cardiomyocytes
482 cm-1 
577 cm-1 
858 cm-1 
937 cm-1 
1083 cm-1 
1340 cm-1
Carbohydrate 
Carbohydrate 
CH bending 
C-O-C 
glycosidic 
bond-H bending 
vibration
Increase during 
differentiation to 
CMs
Pascut 2013
MSCs 785 cm-1 
811 cm-1 
828 cm-2
DNA 
RNA 
RNA
All higher in 
SCs than 
differentiated
Downes 2011
hMSC to 
osteocytes
950-970 cm-1 
1030 cm-1 
1070 cm-1
Phosphate 
groups
hMSC 
differentiation to 
osteocytes
McManus  
2011
hMSCs and 
fibroblasts
Distinguish 
fibroblasts from 
MSC cultures
Pudlas 2011
Rat Adult 
Neural Stem 
Cells 
SERS (gold 
substrate) 
755 cm-1 
838 cm-1 
913 cm-1 
955 cm-1 
1155 cm-1 
1440 cm-1 
1540 cm-1 
690 cm-1 
1120 cm-1
A and Trp 
RNA/DNA 
Proline 
Proline 
Proline 
Carbohydrate 
Trp & amideIII 
DNA 
Carbohydrate
755-1540 cm-1 
higher in SC 
than 
differentiated 
Increased 
during 
differentiation
El-Said 2015
Mouse Neural 
Stem Cells
650 cm-1 
828 cm-1 
1160 cm-1 
738 cm-1 
1617 cm-1 
1001 cm-1 
1580 cm-1 
Tyr 
DNA/RNA 
Proline 
Trp 
Proline 
Phenylalanine 
DNA/RNA
Appeared and 
increased for up 
to 2 week sand 
then 
disappeared 
Decreased  
Increased
El-Said 2015
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vibrational spectroscopy but in contrast to Raman spectroscopy it relies 
on the absorption of infrared radiation rather than the scattering of light 
from a laser beam. Each chemical bond in a molecule has defined 
vibrational frequencies that can be absorbed by the FTIR – giving 
biochemical information for each molecule (Sule-Suso et al., 2014). In the 
case of FTIR,  infrared radiation is passed through the sample via a laser 
beam which vibrates the atoms in the molecules. For a molecule to be 
infrared active, the electric dipole moment must change in response to 
atomic displacement. The FTIR quantifies the vibrational modes. FTIR 
relies on one laser beam splitting to two via an interferometer yielding a 
signal that is a function of the difference in path length between the two 
beams. The resulting signal is an amplified signal with the noise 
reduced(Stuart et al., 2004). 
Figure 1.5. Modes of FTIR. Common modes of FTIR; adapted from 
Baker et al. 2014. The three main modes of FTIR (1) transmission mode, 
directing a laser through a sample to the detector, (2) transflection mode, 
reflecting the laser source from the sample to the detector, (3) attenuated 
total reflectance mode (ATR), directing a laser source through a highly 
refractive element to the detector.
There are three main modes of FTIR, transflection, transmission and 
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attenuated total reflection (ATR). Transflection directs the laser beam 
through the sample to an IR-reflective surface that sends the beam back 
to the detector. Transmission sends the beam through the sample and 
substrate to the detector below. Attenuated total reflection involves 
directing the beam through an internal reflective element with a high 
refractive index, for example a diamond. The mode depends on the 
thickness of the sample, for example, can the beam get through the 
sample in transmission mode? Most cell samples are thin enough for 
transmission mode to be used. However, ATR could be used for a tissue 
sample (Baker et al., 2014).
For biological samples, the ‘fingerprint’ region lies between 600-1450 cm-1 
of the spectra (Baker et al., 2014). A detailed table outlining the peak 
assignments for the FTIR fingerprint region have been reported 
(Movasaghi et al. 2008). In broad terms, the fingerprint region of 
mammalian cells can generally be divided into sections of the spectrum 
where the region of approximately 1000 cm-1 corresponds to 
carbohydrates, from 1050 cm-1 to 1400 cm-1 is attributed to nucleic acids, 
1400 cm-1 to 1800 cm-1 corresponds to proteins and lipids and finally the 
high wavenumber region from about 2800 cm-1 relates to lipids (Baker et 
al., 2014). 
Like Raman spectroscopy, a lot of the research has focused on cancer 
detection. FTIR and spectral imaging were carried out in conjunction with 
conventional Haemotoxylin and Eosin (H&E) staining for breast cancer 
tissue. FTIR spectroscopy accurately assembles a clusteral graph 
mimicking the histological pattern of axillary lymph nodes and metastatic 
breast cancer tissue (Bird et al., 2008). ATR-FTIR was also used to 
distinguish between epithelial, myoepthelial and stromal tissue in benign 
or cancerous tumours. It also is capable of identifying terminal ductal 
lobular units (TDLU) which are commonly the primary site of breast 
cancer and can be difficult to diagnose by histology in malignant tumours 
(Walsh et al., 2012). Focusing on the collagen region of the FTIR spectra, 
Ooi et al., demonstrated that the FTIR collagen region was higher in 
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cancerous samples than healthy samples in relation to tissue samples 
from mastectomy, mammoplasty and excisional biopsy which was 
attributed to the structural disruption of collagen in cancerous tissues (Ooi 
et al., 2008). Complementary to the previous studies, FTIR has been 
shown to identify the main cell types in breast tissue sections including 
epithelial, stromal, lymphocytes, vascular, connective tissue and 
erythrocytes, to distinguish between cancerous and healthy tissue 
sections and present spectral differences between the stroma spatially 
close and un-associated stroma to the tumour (Verdonck, 2016). In 2010, 
Backhaus et al., utilised the unsupervised learning technique to classify 
breast cancer spectrally from serum samples in total of 196 patients. The 
clusteral analysis had a sensitivity of 98% and specificity of 95%. Using a 
supervised learning technique, the sensitivity of 92% and specificity of 
100% was achieved for classifying cancerous samples (Backhaus et al., 
2010). Similarly, FTIR spectroscopy has been employed to compare 
normal, dysplastic, early carcinoma and advanced carcinoma in rat colon 
cancer models with an accuracy of 100%, 94%, 97.5% and 100% 
respectively (Cheng et al., 2009). Complementary results have been 
reported in the field of colon cancer including correlating FTIR maps with 
histopathological sections (Piva et al., 2015), detection of colon and 
rectum cancer in vitro and in vivo (Li et al., 2005) and comparing healthy 
tissue with cancerous and post-chemotherapy tissue (Kaznowskia et al., 
2017). 
A detailed review on the sample preparation, spectral acquisition, data 
processing and applications of FTIR for prostate cancer has been 
recently published (Siquiera et al., 2016). In the case of brain tumours, 
FTIR successfully discriminated normal brain tissue, tumours and tissue 
surrounding tumours and can diagnose cancer compared to non-cancer 
serum samples with a sensitivity of 93.75% an specificity of 96.53% 
(Hands et al., 2014). For cervical cancer, FTIR has a higher classification 
accuracy than the basic Pap-Smear, 72% vs 43% respectively (Njoroge 
et al.,  2006). Further studies utilised FTIR for cervical cancer screening 
and achieved results of 85% sensitivity, 91% specificity, a positive 
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predictive value of 19.5% and negative predictive value of 99.5% (El-
Tawil et al., 2008). As the commonly used pap smear frequently obtains 
false positives, this study demonstrates the true benefit of using FTIR as 
a diagnostic tool for cervical cancer over the typical pap smear (El-Tawil 
et al., 2008).  As FTIR successfully detects biochemical changes in a cell, 
pre-cancerous cervical cells can be identified by FTIR before the 
morphological changes occur that are usually detected by microscopy. A 
system coupled with multivariate statistical analysis that could 
successfully identify pre-cancerous cervical cells with an accuracy of 92% 
was subsequently  developed, further demonstrating the application of 
FTIR in particular in the area of cervical cancer diagnostics (Jusman et 
al., 2016). FTIR has also been deployed to assess bladder cancer for 
diagnostic purposes. A 100% sensitivity for classifying bladder carcinoma 
in human bladder wash samples has been reported (Gok et al., 2016). 
Cancerous and non-cancer bladder tissue has also been assessed and 
successfully discriminated (Al-Muslet et al., 2011) while FTIR classified 
urinary bladder cancer from urinary tract infections from patient blood 
samples with a classification accuracy of 80%, and sensitivity and 
specificities of 78% and 81% respectively (Ollesch et al. 2014).
The focus of FTIR in the area of cancer research has been primarily on 
classification and the diagnostic potential of FTIR rather than the specific 
biochemical and biomarker identification which is more the focus of much 
of the Raman research. As the techniques are complementary, the use of 
FTIR for the classification of cancerous versus non cancerous models 
with the use of Raman spectroscopy for the sensitive molecular 
identification within the models could provide a gold standard vibrational 
spectroscopy system to accurately diagnose and study cancers.
The study of FTIR and biological cells has also not been limited to cancer 
models. The application of FTIR to analyse diseases resulting of protein 
mis-folding or aggregation such as Alzheimer’s, Parkinson’s, 
Huntington’s, sclerosis and prions disease has been reviewed (Miller et 
al., 2013). Since then, Tidy et al., identified a distinct peak in the Amide 1 
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region at approximately 1630-1625 cm-1 which appears during protein 
aggregation disease models of Alzheimer’s disease and stroke (Tidy et 
al., 2016). A more detailed review of the common peaks in neurological 
disorders has identified the peak at approximately 1630-1625 cm-1 in 
studies including Alzheimer’s disease, Parkinson’s disease, multiple 
sclerosis and brain tumours suggesting a common peak for neurological 
disorders (Caine et al., 2012). 
FTIR has also been utilised in the pharmaceutical industry mostly to 
analyse the content of formulated drugs. FTIR was first successfully used 
to assess the quantity of ibuprofen in pharmaceutical formulations 
(Matkovic et al. 2005) while ATR-FTIR was used to successfully predict 
solution concentration in a compound produced by the solution 
crystallisation method (Togkalidou et al. 2002) and distinguish between 
polymorphs in a pharmaceutical mixture (Salari et al., 1998). FTIR has 
also been applied to microbiological cells and tissue (Naumann et al., 
1991) and has been utilised in the analysis of E. Coli biofilm dynamics 
(Holman et al., 2009), the identification of unknown bacteria and also in 
the analysis of yeast and fungi (Beekes et al., 2010). 
The focus of this section of the review however, is the utilisation and 
current trends of FTIR in the broad area of heart disease and in particular 
vascular remodelling. 
1.3.7 FTIR & Atherosclerosis
The frequent FTIR spectra features of atherosclerotic plaques has also 
been addressed (Wrobel et al., 2014). Table 1.4 provides a foundation for 
an infrared radiation (IR) library for the detection of atherosclerosis 
biomarkers such as oligosaccharides and polysaccharides (1041 cm-1), 
cholesterol (1055 cm-1, 3035 cm-1), phospholipids, glycolipids and 
calcification (1080-1095 cm-1),  glycogen (1080-1095 cm-1, 1151 cm-1), 
cholesterol esters (1170 cm-1), collagen (1203 cm-1), lipids (1395-1377 
cm-1, 1460 cm-1, 1733-1750 cm-1, 2850 cm-1, 2925 cm-1, 2954 cm-1) and 
proteins (1552 cm-1, 1666 cm-1, 2873 cm-1, 3080 cm-1, 3500-3200 cm-1). 
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Further research to expand the FTIR spectra library for atherosclerosis to 
facilitate the early detection of atherosclerosis has been desirable 
(Wrobel et al. 2014). FTIR analysis of human atherosclerotic carotid 
arteries has been performed to determine the biochemical markers of 
mechanical stiffness during atherosclerosis and revealed that a decrease 
in lipid content and an increase in calcification in the plaque groups 
displaying mechanical stiffness (Barrett et al. 2015). FTIR spectra for 
atherosclerotic plaques from ApoE/LDLR-/- mice fed on a normal diet and 
on a low carbohydrate high protein diet (LCHP) have been generated and 
compared with higher cholesterol and cholesterol esters found in the 
LCHP mouse model (Wrobel et al., 2014). Chemical changes in grey and 
white matter of brains from C57/BL6 and ApoE/LDLR-/- mice have also 
revealed higher lipid to protein content and cholesterol, in contrast to 
lower haem groups in the red blood cells of the white matter 
demonstrating that atherosclerosis can effect brain tissue and therefore 
could contribute to brain-related diseases (Kochan et al., 2016). Finally, 
the effects of pravastatin on the FTIR spectra from ApoE/LDLR-/- mice 
have also been evaluated (Kostogrys et al., 2017). Pravastatin decreased 
the effects of a pro-atherogenic diet on lipid content, cholesterol and 
cholesterol esters and the levels of phospholipids but increased the levels 
of unsaturated compounds compared to control or atherosclerotic mice. 
The study demonstrated the potential of FTIR to not only compare 
control, diseased and diseased treated models but also to identify the 
biochemical changes in each of the groups (Kostogrys et al., 2017). The 
application of FTIR to atherosclerosis models is currently well 
characterised and demonstrates great potential for the diagnosis of 
atherosclerosis.
1.3.8 FTIR  and Vascular Remodelling
One of the first studies reporting the use of FTIR for vascular tissue was 
carried out on rabbit aortas. FTIR identified several peaks in the tunica 
media as outline in Table 1.5 (Colley et al., 2004). FTIR was also 
performed on aortic tissue and diseased (aneurysm) aortic tissue to 
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evaluate the diagnostic potential of the technique. Healthy and diseased 
aortic tissue could be distinguished from one another with 95% 
confidence (Bonnier 2008). The structure of elastin which is a structural 
component of the aorta and can be modified in disease progression was 
originally mapped by FTIR (Debelle  et al.,1998) and was subsequently 
used to analyse the elastin and collagen content of the aorta and track 
structural changes in the extracellular matrix of the aorta during disease 
progression (Cheheltani et al., 2014). FTIR spectra of the proteins from 
human vSMCs versus vSMCs cultured with aggregated LDL were also 
analysed to map changes elastin content (Table 1.6, Samouillan et al., 
2012). Sham and injured (arteriosclerotic) arteries treated Connective 
Tissue Growth Factor (CTGF) were also analysed by FTIR and displayed 
a 50% decrease in the 1338/AM2 area ratio and a 600% increase in the 
1660/1690 peak height ratio (attributed to collagen). The CTGF treated 
samples reversed these ratios back to control sham levels (Herman et al., 
2009). All of these studies contain valuable information of the peaks 
present in various parameters of vascular remodelling and have been 
recorded in Table 6 as a basis of an FTIR ‘library’ for vascular remodelling 
which can be expanded with further research.
Peak Attributed to Vascular Relation Reference
530 v(S-S) SMC protein Samouillan 2012
930 ν(Cα-C) 
characteristic of α- 
helices.
SMC protein Samouillan 2012
1039 ν(C-C), ν(C-O), 
Phe, Ser
SMC protein Samouillan 2012
1178 γ(CH2) Pro, Tyr SMC protein Samouillan 2012
1206 δ(COH)Tyr SMC protein Samouillan 2012
1224 amide III δplan (N-
H)
SMC protein Samouillan 2012
1408 v(COO-) SMC protein Samouillan 2012
1464-1452 δ(CH2,CH3) 
aliphatic side chains
Smooth muscle cell 
protein
Samouillan 2012
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Table 1.4: FTIR and Vascular Remodelling. Table of peaks reported in 
1548 Amide II v(CN), 
∂NH
Smooth muscle cell 
protein
Samouillan 2012
1591 V(C-C) ring Tyr, Phe Smooth muscle cell 
protein
Samouillan 2012
1651, 1632 Amide I v(C=O) Smooth muscle cell 
protein
Samouillan 2012
2955, 2922, 2850, 
2827
v(C-H) aliphatic Smooth muscle cell 
protein
Samouillan 2012
3446; 3361; 3197 Amide A H-bonded 
v(O-H) and v(N-H)
Smooth muscle cell 
protein
Samouillan 2012
969; 1063; 1241; 
1378; 1464; 1539; 
1645; 1734; 2854; 
2927; 2958; 
300-3450
Aggregated LDL Samouillan 2012
1030 
1080 
1163 
1403 
1456
C-O Stretching 
C-O Stretching 
CH2 Wagging 
C-H deformation   
C-H stretch of 
protein 
Aortic wall (Collagen 
and elastin)
Bonnier 2008
525; 645; 752; 836 
852; 905; 928; 960; 
1004; 1031; 1103; 
1123; 1175; 1207; 
1246; 1313; 1336; 
1414; 1452; 1565;  
1613; 1659 
V(S-S) bridge G-G-
T; Tyr; Tyr; v(C-C) 
v(C-C); v(C-C); Phe 
Phe; v(C-N); Tyr 
Tyr, Phe; Amide II;  
∂(CH); 
(C0)2 ;∂(CH2CH1) 
Phe; Phe/Tyr; 
Amide I 
Human Elastin Debelle 1998e
1338 
1480-1580 
1580-1718 
CH2wagging 
vibration of proline 
side chains 
Amide II 
Amide I 
Elastin/Collagen 
Elastin/Collagen 
Collagen Scar 
deposition in cardiac 
tissue sections
Cheheltani 2014
1610-1645 
1643-1667
β Sheets 
Amide I
Elastin Cheheltani 2014
1338 
1660/1690
Collagen Integrity 
Collagen Maturity
Vascular 
Remodelling 
Vascular 
Remodelling
Herman 2009
1237 
1448 
1634 ;1529 
3081; 2934
Phospholipids 
Protein 
Protein 
Saturated C-H 
modes
Tunica Media 
Tunica Media 
Tunica Media 
Tunica Media
Colley 2004 
Colley 2004
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the literature.
As mentioned above, the role of stem cells in contributing to vascular 
remodelling has come into focus in the recent literature. With that in mind, 
Table 1.5 below is a collection of peaks attributed to stem cells and 
differentiation that have been outlined in the literature so far.
Stem Cell 
Type
Peak Attributed To Phenotype Reference
hESC and 
hMSC
2920 cm-1 & 
2850 cm-1
1740 cm-1
CH2 stretching 
mode of 
methylene 
chains;
carbonyl C=O 
stretching 
mode.
Membrane 
lipids
Phospholipids
both higher in 
hESC than 
hMSC
Pijanka et al. 
2010
hESC 
differentiation 
to neural stem 
cells
2959 cm-1; 
2923 cm-1; 
2853 cm-1;
1659 cm-1 
&1637 cm-1
CH2 CH3 
stretching 
vibrations
Amide I 
Lipids
&
Proteins
Increase during 
differentiation
Tanthanuch et 
al. 2010
mESC 
Spontaneous 
Differentiation
1692 cm-1 & 
1657 cm-1
994 cm-1; 914 
cm-1; 966 cm-1
899 cm-1
Amide I
Nucleic Acid
DNA
Proteins; 
increase during 
differentiation
Decrease 
during 
differentiation
Appeared 
during 
differentiation
Ami et al. 2008
rBM-MSC 
differentiation 
to hepatocytes
3012 cm-1
2952 cm-1
2854 cm-1
1722 cm-1
C=O stretch
VasCH3 stretch
vsCH2 stretch
C=O stretch
All from lipids
Triglycerides 
and fatty acids.
Ye et al. 2012
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Table 1.5. FTIR peaks for stem cells and their progeny. Table of stem 
cell FTIR peaks reported in the literature.
The substantial evidence of the specificity and sensitivity of Raman and 
FTIR as diagnostic tools suggests that these platform technologies are 
critical to the future of biomedical diagnostics. Further research is 
required in the areas of CVD and in particular vascular remodelling. The 
first aim of this research was to determine if the cells composing the 
injured and healthy vessel models could be discriminated from one 
another, and if so, could the aforementioned photonic platforms be 
sensitive enough to discriminate a variety of stem cells from their 
myogenic progeny, differentiated smooth muscle cells and de-
differentiated smooth muscle cells.
mPSCs to 
differentiated 
pancreatic cells 
(DPCs)
1650 cm-1
1540 cm-1
1030 cm-1
1080 cm-1
992 cm-1
914 cm-1
986 cm-1
899 cm-1
Amide I
Amide II
Glycogen
Phosphate
Nucleic Acid
Nucleic Acid
Nucleic Acid
DNA
broadens in 
DPCs
decrease in 
DPCs
Increase during 
differentiation
Decrease 
during 
differentiation
Appears in late 
differentiation 
stage
Vazquez-
Zapien et al. 
2016
mPSCs to 
differentiated 
kidney cells 
(DKCs)
16751 cm-1
1650 cm-1
1633 cm-1
Asparagine
Glutamine
Arginine
All lower in 
DKCs than 
mPSCs
Mata-Miranda 
et al. 2017
hMSCs to 
chondrocytes
1338 cm-1
1230 cm-1
1203 cm-1
1152 cm-1
1107 cm-1
1080 cm-1
1019 cm-1
993 cm-1
Amide III
P-O stretching-
C-O-C 
stretching 
Aggrecans
Collagen type II
(all higher 
chondrocytes
Higher in 
chondrocytes
Chonanant et 
al. 2011
murine 
haematopoietic 
stem cells 
(HSCs) from 
bm-MSCs
966 cm-1
1088 cm-1
1240 cm-1
DNA bands Higher in 
mHSCs than 
BM-MSCs
Zelig et al. 
2010
Attributed To Phenotype ReferenceStem Cell 
Type
Peak
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1.4 GSK3β and Notch in Myogenic Differentiation
Recent evidence suggests that the source of the SMC-like cells in the 
vascular lesion are of a stem cell origin. There are no current drugs on 
the market to target this pathway for in-stent restenosis. Therefore, the 
mechanisms for vascular stem cell transition to smooth muscle-like cells 
will be discussed with the aim of identifying a suitable drug target for 
vascular remodelling due to the accumulation of stem cell-derived 
progeny.
1.4.1 Mechanisms for myogenic differentiation
Figure 1.6 Myogenic Differentiation of stem cells to smooth muscle-
like cells.  Process of vascular stem cell differentiation to smooth muscle 
cells through signalling molecules TGF-β1, Notch, PDGF-BB and 
Hedgehog. 
The formation and remodelling of vessels during development and 
disease, respectively, has been recently reviewed and highlights the 
importance of smooth muscle cells during angiogenesis, the formation of 
veins and arteries in the developing embryo, and the recruitment and 
differentiation of SMCs (Wang, 2015). Two of the factors that are critical 
for smooth muscle cell formation are platelet-derived growth factor 
(PDGF-BB) and TGF-β1, both of which are multifunctional during 
development. Further to this, another factor identified to be essential for 
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vascular development is the morphogen, sonic hedgehog (SHh) which 
up-regulates PDGF-BB and Akt phosphorylation to stimulate SMC 
migration for neovessel formation (Wang, 2015).
1.4.2 TGF-β1 Signalling Contributes to Myogenic Differentiation
Not surprisingly, TGF-β in its three isoforms TGF-β1, TGF-β2 and TGF-β3 
is involved in SMC differentiation, proliferation, survival and apoptosis 
with significant detrimental effects observed in mice deficient in TGF-β1/
TGF-β2/TGF-β3 in vivo. TGF-β1 signalling positively regulates Myh11 and 
smooth muscle alpha actin (ACTA2) expression through the SMAD 
complex and Notch signalling in embryonic stem cells and suggests that 
TGF-β1 contributes to myogenic differentiation both in vitro and in vivo 
(Wang 2015). 
The mechanisms of TGF-β1 induction of stem cells to smooth muscle-like 
cells has been assessed by many groups and involves four signalling 
pathways (i) the TGF-β1 control element, (ii) the Smad binding elements 
(SBE), (iii) the CArG box, (iv) cross-talk with Notch and regulation with 
microRNAs. Briefly, the TGF-β1 control element has been found in the 
promotor region of the SMC marker genes SM-22α, SMA, CNN1 and 
SMMHC (Myh11). TGF-β1 forms a complex with TCE and up-regulates 
SM-22α and SMA. In a C3H T10/2 mesenchymal like stem cell model, 
over-expression of Kruppel like factor-4 (KLF4) attenuates the stimulation 
of TGF-β1 induction of smooth muscle markers. Inhibition of KLF-4 has 
also been shown to increase SMA and Myh11 markers (Liu et al., 2003; 
Guo & Chen, 2012).
The Smad binding element (SBE) is essential in the promotor region of 
the SMC marker genes. The SBE provides a binding region in its 
sequence for the Smad proteins which regulate TGF-β1 induced gene 
expression. In particular, the SM22α promotor SBE is a direct binding site 
for Smad3. Another pathway shown to be involved in the Smad 
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dependent TGF-β1 induction of stem cells to SMCs is RhoA. RhoA 
inhibits Smad2 and Smad3 phosphorylation which is essential for TGF-β1 
gene expression and thus attenuates SMC marker expression. Smad-
dependent promotor activity is enhanced by constitutively active RhoA 
(Chen et al., 2006b; Guo & Chen, 2012). 
The CArG box AKA serum response factor (SRF) is also involved in TGF-
β1 induction of SMCs. Enhanced expression of SRF leads to an increase 
in SMC marker expression in C3H 10T1/2 cells. Mutations in the SRF 
lead to attenuation of SMC marker expression. Myocardin, a co-factor of 
SRF, enhances the effect of TGF-β1 on the SM22α promotor of C3H 
10T1/2 cells and increases the Smad3-mediated up-regulation of SM22α, 
SMMHC (Myh11) and SMA. Although myocardin is critical in development 
and enhances TGF-β1 induction of SMCs, there is evidence in the 
literature that demonstrates that myocardin is not essential for myogenic 
differentiation (Guo & Chen, 2012).
Notch signalling is also involved in SMC differentiation. The binding of 
Notch ligands (Delta and Jagged) up-regulates SMC genes SMA, 
SM22α, Cnn1 and Myh11 in numerous cell lines. Notch increases the 
binding of TGF-β1 to the Smad promotor and TGF-β1 increases Notch 
ligand Jag-1 expression in hMSCs suggesting a cross-talk between Notch 
and TGF-β1 signalling. (Kurpinski et al., 2010; Guo & Chen., 2012).
1.4.3 PDGF-BB and myogenic differentiation
PDGF-BB is involved in neo-vessel formation during development and 
myogenic differentiation. PDGF-BB increases SMC marker expression in 
C3H 10T1/2 cells and Sca1+ and Flk1+ progenitors (Wang 2015). PDGF-
BB was also induces SMC marker expression in human bm-MSCs (Wu et 
al., 2007) and rat CD34+ resident vascular wall stem cells (Shen et al., 
2016). 
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1.4.4 Notch signalling contributes to myogenic differentiation.
Notch signalling has been shown to be critical during embryogenesis, 
particularly in vasculogenesis. Mutations in the Notch receptors Notch-1, 
Notch-2, Notch-3 and Notch-4 and Notch ligands, Delta-like 1, Delta-like 
2, Delta-like 3, Delta-like 4, Jag-1 and Jagged-2 have resulted in 
abnormalities and sometimes fatalities in the developing embryo (Gridley, 
2010).
Figure 1.7 Notch signalling in the vasculature, as adapted by 
Gridley, 2007. The binding of Notch ligands Jagged or delta-like ligands 
(1-4) from a signalling cell to an adjacent Notch (1-4 receptor) of a 
receiving cell. The diagram demonstrates the cleavage of the Notch 
intracellular domain (NICD) by a disintegrin and metalloproteinase 
domain containing protein (ADAM) and translocation of the NICD by γ-
secretase. The NICD then binds to the transcription factor RBJ-k through 
the mastermind like protein (MAML) to turn on transcription of Notch 
target genes e.g. Hey, Hes, HRT.
The Notch receptor is a trans-membrane protein that requires the binding 
of its ligand to undergo a series of proteolytic cleavage steps. The first 
step, initiated by furin convertase aids in the ligand receptor binding of 
Notch to the adjacent cell. The second proteolytic step is mediated by 
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disintegrin and metalloproteinase domain containing protein 10 or 17 
(ADAM10/ADAM17) which internalises the Notch receptor by cleaving its 
extracellular domain (Andersson & Lendahl, 2014). The next step which 
is driven by ϒ secretase releases Notch from the membrane to allow it to 
translocate to the nucleus through the signals in the Notch intracellular 
domain (NICD). The NICD then binds to the RBP-Jk transcription factor 
and mastermind like protein (MAML) that can turn on the Notch target 
genes, hairy and enhancer of split (HES-1, -5, -7), HES-related repressor 
protein (HERP-1 to -3) and hairy/enhancer of split related with YRPW 
motif protein (Hey1 to 3) in humans (Gridley, 2010).
1.4.5. Notch signalling in arterial development.
One of the major roles of Notch signalling in arterial development is the 
fate specification of arterial endothelial cells. Notch signalling has been 
shown to be downstream of the vascular endothelial growth factor A 
(VEGF-A). In cell culture, stimulation of VEGF-A in human arterial 
endothelial cells resulted in an up-regulation of the Notch ligand Dll4 
expression (Liu et al., 2013). In vivo, injection of zebrafish with VEGF-A 
mRNA increased arterial differentiation markers, inhibition of VEGF-A led 
to a loss of dorsal aortic arterial markers, but injection of Notch-1 mRNA 
rescued the arterial marker expression in VEGF-A deficient zebrafish 
demonstrating the role of Notch in VEGF-A directed arteriogenesis 
(Lawson et al., 2002; Gridley, 2010). 
Notch signalling has also been demonstrated to specify smooth muscle 
cell fate. In particularly, Notch-3 has been reported in the literature to be 
present in arteries but not veins. Notch-3 deficient mice presented arterial 
defects such as thinner weakened arteries and also the smooth muscle 
cells isolated from Notch-3 deficient mice had a downregulation of SMC 
markers smoothelin and SM22α (Domenga et al., 2004; Gridley, 2010).
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1.4.6 Notch signalling in disease.
Notch signalling has been implicated in disease and injury models. 
Liedner et al., first performed in situ hybridisation of denuded rat carotid 
arteries (to induce IMT) and compared the gene expression for Jagged 1 
and 2, and Notch 1-4. Low levels of Jagged 1, Jagged 2 and Notch-1 
were found in the uninjured model, however these levels (along with 
Notch-2 to -4 levels) significantly increased after injury (Liedner et al., 
2001). In Hey2 knockout mice, the levels of neointima formation following 
injury were markedly reduced compared to wildtype mice and isolated 
SMCs from the Hey2 deficient mice exhibited reduced proliferation 
capabilities compared to control SMCs (Sakata et al., 2004). The 
neointima of heterozygous Notch-1+/- mice and mice with a smooth 
muscle cell specific Notch-1 deletion resulted in a 70% neointimal 
reduction compared to wildtype or Notch-3 deficient mice (Li et al., 2009). 
Perivascular delivery of Notch-1 siRNA can inhibit neointima formation 
following mouse carotid ligation (Redmond et al., 2014). Levels of 
Notch-1 protein and mRNA have also been shown to increase in 
conjunction with levels of sonic hedgehog following carotid ligation in 
mice (Morrow et al., 2009).  Finally, Notch-1, -2 and Jagged 1 are up-
regulated in rat carotid arteries following balloon injury. The addition of 
soluble Jagged1 (which when solubilised is inhibitory for Notch signalling) 
attenuates this response and the formation of the neointima is disabled 
(Caolo et al., 2011).  
1.4.7 Notch signalling in myogenic differentiation.
Several recent studies have demonstrated a putative role for Notch 
signalling in promoting myogenic differentiation. Mesenchymal C3H/
10T1/2 cells were used to examine the role of Notch signalling in 
controlling myogenic differentiation in response to Jag-1 stimulation. 
Jag-1 increased Myh11 expression independent of the myocardin serum 
response factor – CarG complex but dependent on the Notch 
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transcription factor RBP-jk complex (Doi et al., 2006). Similarly, human 
embryonic stem cells (hESCs) and bm-MSCs undergo myogenic 
differentiation through a TGF-β1/Notch signalling axis. The myogenic 
differentiation response  was dependent on the activation of SMAD3 and 
Rho kinase. In addition, Jag-1 knockdown partially blocked smooth 
muscle α actin ACTA2 and CNN1 expression and completely blocked 
MYOCD expression, suggesting that Jag-1 plays an important role in 
TGF-β1-induced expression of SMC markers. Notch activation also 
resulted in an increase of neural markers and a decrease of endothelial 
markers in hESCs (Kurpisnki et al., 2010). Jag-1 also increased CNN1 
and smooth muscle α actin (ACTA2) levels in rat mesenchymal stem 
cells, a response that was attenuated following inhibition with a Notch γ-
secretase inhibitor, DAPT (Mooney et al., 2015). In addition, neural crest 
stem cells from explanted neural tubes undergo myogenic differentiation 
and increase their expression of SM22α and smooth muscle α-actin. 
However, neural crest stem cells from explanted tubes of Cre-Pax mice 
with dominant negative MAM (Mastermind, a complex critical for Notch 
signalling) had a significant reduction in myogenic cell differentiation 
capability compared to the control, demonstrating a role for Notch 
signalling in neural crest stem cell differentiation to smooth muscle-like 
cells (High et al., 2007). MVSCs have also been shown to differentiate to 
smooth muscle-like cells in the presence of Notch. Co-cultured MVSCs 
grown with OP9-Delta 1 feeder cells to supply Notch ligand stained 
positive for SM-MHC (Tang et al., 2012). 
Collectively, these studies suggest that Notch is an important regulator of 
myogenic differentiation in vitro and neointimal formation in vivo. The 
presence of resident vascular stem cells and their myogenic progeny in 
arteriosclerotic lesions suggests that the Notch pathway may be activated 
during neointimal formation making Notch a potential therapeutic target 
for inhibiting myogenic differentiation and the accumulation of stem-cell 
derived myogenic progeny within a lesion. 
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1.5 Targeting Notch
Several methods to specifically target and inhibit Notch signalling have 
been reported (Andersson & Lendahl, 2014). Targeting Notch signalling at 
the first proteolytic step and ligand/receptor binding phase has been 
addressed. Inhibition of furin convertase has no effect on Notch-2 and 
little effect on Notch-1 signalling (Kidd & Lieber, 2002). As furin 
convertase is a multifunctional enzyme and inhibition of it did not have 
significant effects on Notch signalling, the risk of off target effects 
outweighs the benefit of inhibition and therefore is not an optimal target 
for Notch inhibition. Similar off target effects are associated with inhibiting 
the ADAMs that internalise the Notch receptor to the cell as they are 
involved with vital proteins tumour necrosis factor (TNF-α) and 
interleukin-receptor 6 (IL-6) (Andersson & Lendahl, 2014).
It is not surprising, that the enzyme 𝜸-secretase that releases the NICD to 
turn on transcription of its target genes is the most popular target for 
Notch inhibition. Many 𝜸-secretase inhibitors have been developed by 
pharmaceutical companies and have made it to clinical trials. These 
include DAPT (Eli Lili), BMS-906024 (BMS), MK0752 (Merck), 
PF-03084014 (Pfizer) and RO4929097 (US National Cancer Institute). 
The focus of these clinical trials were both Alzheimer’s disease or cancer, 
where Notch signalling has been roundly implicated. The Eli Lily 𝜸-
secretase inhibitor trials had to be stopped prematurely due to the 
discovery that the Alzheimer’s patients performed worse compared to the 
placebo control. The Merck MK-0752 clinical trial and RO4929097 trials 
had mixed results, particularly when translating the therapy to children but 
showed a reduction in colonic and glioblastoma tumours respectively. The 
Pfizer PF-03084014 was also reported to significantly reduce tumour size 
and decrease Notch target gene mRNA expression in desmoid tumours 
(Andersson & Lendahl, 2014).
Single chain antibodies have been generated for the Notch ligand binding 
domain in Notch-1 and -2, but have only been proven to be effective in 
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mouse models (Falk et al., 2012; Andersson & Lendahl, 2014). The 
monoclonal antibodies have also been developed for the DLL4 ligand and 
were shown to be more effective than the gold standard 𝜸-secretase 
inhibitor in postponing tumour growth in mice. However, this study was 
limited to a cancer and not vascular model (Liu  et al., 2011). 
The Notch intracellular domain also undergoes several post-translational 
modifications that can affect it’s signalling and functions. This includes 
phosphorylation by GSK3β, cyclin-dependent kinase 8 and atypical 
protein kinase C. These enzymes, in particular GSK3β has been 
evaluated for its ability to inhibit Notch signalling.
1.5.1 Glycogen synthase kinase 3 beta (GSK3β)
Glycogen synthase kinase 3β is a serine threonine kinase that cross-talks 
with Notch to regulate it’s signalling. It was initially discovered in the 
glycogen synthase pathway, hence its name (Hall et al., 2001). GSK has 
two structurally similar domains denoted the α-domain (51kDa) and the β-
domain (47kDa) (Woodgett et al., 1990). GSK3β has a broad range of 
substrates and is unique because of the priming phosphorylation the 
majority of substrates undergo before further phosphorylation by GSK3β. 
Basal levels of GSK3β are expressed in resting cells. The activation of 
GSK3β is due to phosphorylation of it’s tyrosine residue at the 216 site 
(Wang et al., 1994). It is negatively regulated in response to 
phosphorylation at the serine 9 residue (Pearl & Barford, 2002) .This 
phosphorylation causes the N-terminal domain of the kinase to fold over 
and block the site from a substrate (Doble & Woodgett, 2003). GSK3β 
has been implicated in many diseases such as Alzheimer’s disease, 
tumorigenesis, diabetes and CVD (Guha et al., 2011; Kim et al., 2002). 
1.5.2 GSK3β in embryonic development
GSK3β is crucial for development as GSK3β knockdown leads to 
embryonic death in late development in mice. This is thought to be due to 
hyperproliferation of early cardiomyocyte precursors that could be 
 47
regulated by GSK3β (Force & Woodgett., 2009). GSK3β was first 
implicated in development in the drosophila model where genetic analysis 
showed that the GSK3β homologue ‘shaggy’ was important for cell fate 
specification in the developing embryo. Wingless, a β-catenin homologue, 
switched on shaggy during embryogenesis. β-catenin belongs to the Wnt 
signalling pathway which has an essential and highly conserved role in 
the embryogenesis of drosophila, zebrafish and mammals. Briefly, the 
hallmark of the canonical Wnt pathway is accumulation of β-catenin 
within the nucleus. In the absence of Wnt, cytoplasmic β-catenin is 
enzymatically degraded by a complex including GSK3β, Axins, casein 
kinase 1α, adenomatosis polyposis coli and protein phosphatase 2a 
(Komiya et al., 2008). In the presence of Wnt binding to its receptor 
complex, frizzled and LRP5/6 disrupts the β-catenin destruction complex 
releasing β-catenin for signalling. Another protein, disheveled, can bind to 
the frizzled-LRP5/6 complex and inhibit the destruction complex by 
inactivating GSK3β which results in an intact and stabilised β-catenin for 
accumulation in the cytoplasm. The accumulated β-catenin is transported 
to the nucleus where it binds to the LEF/TCF DNA binding transcription 
factor complex and turns on genes for embryogenesis. Some of these 
genes include Twins and Siamois which are organiser-specific genes. 
The Wnt pathway has also been associated in the anterior head 
formation, neural patterning, posterior patterning, tail formation and the 
formation of the internal organs. Due to its crucial role in many pathways 
in development, Wnt/β-catenin needs to be highly regulated and GSK3β 
has been shown to regulate Wnt signalling at the β-catenin level (Komiya 
et al., 2008). 
The presence of GSK3β is crucial for vascular development. Targeted 
knockdown or pharmacological inhibition of GSK3β in developing 
zebrafish embryos has significant phenotypic defects including incorrect 
patterning and positioning of blood vessels. This suggest a positive role 
for GSK3β in the specification of cell fate in the vasculature (Lee et al., 
2014). However, inactivation of GSK3β signalling has also been shown to 
be of importance in angiogenesis. Previously it has been shown that β-
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catenin signalling increases following the inactivation of GSK3β and the 
subsequent formation of capillaries from endothelial cells in Matrigel plug 
assays in vivo. In contrast to this, the activation of GSK3β inhibited the 
angiogenesis pattern suggesting that GSK3β regulates angiogenesis at 
the nodal point of endothelial cell signalling (Kim et al., 2002). 
Figure 1.8 Wnt and GSK3β signalling in embryonic development. 
Demonstration of the Wnt ligand binding its receptor frizzled and 
activating dishevelled to inactivate the destruction complex including 
GSK3β to release β-catenin for translocation to the nucleus to drive 
transcription of embryogenesis genes. Figure adapted from Majid et al., 
2012.
1.5.3 Targeting GSK3β
GSK3β has been evaluated as a drug target for diseases such as 
Alzheimer’s and cancer. The initial prescribed GSK3β inhibitor was 
lithium, which was prescribed to patients with neurological disorders such 
as depression. Lithium simply phosphorylates GSK3β to its inactive state 
and studies have shown a decrease in active GSK3β signalling within 2 
days of lithium treatment and stabilisation in patient moods (Jope et al., 
2003). Lithium has also been used in clinical trials involving bone marrow 
 49
transplants and was shown to aid in the mobilisation of haematopoietic 
stem cells. Lithium carbonate has also reached clinical trials for 
Alzheimer’s and bipolar disorder.  In cancer research, lithium has been 
shown to suppress cell migration in spheroid cultures of glioma cells 
(McCubrey et al., 2016). There have been many pharmaceutically derived 
GSK3β inhibitors manufactured. Some of these include AR-A014418, 
AZD1080, CHIR-99021, SB216763, SB415286 and TDZD-8. The majority 
of the inhibitors do not discriminate between the α- and β-forms of GSK3 
and work in an ATP-competitive manner. GSK3β inhibitors including 
Tideglusib has made it to clinical trails for Alzheimer’s treatment and 
Divalproex for mood disorders. In pre-clinical cancer trials, GSK3β 
inhibitors such as SB415286 were shown to inhibit proliferation, promote 
cell cycle arrest and cause apoptosis in leukaemia cells. Other inhibitors 
SB216763, GSK-3 IX and allsterpaullone have also shown to suppress 
leukemia cell growth (McCubrey et al., 2014). 
Although inhibition of GSK3β has been shown to be highly successful for 
the treatment of mood disorders, Alzheimer’s disease and some cancers 
so far, the focus for this thesis work is vascular remodelling. In 2009, Ma 
et al., compared restenosis rates in rabbits that contained bare metal 
stents, stents coated with a typical drug rapamycin, stents coated with 
AR-A014418 or stents coated with rapamycin and AR-A014418. The 
researchers found that the neointimal size was 45% lower in the GSK3βi 
coated stent than bare metal stent and 49% lower compared to the 
rapamycin only stent. The researchers also showed that the combination 
of the GSK3βi and rapamycin resulted in faster re-endothelialisation on 
the stent (Ma et al., 2009).
Initial studies targeting GSK3β inhibitors have shown success however 
much of the focus has been directed towards endothelial cells. The aim of 
this thesis is to evaluate the role of GSK3β inhibition on stem cell 
transition to SMCs, particularly through the Notch pathway which has 
been shown by us and others to be significant in vascular remodelling 
(Redmond et al., 2014, Morrow et al., 2009, Li et al., 2009).
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1.5.4 GSK3β Signalling in the vasculature
GSK3β signalling is functional within vascular smooth muscle cells. 
Pharmacological inhibition and siRNA knock down of GSK3β showed an 
attenuation in myocardin and smooth muscle markers CNN1, SMA and 
SM22α in human vascular smooth muscle cells. Complementary to this, 
enhanced GSK3β expression through a constitutively active mutant 
showed an increase in the myocardin/SMC markers (Zhou et al., 2016). 
1.5.5 GSK3β in vascular disease
Several studies have addressed the putative role of GSK3β in vascular 
disease. Woulfe et al. (2010) generated a mouse model that allowed for 
inducible deletion of GSK3β and reported an improvement in ventricular 
diameter and function and subsequently vascular remodelling following 
knockdown (Woulfe et al., 2010).  In another mouse, pharmacological 
inhibition of GSK3β resulted in a significant attenuation of atherogenesis 
in hyperglycaemic ApoE-deficient mice compared to the no-drug control 
(Bowes 2009). Inhibition of GSK3β also improved vessel diameter and 
blood flow in porcine vascular disease models (Potz et al., 2016). In a rat 
atherosclerotic model, there was a significant decrease in inactivated 
GSK3β (Ser9) which would suggest a concomitant increase in activated 
GSK3β signalling along with typical atherosclerotic markers such as 
increased total cholesterol, triglycerides and LDL and a decrease in LDL 
(Wang et al., 2013). Similarly, the levels of inactive GSK3β 
phosphorylated at Ser9 were substantially lower within the neointima 
following carotid artery ligation suggesting the accumulation of the active 
form of GSK3β (Guha et al. 2011). 
1.5.6 GSK3β and Notch Signalling
GSK3β has previously been shown to act downstream of Notch in 
drosophila models (Ruel et al., 1993) and to regulate and phosphorylate 
the Notch intracellular domain (NICD) (Foltz et al., 2002). Using GSK3β 
null and wildtype mice the levels of phosphorylated Notch NICD increase 
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following the addition of GSK3β suggesting that GSK3β directly 
phosphorylates the Notch intracellular domain and aids in Notch 
signalling by protecting the intracellular domain from proteosomal 
degradation (Foltz et al., 2002). A similar role of GSK3β in Notch 
signalling in rat aortic smooth muscle cells (SMCs) has also been 
reported (Guha et al., 2011). Notch-3 NICD and Notch target genes Hey1 
and Hey2 were enhanced following ectopic expression of GSK3β 
whereas these levels decreased following either siRNA knockdown of 
GSK3β or pharmacological inhibition of GSK3β. These results suggest 
that active GSK3β is essential for Notch signalling in vascular SMCs 
(Guha  et al., 2011). 
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1.6 Nanoparticles as drug delivery platforms for stents
1.6.1 In-Stent Restenosis (ISR) 
The most common form of therapy for cardiovascular related events is 
balloon angioplasty and subsequent stent placement. Balloon angioplasty 
involves minor surgery inserting a balloon inside the vessel occluded with 
the plaque, inflating the balloon so that the plaque is pushed back against 
the vessel wall and thus the artery is opened (White et al., 2005). 
However, up to 40% of patients resulted in a re-occlusion of the artery, 
this is referred to as restenosis. Clinicians then began to insert bare metal 
stents during balloon angioplasty to hold the artery open after the 
procedure. Even after stent placement, 25% of patients displayed what is 
called ‘in-stent restenosis’ (Dangas et al., 2002). Other than the necessity 
to identify and further target the cells that contribute to the neointimal 
hyperplasia, another issue contributing to the high failure rate of stents is 
the eventuality that all drugs will deplete over time. It is a secondary aim 
of this thesis to develop a novel delivery platform for replenishing the 
stents with drugs. 
Various types of stents have been developed over the last number of 
years to combat in-stent restenosis (See Table 1.6). 
Stent	  Type Composed	  of Advantages Drawbacks Reference
Stainless	  Steel Iron	  and	  chromium Re-­‐opens	  occluded	  artery Disrupts	  endothelium	  and	  causes	  restenosis
Alberts	  et	  al.,	  2002;	  Palmaz	  et	  al.,	  1992
Cobalt	  
Chromium
Cobalt	  Chromium Thinner	  than	  stainless	  steel Causes	  restenosis Kereikas	  et	  al.,	  2003
Absorbable	  
Metal	  Stent
Biodegradable	  magnesium Reduces	  restenosis	  rate	  compared	  to	  stainless	  steel
Causes	  restenosis Bose	  et	  al.,	  2006
Polymer	  coated	  
stent
Coatings	  e.g.	  phosphorylcholine	  and	  polyvinyl	  purrolidone
Prevents	  contact	  of	  metal	  stent	  with	  blood TBD Yin	  et	  al.,	  2014
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 Table 1.6. Table of DES stent types used for CVD models. 
 
The original stent introduced was the stainless steel bare-metal stent that 
resulted in restenosis in 25% of patients (Dangas et al. 2002). Following 
that, cobalt chromium stents were employed in a clinical trial where 
15.7% of patients suffered binary restenosis by day 180 (Kereikas et al., 
2003). Clinical trials were also carried out for absorbable metal stents 
such as biodegradable magnesium stents and binary restenosis was 
detected by 1 year (Bose et al., 2006). Various polymers are being 
constructed as stent models and for coating of stents to attempt to reduce 
restenosis rates in patients, however none have made it to market yet 
(Yin et al., 2014). Stents coated with drugs such as rapamycin and 
sirolimus are currently used in up to 90% of patients (Jeremias et al. 
2008) yet the rate of restenosis is still unacceptably high (White et al. 
2005). In vitro studies have determined that the commonly used drugs 
rapamycin and sirolimus deplete after 30 and 14 days, respectively 
(Lüscher et al., 2007; Halkin et al., 2004) which suggests a reason for 
current failure rate of drug-eluting stents (DES). The ability to replenish a 
stent with a drug is an attractive solution to the current issue. 
1.6.2 Nanoparticles for drug delivery
The first nanoparticles developed for drug use were formulated by 
Speiser and colleagues in the late 1960’s. They were initially developed 
to achieve a controlled release of antibodies from tetanus vaccines 
(Kreuter et al., 2007). Nanoparticles are particles that range between 1 
and 100 nm in size and show great promise as drug delivery vehicles due 
to their small size. Nanocarriers ranging from approximately 50 to 400 nm 
can easily transport drugs around the blood-stream, whilst nanoparticles 
Drug	  eluting	  
stent
Metal	  mesh	  stents	  coated	  with	  drugs	  e.g.	  rapamycin	  and	  sirloins
Reduces	  neointimal	  formation	  compared	  to	  bare	  metal	  stents
Drugs	  deplete	  over	  time	  e.g.	  rapamycin	  by	  day	  30	  and	  sirolimus	  by	  day	  14
Lüscher	  et	  al.,	  2007;	  Halkin	  et	  al.,	  2004
Composed	  of Advantages Drawbacks ReferenceStent	  Type
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of less than 1 nm in size can even cross the blood-brain barrier (Siafaka 
et al., 2016). Nanoparticles are therefore, ideal vehicles for drug delivery 
and targeting.
1.6.3. Important characteristics of nanoparticles for drug delivery 
systems
• Size
Particle size is the most important characteristic when considering 
nanoparticles for drug delivery systems. The size of the NP determines 
the toxicity, in vivo distribution, stability, drug release (smaller the particle, 
the closer to the surface the drug is for release) from the nanoparticle, 
cellular uptake in vitro and in vivo, and if small enough, can cross the 
blood-brain barrier. The most common method to determining the size of 
nanoparticles is Dynamic Light Scattering (DLS), which relies on 
scattering of light from nanoparticles in response to a laser source (Singh 
et al., 2009).
• Surface Properties
Nanoparticles can be recognised as foreign particles by the body and 
therefore functionalisation of nanoparticles, as discussed below, can aid 
nanoparticles to evade the immune response and increase cellular 
uptake by cells. Also, the surface charge, or zeta potential, is of critical 
importance. Nanoparticles with a surface charge of ±30mV have greater 
stability in suspension as the charged particles will repel each other and 
thus prevent aggregation. Zeta potential is also determined by DLS. 
(Singh et al., 2009; Zhang et al., 2008). 
• Drug Release
The rate of release of a drug from a nanoparticle must be carefully 
monitored to prevent toxicity but also to ensure enough is released for 
disease targeting. Drug release from nanoparticles usually occurs by 
diffusion through or dissociation from the encapsulating matrix. Rapid 
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release from nanoparticles can occur if the drug weakly binds the 
associated matrix. More sustained drug release can be attained by 
incorporating the drug inside a shell such as a polymer. Release studies 
are most commonly carried out by controlled agitation and centrifugation 
or by dialysis whereby the drug released from nanoparticles are in 
supernatants (Singh et al., 2009). In this context, a Her2 receptor ligand 
humanised mAb trastuzumab has been conjugated to nanoparticles and 
targeted to breast tumour cells in vitro and in vivo and is currently being 
evaluated as a specific breast cancer detection probes for MRI contrast 
agent (Bazak et al., 2015). Passive targeting on the other hand involves 
incorporating the therapeutic agent inside the nanoparticle for cellular 
uptake. 
• Passive targeted nanoparticles for dug delivery
One of the main benefits to using nanoparticles is the potential to 
specifically target cells and tissue. There are various types of 
nanoparticle formulations described for targeted transport of drugs to 
cells. These include but are not limited to, lipid-based nanocarriers, 
liposomes, chitosan nanoparticles, hyaluronic acid and polymers. Each of 
these formulations are outlined briefly below (Siafaka et al., 2016).
- Lipid-Based Nanoparticles
Lipid based nanoparticles are desirable nanocarriers for hydrophobic 
drugs as they enhance the stability of the drug in solution. Lipids are 
naturally variable in their physiochemical, absorption and digestible 
properties and therefore there are a wide range of lipid-based 
nanoparticles to choose from based on the properties and target of the 
drug (Siafaka et al., 2016).
- Solid Lipid Nanoparticles
Solid lipid nanoparticles are nanocarriers consisting of a solid 
hydrophobic core containing a solid lipid matrix that the drug can be 
dispersed or dissolved in. The lipids can be anything from triglycerides, 
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glycerides, fatty acids to steroids and waxes. Drugs such as pilocarpine, 
paclitaxel, doxorubicin (DOX), timolol, tobramycin, diazepam, nifedipine, 
hydroxcortisone and desoxycorticosterone have been successfully loaded 
into SLNs (Siafaka et al., 2016).
-  Lipid Nanocarriers (NLNs)
Nanostructured lipid nanocarriers are lipid nanoparticles containing a 
solid and liquid core matrix. NLNs have shown greater drug solubility, 
bioavailability, permeability, decreased adverse effects and prolonged 
half-life in comparison to solid lipid nanoparticles. Therefore, they are a 
more attractive nanocarrier to the SLN provided the inner core can 
tolerate the hydrophobicity of the drug (Siafaka et al., 2016).
- Liposomes
Liposomes are lipid nanoparticles of an aqueous core entrapped in a lipid 
bilayer. The hydrophobic and hydrophilic portions of the liposome make it 
possible to incorporate hydrophobic or hydrophilic drugs. Liposomes have 
been widely successful so far. For example, liposomes functionalised with 
polyethylene glycol (PEG) and folate have been shown to be ideal 
carriers for paclitaxel to the lymphatic system. Liposomes functionalised 
with a specific breast cancer targeting peptide (H6, YLFFVFER) has 
successfully targeted Her2 positive cancer cells in vitro and in vivo. 
Finally, PEGylated liposomes modified with ox26 and chlorotoxic have 
managed to cross the blood brain barrier to promote brain glioma cell 
transfection with anti-cancerous plasmid DNA (Jia et al., 2016; Siafaka et 
al., 2016).
- Chitosan NP
Naturally occurring cationic polymer chitosan can be found in the exterior 
skeleton of crustaceans and is showing promise as a nanocarrier system. 
Due to the active amino and hydroxyl groups on its surface, chitosan can 
be easily modified for functionality. For example, pure chitosan based 
Nanoparticles have been used in conjunction with sodium alginate beads 
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to improve the oral delivery of DOX and PEGylated CS functionalised 
with folate and with paclitaxel incorporated has shown to enhance tumour 
penetration of PTX (Li et al., 2016; Siafaka et al., 2016).
- Hyaluronic Acid
Hyaluronic acid (HA) is a cyto- and histo-compatible polysaccharide 
consisting of D-glucuronic acid and D-N-acetylglucosamine. HA can be 
used as a nanocarrier itself or as a functionalizing agent for some of the 
aforementioned nanoparticles. PEGylated HA nanoparticles have been 
developed for anti-cancer drugs. HA Nanoparticles modified with 
cholesterylhemisuccinate have been used to incorporate docetaxal for 
tumour tissue targeting. The major drawback of HA is that it can 
accumulate in the liver and therefore could be harmful in high doses 
(Song et al., 2014; Siafaka et al., 2016).
- Nanocarriers of synthetic polymers
Synthetic polymers such as poly(lactic acid) (PLA), poly(e-caprolactone) 
(PCL) and poly(lactic acid co-glycolic acid) (PLGA) have been examined 
as potential nanocarriers for various drugs over the last decade. They are 
all aliphatic polyesters and other than PCL have been generally regarded 
as safe by the FDA. PCL has crystallinity issues making it a less attractive 
carrier than PLA and PLGA. Like the aforementioned nanoparticles, 
polymer nanoparticles such as PLA and PLGA can be further 
functionalised by coatings such as PEG or HA (Siafaka et al., 2016). 
Coating PLA with PEG has been shown to aid the transport of PLA 
nanoparticles to the intestine and subsequently to the epithelium. 
Multiblock polymer nanoparticles consisting of PLA and poly(methacrylic 
acid) have been utilised to incorporate paclitaxel and target intestinal 
cancer (Luo et al., 2014). PLA has also been functionalised with a folate-
core polylactide-D-α-tocopheryl polyethylene glycol 1000 succinate (FA-
PLA-TPGS) to load emtansine (DM1) to target breast cancer in vitro and 
in vivo and resulted in greater anti-cancer activity than the non-drug 
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loaded copolymer nanoparticles (Tang et al., 2013). Similarly, FA-PLA-
TPGS nanoparticles loaded with paclitaxel have shown greater activity 
than free paclitaxel. Multiblock polymer of thiolated chitosan-modified-
PLA-PCL-TPGS-PTX successfully targeted lung cancer orally (Jiang et 
al., 2013).
Similar to the PLA copolymer model, PLGA functionalised with TPGS and 
cholic acid were employed as transport agents for docetaxal to cervical 
cancer cells (Zeng et al., 2013). PEGylated PLGA loaded with oleanolic 
acid expressed greater cancer cell cytotoxicity in vitro. PEGylated PLGA 
Nanoparticles have also been functionalised with HA to target ovarian 
cancer cells (Vangara et al., 2013; Siafaka et al., 2016).
1.6.4. Externally controlled drug delivery system:
The most recent method of specific targeting involves the use of magnetic 
nanoparticles that can be externally targeted to the site of injury or tumour 
based on an external magnetic field (Li et al., 2012). 
The most extensively studied magnetic nanoparticle for biomedical 
purposes is the iron oxide Fe(II)Fe(III) nanoparticle, Fe3O4 NP. In general, 
the iron oxide magnet nanoparticle (MNP) has a net zero magnetic 
charge although it has randomly aligned magnetic moments. This means 
that the MNP requires external magnetic fields to align the magnetic 
moments and activate the magnetic property of the nanoparticle. The 
most common form of magnetic nanoparticle is the superparamagnetic 
iron oxide nanoparticle (SPION) which is characterised by its small size 
(<20 nm) and its single magnetic domain region. The SPION is the more 
attractive form of the MNP for biomedical applications as it requires 
external magnetic fields for magnetisation and exhibits no residual 
magnetism post magnetisation which reduces the risk of aggregation of 
the MNPs in vivo (Mohammod et al., 2017). 
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MNPs must be polymer coated to become more biocompatible and 
reduce toxicity. The main methods of coating are ligand addition or ligand 
exchange. Ligand addition involves the hydrogen bonding or hydrophobic 
interactions of, most commonly, a polymer to the surface of the MNP. This 
can result in the encapsulation of the MNP inside the polymer coat. 
Ligand exchange involves replacing the surface of the nanoparticle with 
functional groups, this can be done with a polymer. A range of polymers 
have been used to coat MNPs in the literature and include, but are not 
limited to, PEG, PVA, PLGA, dextran, gelatin and chitosan (Mohammod 
et al., 2017). 
There has been much success in drug loading polymer coated MNPs, 
particularly,  in the areas of cancer. The use of the external magnetic field 
to specifically target drugs to disease cells results in higher specificity of 
drug targeting in vitro and in vivo. Anti-cancer drugs DOX, PTX, 
methotrexate (MTX) and epirubicin have all been reportedly formulated 
with MNPs. MNPs loaded with MTX and targeted to cancer cells with an 
external magnetic field resulted in controlled release of MTX in vivo 
(Kohler et al., 2006). DOX and curcumin loaded PVA-PAA (polyacrylic 
acid) coated MNPs resulted in higher tumour suppression in mice than 
DOX alone (Fang et al., 2014). Chitosan functionalised MNPs loaded with 
PTX have been reported for targeted delivery in lung cancer and Fe3O4-
carboxymethyl chitosan nanoparticles loaded with rapamycin have also 
been targeted to cancer cells (Mangaiyarkarasi et al., 2016). Some 
SPIONs have been clinically approved for drug delivery, mainly in the 
area of cancer treatment. These include Feridex® and Resovist® for liver 
cancers, Abdoscan® and Lumirem® for bowel cancers and Feraheme® for 
the vasculature (Mohammod et al., 2017).
1.6.5 Methods to generating polymer coated SPIONs
Various methods for synthesising SPIONs and particularly encapsulated 
SPIONs have been described in the literature and has been described in 
detail in a review by Wu et al. (2015). The most common technique for 
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synthesising MNPs is the co-precipitation method. Briefly, the method 
involves combining ferric and ferrous oxide ions at a 1:2 molar ratio in 
basic conditions at room temperature to give the resulting Fe3O4-NP. 
Following this, the synthesised MNPs are typically encapsulated into 
polymers or undergo ligand exchange with polymers, as described above, 
with or without drugs for functionalisation. Magnetic nanoparticles are 
typically encapsulated in polymers such as PLGA or PEG by either the 
single or double oil in water emulsion solvent evaporation method. This 
method involves adding the magnetite to the polymer and adding this 
phase to an aqueous phase containing a stabilising superfactant. This 
solution is then agitated or most commonly sonicated to form polymer-
magnetite droplets, or nanoparticles, in the aqueous phase. The organic 
solvent at which the polymer and magnetite were dissolved in, prior to 
mixing with the aqueous phase, subsequently evaporates leaving 
hardened nanoparticles (Massart, 1981; Wu et al., 2015).
1.6.6 Drug-Carrying Nanoparticles for Drug Eluting Stents
Figure 1.9. Drug loading of magnetic nanoparticles. Magnetic 
nanoparticles coated in polymers and co-polymers with the therapeutic 
agent attached to the surface or incorporated inside the nanoparticle. 
Figure adapted from Luoguet et al. (2012).
 
One of the first studies to use nanoparticles for in-stent restenosis 
treatment was carried out by Danenberg et al., in 2002. This group 
incorporated a bisphosphonate agent (clodronate), to target monocytes 
and macrophages at the site of injury, into a liposome and targeted 
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neointima formation in rabbits. The results showed a significant reduction 
in neointimal formation following balloon angioplasty and treatment with 
the liposome clodronate (Danenberg et al., 2002). The group also 
compared methods of delivery of the liposome by administering the 
liposome clodronate intraluminally, IV and subcutaneously. They reported 
systemic delivery as the best delivery platform to have the greatest effect 
on restenosis in rabbits (Danenberg et al., 2003).
Alendronate, a bisphosphinate agent, encapsulated into a polymer PLGA 
nanoparticle, has also shown success in inhibiting macrophage like cells 
and smooth muscle like cells in vitro by 98% and 61% respectively. In 
vivo, the alendronate PLGA-NPs (ALN-NPs) reduced the neointima to 
media ratio by 52.7% and stenosis rate by 39.7% in rabbits after 28 days 
(Cohen-Sela et al., 2006).
Paclitaxel loaded PLGA:PEG polymer shells which were functionalised 
with heptameric peptides referred to as ‘nanoburrs’ were targeted to rat 
coronary arteries after balloon angioplasty. The nanoburr treated group 
had the greatest reduction in N/M ratio at 0.662+- 0.169, approximately 
53% lower than the control group. A free paclitaxel group also exhibited a 
lower rate of restenosis than the control but not as significantly reduced 
as the nanoburr group at 0.937±0.126μM which is approximately 25% 
less than the sham control. The NP only group had the least N/M ratio 
reduction at 1.063±0.097μM which is approximately 11% less than the 
untreated control (Chan et al., 2011).
Paclitaxel loaded polymer coated MNPs (like Figure 1.9) have recently 
inhibited 98% of smooth muscle cells growth, however this result was 
dependent on an external uniform magnetic field. Without the presence of 
a magnet, only 45% of SMC proliferation was inhibited. In vivo, there was 
a 4 fold increase in MNPs localised to a rat carotid stent when the 
external magnetic field was applied and this led to a 63% reduction in 
neointimal formation compared to a traditional stent control. The PTX-
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MNPs under non-magnetic conditions had a statistically insignificant 
effect on neointimal formation compared to the traditional stent control 
(Chorny et al., 2010). 
MNPs loaded into endothelial cells (ECs) have been targeted stents in rat 
carotid arteries using a uniform magnetic field. This results in a 1.7 fold 
less loss of lumen diameter and 2.1 fold reduction in stenosis in the EC-
MNP treated group compared to the non-treated control (Polyak et al., 
2016). In a similar concept, endothelial cells genetically modified with 
enhanced eNOS (endothelial nitric oxide synthase) were loaded with 
MNPs and targeted to the vascular wall following injury via an external 
magnetic field. The injured vessel wall showed an increase in the 
vasoprotective eNOS marker and restoration of endothelial function 
following eNOS EC-MNP treatment compared to the control (Vosen et al., 
2016).
Although polymer coated SPIONs have shown great promise for specific 
drug delivery and improved drug targeting and effects, most of the 
research is limited to cancer models. Within the area of vascular 
diseases, the focus has been on targeting stents with SPIONs to improve 
re-endothelialization following injury. The aim of the research in this thesis 
therefore, is to incorporate an inhibitor into a polymer coated SPION to 
attenuate resident vascular stem transition to smooth muscle-like cells 
which may be used in the future as a novel method of inhibiting in-stent 
restenosis (ISR).
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1.7 Aims & Objectives:
The following aims and objectives were addressed:
Aim 1: To establish whether stem cell-derived myogenic progeny could 
be distinguished from differentiated (normal healthy, dSMCs) and de-
differentiated (arteriosclerotic, ddSMCs) vascular smooth muscle cells in 
vitro using microfluidic capture of individual cells and measurement of 
the autofluorescence (AF) signatures in response to broadband light.
• Objective 1: Evaluate AF photonic differences between healthy 
differentiated vascular smooth muscle cells (dSMCs) and injured 
arteriosclerotic de-differentiated medial and neointimal cells 
(ddSMCs) following carotid artery injury.
• Objective 2: Generate AF photonic signatures for undifferentiated 
stem cells, their myogenic progeny and differentiated smooth 
muscle cells.
• Objective 3: Compare AF photonic signatures for stem cell-
derived myogenic progeny with differentiated vascular smooth 
muscle cells (dSMCs) and arteriosclerotic medial and neointimal 
cells following carotid artery ligation-induced injury.
• Objective 4: Identify the specific role of auto-fluorescent 
molecules collagen and elastin in contributing to the the spectral 
differences between undifferentiated stem cells, their myogenic 
progeny.
Aim 2: To establish whether stem cell-derived myogenic progeny (St-
SMCs) could be distinguished from de-differentiated (arteriosclerotic, 
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ddSMCs) vascular smooth muscle cells in vitro using vibrational 
spectroscopy, FTIR and Raman.
• Objective 1: Validate FTIR and Raman spectroscopy at 
discriminating undifferentiated mesenchymal stem cells (bm-
MSCs) from their osteogenic progeny (St-Osteo).
• Objective 2: Generate photonic signatures and discriminate 
populations of undifferentiated stem cells (bm,-MSCs), their 
myogenic progeny (St-SMCs) from de-differentiated smooth 
muscle cells (ddSMCs) in vitro using FTIR.
• Objective 3: Generate photonic signatures and discriminate 
populations of undifferentiated stem cells (bm,-MSCs), their 
myogenic progeny (St-SMCs) from de-differentiated smooth 
muscle cells (ddSMCs) in vitro using Raman spectroscopy.
• Objective 4: Identify the specific molecular signatures that 
contribute to the spectral differences between undifferentiated 
stem cells, their myogenic progeny and de-differentiated ddSMCs 
by Raman spectroscopy.
• Objective 5: Establish a novel platform that discriminates stem 
derived myogenic and osteogenic progeny from the same 
undifferentiated stem cell population.
Aim 3: Identify an effective GSK-3β inhibitor of myogenic differentiation 
and incorporate the inhibitor into novel polymer-coated magnetic 
nanoparticles in vitro.
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• Objective 1: Identify a suitable GSK-3β inhibitor to attenuate 
myogenic differentiation of undifferentiated resident vascular stem 
cells in vitro.
• Objective 2: Optimise the fabrication of polymer coated magnetic 
nanoparticles and functionalisation with a GSK-3β inhibitor using 
an oil in water emulsification technique
• Objective 3: Determine the functionality of inhibitor-loaded 
magnetic nanoparticles in vitro.  
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Chapter 2
Materials & Methods
2.1 Materials
All materials were of the highest purity commercially available and were 
of cell culture standard where applicable. See appendix A for a full list of 
materials. 
2.2  Cell Culture & Maintenance
All cell culture techniques were carried out in a clean and sterile 
environment using a Bio air 2000 MAC laminar flow cabinet. Cells were 
visualised using an Olympus CK30 phase contrast microscope and 
maintained in a Hera water jacket cell incubator at 37˚C in an atmosphere 
humidified with 5% CO2. 
2.2.1 Primary Aortic Smooth Muscle Cell Isolation and Culture
The thoracic aorta was isolated from Sprague-Dawley rats and C57/BL6 
mice and placed in Hanks balanced salt solution (HBSS), pH 7.4, before 
adipose fat and the endothelium were removed by gentle rubbing. Once 
the aorta was cleaned, it was placed into a Dulbecco's Modified Essential 
Medium (DMEM) solution containing 0.7 mg/ml collagenase (Sigma/
C9891-500 mg) in TNS (Soybean Trypsin Inhibitor in MEM with 0.1% 
FBS, Roche, Dublin/Ireland) for 20 min at 37°C to loosen the adventitia 
before complete removal using a fine-forceps under a dissecting 
microscope. The remaining medial layer was placed in the DMEM 
solution containing 1.25 mg Elastase Type III (Sigma, E0127) and 
incubated at 37°C for a further 2h with repeated gentle agitation until the 
medial layer was completely dissociated. Once fully dissociated, the 
aortic medial cells were centrifuged and washed twice in complete 
medium (DMEM supplemented with 10% FCS and 1% penicillin/
streptomycin) before the cells were plated and grown in RPMI-1640, 20% 
FBS (Sigma, F9665) and 1% Penn-Strep (Sigma, P4333) to passage 4. 
The mouse aortic medial cells were generally fixed with 3.7% 
 68
formaldehyde, dissociated and added directly to the microfluidic chip 
rather than cultured.
2.2.2 Primary Multipotent Vascular Stem Cell Isolation and Culture
Multipotent vascular stem cells (MVSCs) were isolated from rats as 
described by Tang et al. (2012). Briefly and as described above, the aorta 
from Sprague-Dawley rats were isolated and stripped of fat and the 
endothelium in Hanks balanced solution (HBSS), pH 7.4. To remove the 
adventitia, the aorta was cleaned and was placed into a Dulbecco's 
Modified Essential Medium (DMEM) solution containing 3.5 mg/ml 
collagenase (Sigma/C9891-500 mg) in TNS (Soybean Trypsin Inhibitor in 
MEM with 0.1% FBS, Roche, Dublin/Ireland) for 20 min at 37°C to loosen 
the adventitia before complete removal using a fine-forceps under a 
dissecting microscope. The resulting media was finely sliced and placed 
on tissue culture plates. The explanted cells were then grown in 
maintenance media containing DMEM (ATCC-30-2002), 1% FBS (ATCC-
SCRR-30-2020), 1X B-27 supplement (Gibco A17504-044), 1X N2 
supplement (Gibco A13707-01), 2% chick embryo extract (Seralab 
CE-650-J), 20 mg/ml of rmFGF (3139-FB-025; Bio-techne), 10mM 
retanoic acid (R2625) and 500μM β-mercaptoethanol (M7522; Sigma).  
2.2.3 Cell Line Culture
Rat and mouse mesenchymal stem cells (Gibco S1601-01, Gibco 
S1502-01 respectively) and mouse C3H 10T ½ cells (ATCC-CCL-226) 
cells were purchased and cultured as per the manufacturers instructions. 
Cells were grown in alpha MEM + Glutamax and Eagles Modified MEM 
respectively with 10% stem cell qualified FBS  (ATCC-SCRR-30-2020) 
and 1% penicillin/streptavadin (Sigma; P4333-100 ml). Cells were 
subcultured by washing three times with PBS, incubating the adherent 
cells with Triple E Select (Thermofisher; 12563029) for 3 minutes. The 
Triple E was neutralised with serum containing media and the cells were 
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centrifuged at 400 x g. The resulting pellet was resuspended in fresh 
medium and seeded based on experimental requirements.
2.2.4 Carotid Artery Ligation
Sham and ligated carotids from the same C57/BL6 mouse were obtained 
from a collaborator, Prof Redmond at the University of Rochester (NY). 
Briefly, cervical incisions were made to anaesthetised mice and the left 
carotid artery was ligated using a 6-0 silk structure near the carotid 
bifurcation. The sutures were closed and the animals allowed recover. 
Vessels were harvested 14 days post-ligation. The morphometric analysis 
was carried out in collaboration with Prof Eileen M Redmond at the 
University of Rochester, Rochester NY.
2.2.5 Stem Cell Myogenic Differentiation 
To induce osteogenic differentiation, rat mesenchymal stem cells were 
grown in StemPro Osteogenesis medium (Thermo-fisher A1007201) for 
21 days as per the manufacturers protocol. Myogenic differentiation was 
achieved with TGF-β1 (R&D 7666-MB-05) (2-10ng/ml) for 2-14 days or 
Jagged1-1Fc (2 μg/ml) (R&D, 599-JG-100). The dose chosen to treat 
cells was decided by a trial and error approach where the least dose that 
elicited a significant effect was used for all similar experiments. The time 
chosen for myogenic differentiation was dependent on the process 
intended to up regulate whereby promotor activity takes the least time 
and protein expression takes the most time.
To immobilise Jag-1 to a cell culture plate, each well was first immobilised 
with protein G (MSC 21193) (20 μg/ml) overnight at 4˚C. Following the 
overnight incubation, the wells were washed three times with sterile PBS 
and blocked with 1% BSA for 2 hours at room temperature. This was then 
removed and  the wells washed as before before addition of 2 μg/ml 
control IgG-Fc (R&D, 110-HG-100) or Jag-1-Fc and further incubation for 
2 hours. This solution was removed and the wells washed again before 
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cells were seeded at a density of 20,000 cells/well directly onto the 
treated plates and incubated at 37˚C for 1-7 days.
2.2.6 RNA Interference and gene manipulation
The Mirus TransIT-X2 Dynamic Delivery System was used for all siRNA 
transfections and was carried out as per the manufacturers instructions. 
Briefly, approximately 20,000 cells/well were seeded on 6-well plates 24 
hours prior to transfection. On the day of transfection, 25 nm of siRNA 
was added to 250μL of opti-MEM I reduced serum media and 7.5μL of 
TransIT-X2. This was left for 25 minutes to allow complexes to form. The 
complexes were then added and incubated for up to 72 hours before RNA 
was isolated for gene expression analysis and 7 days for LiPhos 
measurements.
2.2.7 Pharmacological Inhibition of GSK3β activity
Inhibitors of GSK3β: SB-216763 (S3442), Bio (B1686) and 1-
Azakenpaullone (1-Aza) (A3734) were compared for their inhibitory 
actions.
2.3 Living Photonics (LiPhos) of individual cells
LiPhos platforms are biophotonic tools deployed to interrogate individual 
cells using microfluidics and determine their photonic fingerprint (PIN) to 
broadband light.
2.3.1 Biochip Preparation and Microfluidic Testing: Biochips were 
prepared as described previously [Burger 2015]. Briefly, the biochip was 
fabricated in PDMS (Sylgard 184, Dow Corning GmbH, Germany) in pre-
casted PDMS moulds that were surface micromachined using SU8-3025 
(Microchem, USA) to include the V-cup array (47 x 24 cups) and 
reservoirs. The middle chip supporting layer consisted of poly(methyl 
meth-acrylate) (PMMA) with a thin layer of pressure sensitive adhesive 
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(PSA), this layer was defined using a laser cutter (Epilog Zing Laser, 
Epilog USA) and a microscope slide was bound to the PSA. The chip was 
treated by air plasma (1000 mTorr) for 5 minutes and assembled.
2.3.2 Biochip Sample Loading The device was placed in a vacuum 
prior to introducing the liquids for a minimum of 30 minutes ensure 
complete and bubble-free filling. Other than the fresh aortas that were 
already in suspension and the pre-fixed carotids in suspension, all cells 
that had finished their treatments were washed three times and then 
trypsinized with trypLE Select (ThermoFisher 12563029). The trypLE was 
inhibited with media and resulting cell suspension centrifuged and 
washed twice with media. Cells (including the digested aorta) were then 
fixed in suspension with 3.7% formaldehyde in media after which time 
they were washed twice with media and resuspended in the appropriate 
media. The PDMS chips were then primed in the respective media and 
the cells in suspension were added to the chips. In all cases, the 
sedimentation in absence of flow led to significantly increased occupancy 
of the V-cups (≥ 95%) compared to common, flow-driven methods.
 
Figure 2.1 Liphos method. Methods for loading, capturing and analysing 
cells by the centrifugal microfluidic method. (a) microfluidic chips on the 
spin stand for centrifugation; (b) components of the microfluidic chip and 
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in particularly the cell chambers and v-cup array; (c) set up of the 
microscope and lasers for auto-fluorescent analysis of cells.
2.3.3 Auto-fluorescence imaging Cells captured in the biochip were 
imaged with an Olympus IX81 motorised inverted microscope with an 
attached Hamamatsu ORCA - ER digital camera C4742-80 using a 10x 
and 20x objective. Excitation was performed to allow both broadband light 
( λ = 360 - 800 nm) and emission wavelengths were 465 ± 20 nm, 530 ± 
20 nm, 565 ± 20 nm, 630 ± 20 nm and 670± 20 nm.
2.3.4 Data Analysis LiPhos: Images were analysed by the open-source 
software ImageJ (version 1.46r). Cell signal intensity was quantified by 
'region of interest' (ROI) analysis. Each signal was divided by it’s 
respective background signal to give fold signal over background. All 
results are reported as mean values ± standard errors (where s = 
standard deviation and n = number of cells). Statistical differences were 
analysed by t-tests or Wilcoxon t-tests depending on the normality of the 
data and probability levels below 5% were considered significant.
2.4 FTIR & Raman Spectroscopy
2.4.1 Sample preparation for Spectroscopic analysis.
 For both FTIR and Raman spectroscopic analyses, cells were seeded on 
calcium fluoride slides in 6 well plates at approximately 10,000 cells/well. 
After 24 hours, the medium was changed and the cells were treated in 
the respective maintenance or myogenic differentiation media for 14 d 
before the cells were washed three times with PBS and formalin fixed for 
15 minutes. After fixation, the slides were washed with PBS and placed 
briefly in distilled water. The slides were left to air dry before recording 
spectra.
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2.4.2 FTIR Spectroscopy.
IR absorption measurements were carried out using a Perkin Elmer 
Spotlight 400N FTIR imaging system. The system is also equipped with 
an AutoImage microscope system operating with a x 40 Cassegrain 
objective, and can operate in transmission or reflection mode. FTIR 
images were acquired in transmission mode with 10 scans of a 150 X 
150μm area of the slide. Individual spectra are acquired with a liquid 
nitrogen cooled mercury cadmium telluride (MCT-A) line detector of pixel 
size 6.25 μm x 6.25 μm at a spectral resolution of 4 cm-1, interferometer 
speed of 1.0 cm/s and the useable spectral range is restricted to 
1000-4000 cm-1. Background measurements were acquired on a region 
with no tissue with 120 scans per pixel whereas 32 scans per pixel were 
recorded from the sample.
Figure 2.2 Raw FTIR and Raman dataset. Sample raw read outs from 
FTIR and spectral read out from Raman. (a) Sample IR heat map from 
FTIR before undergoing spectral processing. (b) Sample Raman spectra 
that has been meaned and normalised.
2.4.3 Raman Spectroscopy. 
Raman spectra were recorded using a custom-built Raman micro-
spectroscopy system (Kerr et al., 2016a; Kerr et al., 2016b). Briefly, this 
system employs a 150 mW laser with a wavelength of 532 nm (Laser 
Quantum, Torus), spectrograph (Andor, Shamrock 500) operating with a 
600 lines/mm grating, and a CCD camera (Andor; DU420A-BR-DD) 
cooled to −80°C. A 50x microscope objective, with numerical aperture of 
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0.8 (Olympus, UMPlanFl), was used to image the spectral irradiance to a 
100 μm confocal aperture, which isolates the signal from the cell nucleus, 
and minimises background noise from the sample substrate, as well as 
from optical elements in the system. The system provides a spatial 
resolution of 3 μm from the cell nucleus. A long pass filter (Semrock, 
LP03-532RU-25) and a dichroic beamsplitter (Semrock, LPD-01-532RS) 
are also used to filter the laser wavelength from reaching the 
spectrograph, while transmitting the longer Raman scattered 
wavelengths. A dichroic short pass filter (Edmund Optics, 69-202) permits 
imaging of the sample to a digital camera (Basler, acA2000-340km). All 
spectra were recorded using the Andor Solis software system and were 
recorded within the 400-1800 cm-1 range with an acquisition time of 30s 
each. Two spectra were recorded from the same location within the 
nucleus of each cell to allow for cosmic ray removal. The system was 
wavelength calibrated using a Neon lamp as described previously 
(Hutsebaut et al., 2005) with further design considerations for a custom-
built Raman micro-spectroscopy system, as outlined previously (Kiselev 
et al., 2016).
2.4.4 Data Processing and Analysis. 
The different data pre-processing and analysis steps were performed 
using Matlab (Mathworks, USA). For FTIR data, the resonant Mie 
scattering correction algorithm (RMieS-EMSC) was employed to remove 
scattering effects from FTIR spectra as has been successfully 
demonstrated in a number of studies (Hughes et al., 2010). The algorithm 
utilises a scatter-free reference spectrum (ZZRef), to correct the raw 
cellular spectrum (Raw). In the current work, a Matrigel (a commercial 
artificial extra cellular matrix) spectrum was employed as reference. Other 
variable parameters for the algorithm included the number of iterations 
(20), the number of principle components (Byrne et al., 2016), the Mie 
theory option with Resonant Mie (RMieS) correction, a lower range of the 
scattering particle radius (2 μm), an upper range of the scattering particle 
radius (8 μm), lower range of scattering particle average refractive index 
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(1.1), and upper range of scattering particle average refractive index 
(1.5). For Raman data, cosmic ray removal is followed by application of 
an extended multiplicative signal correction (EMSC) algorithm as 
described in detail elsewhere (Kerr et al., 2016a). This algorithm 
computes a background signal in the form of an N-order polynomial to 
remove the baseline signal that results from the cells auto-fluorescence 
or from Mie scattering due to the cell morphology. The background signal 
from the substrate itself is minimised by depositing the cells on CaF2 
Raman grade substrates which are known to produce a relatively flat 
Raman spectrum in the fingerprint region (Kerr et al.,2016a; Kerr et al., 
2015). For this study, a 5th order polynomial was used in the EMSC 
subtraction algorithm for all datasets, and similar results were found for 
n=3. Following the EMSC correction all spectra were smoothed with a 
Savitzky-Golay filter (k = 3; w = 7) to reduce noise.
After pre-processing, Principal Components Analysis (PCA) was 
employed as an unsupervised multivariate analysis tool to differentiate 
the data recorded from different cell phenotypes. PCA allows the 
reduction of the number of variables in a multidimensional dataset, the 
order of the PCs denoting their importance in the dataset, whereby PC1 
describes the highest amount of variation (Ling et al., 2002; Romero et al. 
2013). The combination of PCA-LDA has been demonstrated to be a 
powerful classification technique in vibrational spectroscopic analysis of 
cells and tissues (Byrne et al., 2016). While PCA identifies differences 
between the data sets, Linear Discriminant Analysis (LDA) maximises 
these differences so as to group similar spectral sets. PCA performs a 
feature reduction of the data and LDA classifies the data into one of two 
or more classes. Thus, if a group of spectra have a similar correlation to 
the shape defined by PC1 and that defined by PC2; they are identified as 
the same class. The loading of the PCs provides valuable information on 
the origin of the differentiation, in this case spectral signatures of 
biochemical differences. LDA was then performed on each of the 
datasets scores independently and a 10-fold cross validation was 
performed to produce confusion matrices. In the case of FTIR, LDA 
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accuracy was calculated using a 10-fold cross validation on increasing 
numbers of latent variables (PC scores) for the classification of all cell 
phenotypes. The classification which resulted in the maximum accuracy 
while keeping the number of latent variables to a minimum was chosen 
for all successive models. In the case of the classification of all cell 
phenotypes, from a plot of accuracy as a function of increasing number of 
latent variables, the maximum accuracy was found when 4 principal 
components were used in the classification. Further addition of principal 
components only increased the complexity of the model without further 
improving the performance. In the case of Raman, LDA accuracy was 
determined using a leave one out procedure, utilising the number of 
principal components that accounted for at least 85% of the total variance 
in the dataset.
2.5  Cell Characterisation and Analytical Techniques
2.5.1 Immunocytochemistry
Cells were grown and treated with inductive stimuli and fixed with 3.6% 
formaldehyde for 15 mins. The cells were then washed three times with 
PBS and permeabilised with 0.1% Triton-X100. Cells were blocked with 
5% bovine serum albumin (BSA) in PBS for 1 hour at room temperature 
before they were incubated overnight at 4°C with the primary antibody at 
the appropriate dilution (anti-CD44, Abcam ab24504 at a 1:100 dilution, 
anti-calponin1, Abcam ab46794 at a 1:200 dilution, anti-SM-MHC 
(Myh11), Santa Cruz Sc-79079 at a dilution of 1:100, anti-nestin Abcam 
ab11306 at 1:100 and anti-Sox10 R&D MAB2864 at a 1:100 dilution). The 
cells were then washed three times and incubated with the corresponding 
secondary antibody (Biosciences, anti-goat A-11055, anti-rabbit A11008, 
anti-mouse A11030) at a dilution of 1:1000 for one hour at room 
temperature. Cells were washed twice with PBS containing 0.1% tween 
and cell nuclei were stained using DAPI: PBS (D9542-5 mg Sigma) 
(dilution 1:1000) at room temperature for 15 min. For each secondary 
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antibody used, a control was prepared with no primary antibody to assess 
nonspecific binding of the secondary antibody to cells. 
An Olympus CK30 microscope with Cell^F software was used to capture 
images. A threshold of background staining was defined using the 
secondary antibody control and exposure rates were limited in order to 
rule out false positives. At least five images from the Olympus CK30 
microscopy per experimental group (minimum n=3) were analysed using 
ImageJ software as previously described (Kennedy et al., 2014a; 
Kennedy et al., 2014b).
Figure 2.3 Sample immunocytochemical staining. Sample 
immunocytochemical read out with DAPI staining (blue) and calponin1 
(CNN1)/alexafluor488 staining (green).
2.5.2 RNA & DNA isolation
Harvested cultured cells were centrifuged at 400 rcf for 5 minutes to 
produce a pellet. The RNA/DNA was then isolated using the Magcore 
HF16 Plus system and using the Magcore Total RNA Cultured Cells Kit 
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610 (MRC-02SP; MSC) for RNA and Magcore Cultured Cells DNA Kit 110 
for DNA (MCC-01SP; MSC). RNA was extracted from tissue samples by 
crushing the tissue using a pestle and mortar in a small quantity of liquid 
nitrogen before carrying out the Trisure (Bioline, Bio-38032) protocol.
2.5.3 Quantitative Realtime qRT-PCR
Realtime qRT-PCR: Quantitative real-time RT-PCR was performed using 
the Rotor Gene (RG-3000, Corbett Research) with either the Quantitect™ 
Primer assay system using Quantitect mouse and rat primers (Qiagen, 
Hilden, Germany) or the BioLine Sensifast No Rox kit (MSC, Bio-72005) 
with PrimeTime® IDT primers. The sequence of the primers were as 
follows:
Table 2.1 IDT PrimeTime® primer sequences for q-RT-PCR.
Figure 2.4 Sample cycling amplification curve: HPRT and Myh11 for IgG-
Fc versus Jag-1-Fc.
Gene SequencemHPRT 5’-­‐GGC	  TAT	  AAG	  TTC	  TTT	  GCT	  GAC	  CTG	  -­‐3’Myh11	  Transcript	  1 5’-­‐GCA	  GTG	  AGC	  TCT	  CAG	  TCA	  TC-­‐3’Calponin	  1 5’-­‐CTC	  AGC	  CCT	  CCT	  CAA	  TGA	  AGG-­‐3’Hey1 5’-­‐CAC	  TTC	  TGT	  CAA	  GCA	  CTC	  TCG-­‐3’HeyL 5’-­‐ATT	  CCC	  GAA	  ACC	  CAA	  TAC	  TCC-­‐3’
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2.5.4 Chromatin Immunoprecipitation Assay (ChIP Assay).
Briefly, 5 × 106 cells were cross-linked and used for each 
immunoprecipitation. DNA was sheared to 500-1000 bp by sonication. 
Protein G Dynabeads (Invitrogen, BioSciences Ireland) were used to 
pulldown the antibody-antigen complexes immunoprecipitated with 
antibodies against H3K4me2 and H3K27me3 (Cell Signalling, Leiden, 
The Netherlands) using the MAGnify™ Chromatin Immunoprecipitation 
System (InVitrogen, Bioscience Ireland, cat no 49-2024) according to the 
manufacturer's instruction. IgG was also included as a negative control. 
Immunoprecipitated DNA was extracted with phenol-chloroform, ethanol 
precipitated and eluted. Recovered DNA was analysed by qRT-PCR. 
Primers spanning the promoter regions (within 2500 bp of transcription 
start site) of SM-MHC (Myh11) were used to amplify input and 
immunoprecipitated DNA. Primers were designed to span a CArG (CC(A/
T)6GG) element and sequences were (For - 5' - CCC TCC CTT TGC TAA 
ACA CA - 3' and Rev- 5' - CCA GAT CCT GGG TCC TTA CA - 3'). All 
samples were performed in triplicate, from at least three independent 
experiments and data were normalised to % input. This work was carried 
out in collaboration with Roya Hakimjavadi, Mariana Di Luca and Denise 
Burtenshaw (DCU).
2.5.5 Myh11-promoter luciferase assay. 
The cells were maintained in their respective maintenance growth media 
before plasmid transfection was performed using TransIT-X2® Dynamic 
Delivery System (Mirus Bio, Madison, WI) in OptiMEM according to the 
manufacturer's instruction. For the luciferase assay, 1 μg of the Myh11 
reporter plasmid (Myh11-GLuc, GeneCopoeia, Inc. Cat No; MPRM16957-
PG02) and 0.1 μg of Renilla reporter plasmid (Promega, Madison, WI) 
were transiently transfected into cells for 24 h. The total amount of 
plasmid DNA among samples was kept equal by adding corresponding 
control vector plasmids. The promoter was activated following treatment 
with TGF-β1 (2ng/ml) before dual luciferase assays (Promega) were 
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conducted 24 h after treatment. Luciferase reporter activities were 
determined by the Gaussia luciferase activities normalised to the activity 
of internal control Renilla luciferase activities using the dual luciferase 
assay system described by the manufacturer (Promega, Madison, WI). All 
assays were performed in triplicate in collaboration with Gillian Casey 
(TCD).
2.5.6 SDS- Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Cells were treated either in T75 Flasks or seeded at 10,000 cells/well in 6 
well plates. Cells were scraped in media and spun down @ 1500rpm for 5 
minutes. The pellet was resuspended in 100μl RIPA buffer (Sigma) 
containing 1μl protease inhibitor cocktail and phosstop (Roche). This was 
kept at -20°C overnight. The lysed protein was then thawed and 
centrifuged at 8000rpm for 10 minutes. The soluble fraction (supernatant) 
was taken and the protein concentration was determined using the BCA 
Assay (Pierce). 50 parts of BCA Assay Part A was mixed with 1 part BCA 
Assay part B. 40μl of this was then added to 5μl of the protein and 
incubated at 37°C for 30 minutes. The absorbances were read using the 
Tecan Safire II. The protein was then diluted accordingly in RIPA buffer. 
Figure 2.5. Sample BCA Assay. Sample BCA Assay plot of rMVSC 
protein concentration (μg/ml) versus absorbance readings at 562 nm.
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Samples were prepared using 4X Laemelli Buffer with 3 parts protein and 
1 part LB containing 10% β-mercaptoethanol and this was sonicated for 
10 seconds at 10% amplitude using a probe sonicator.
Gels were prepared as per the following table:
Table 2.2. SDS-Page Gel Components. Components and 
concentrations used to prepare 12.5% and 7.5% bis-acrylamide gels and 
stacking gels.
Running the Gel
Gels were pre-ran for 30 minutes at 15mA per gel. The running buffer was 
made up at a 5X concentration as follows:
Table 2.3. Running buffer components. All components and quantities 
to prepare a 1L sample of running buffer.
This was diluted to 1X accordingly. Gels were then ran at 15mA per gel. 
Pre-stained protein markers (Fischer) were also ran with the proteins. 
Empty wells were loaded with laemelli buffer to balance the gel.
Component Stacking	  Gel 12.5%	  Gel 7.5%	  Gel1.5M	  Tris-­‐HCl -­‐-­‐-­‐-­‐ 1.875	  ml 1.875	  ml0.5M	  Tris-­‐HCl 625ul -­‐-­‐-­‐-­‐ -­‐-­‐-­‐-­‐10%	  SDS 25ul 75ul 75uldH2O 1.54	  ml 2.385	  ml 3.63375	  ml10%	  APS 12.5ul 37.5ul 37.5ulBis-­‐Acrylamide	  30% 325ul 3.12375	  ml 1.875	  mlTEMED 10ul 15ul 15ul
Component QuantityTris	  Base	  (Trizma	  base	  sigma) 15.1gGlycine 95.4g10%w/v	  SDS 50	  mldH2O 950	  ml
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2.5.7 Western Immunoblotting.
The MSC G-Blotter system was used to transfer proteins. Nitrocellulose 
membranes were used for the transfer. Membranes were immersed in 
Ponceau stain (except the membranes with phosphoproteins) to ensure 
efficient transfer has ensued.
Membranes were blocked in 5% w/v BSA in TBS containing 0.1% Tween 
for 1 hour at room temperature. The membranes were then washed 3 
times with TBST for 5 minutes each time.  The membranes were then 
incubated with the optimised amount of primary antibody overnight at 
4°C. . The total GSK-3β XP® antibody and the phospho-GSK3β-(ser9) 
antibody were diluted at 1:500 in blocking buffer. The primary antibody is 
washed off three times again with TBST for 5 minutes each time. The 
membranes are then incubated in secondary antibody (1:1000) 
conjugated to HRP for 1 hour at room  temperature. This is washed again 
as before. The bands are developed using TMB (sigma). 
Figure 2.6 Sample Ponceau stain. Ponceau S stain of mSMC protein 
transferred onto nitrocellulose membrane for Western Blot analysis.
2.5.8 Data Analysis:  
Protein bands were plotted using the gel analysis software in ImageJ. 
Peaks for each protein band were generated by ImageJ and the areas of 
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each peak were quantified so that each protein band could be directly 
compared to one another.
Figure 2.7 Sample western blot densitometry peak. Sample western 
blot band and resulting densitometry peak and peak area generated 
using the ImageJ software.
2.6 Nanoparticle Formulation and Analysis
2.6.1 Nanoparticle preparation:
Blank and drug-loaded polymeric magnetic nanoparticles were developed 
in a technique adapted from McCall et al. (2013).  Briefly,  22.5 mg of 
poly(lactic-co-glycolic acid) (PLGA) (P2066) was weighed out and placed 
in a 13mm X 100mm test tube. The crystals were dissolved in 225μL  of 
dichloromethane (650463) and the top of the tube was sealed with 
parafilm. The level of solvent was marked and the polymer was left to 
dissolve overnight. Meanwhile, 200μL of MNPs (700312) were aliquoted 
into a 13mm X 100mm test tube and placed under nitrogen gas overnight 
to evaporate off the toluene. On the day of formulation, or the day 
previously, 10 ml of 0.3% PVA (363138) and 450μL of 5% PVA in dH2O 
were prepared and boiled at 90°C until dissolved (approximately 45 
minuets). The 10 ml 0.3% PVA solution was placed in a 50 ml conical 
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flask and the 5% solution placed in a 16mm X 150mm test tube. The 
dissolved PLGA in dichloromethane was added to the dried MNPs to 
dissolve them in the polymer complex. This was vortexes for 10 seconds 
to ensure mixing. In the drug-loaded samples, the drug was added at the 
desired concentration at this point to the polymer:Fe3O4-NP mix and 
vortexes for another 10 seconds. The PLGA:DCM;Fe3O4NP:Drug solution 
was added drop wise to the 5% PVA whilst under vortex. The solution 
was vortexed for a further 15 seconds and typically an emulsion would 
form. The emulsion was then sonicated on ice at a 40% amplitude for 10 
seconds (X3) with a 5 second interval in between each sonication. For 
the fluorescently mAB-loaded PLGA-MNPs or fluorescently tagged siRNA 
PLGA-MNPs, the fluorescent agents were added at this step. The 
resulting emulsion was then poured to the 0.3% PVA and stirred over 
night to allow the nanoparticles to harden (McCall et al. 2013).
Figure 2.8 Sample MNP image. Representative image of freshly 
formulated 1-Aza-loaded NPs and blank NPs.
2.6.2 Nanoparticle Collection
Nanoparticle solutions were centrifuged with the Sorvall RC 5B Plus 
centrifuge with the Sorvall SA-600 rotor at 17000g for one hour. The 
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supernatant was collected and kept for HPLC analysis. The nanoparticle 
pellet was then re-suspended in 10 ml dH2O, if the nanoparticles 
aggregated upon re-suspension the solution was sonicated twice for 30 
seconds each at 20% to break up the aggregates, if any. The nanoparticle 
solution was then aliquoted out into 10 1 ml aliquots which were 
centrifuged again at 17000g for 1 hour. The supernatant was kept for 
analysis. The nanoparticle pellets were then placed in the "DNA Speed 
Vac DNA110" for 1-2 hours to remove excess liquid and then stored at 
-80°C.
2.6.3 Analysis of Nanoparticles:
2.6.4 High Performance Liquid Chromatography (HPLC)
The Agilent 1100 HPLC system was used in conjunction with the silica 
packed Supelco Discovery C18 Column (568523-U) to separate the 
molecules in the supernatant samples. The Supelco Discovery C18 
column contains porous silica beads packed inside to separate the 
molecules based on their size. The smaller the molecules, the more they 
will penetrate the pours and interact with the column and therefore the 
slower it will elute from the column to be detected. The time at which it 
takes for a molecule to be eluted and detected from the column is called 
the 'retention time' and varies based on the molecule size, this is referred 
to as size exclusion chromatography.
High pressure pumps transport the mobile phase through the system and 
pump meters regulate the flow rate, usually in millilitres per minute (ml/
min). The mobile phase typically consisted of either 50:50 or 70:30 
acetonitrile:dH2O (Sigma 34851) depending on the hydrophobicity of the 
drug. The flow rate was typically 0.5 ml/min to 1 ml/min. An injector takes 
the sample  to be analysed and injects it into the mobile phase stream to 
be separated by the column. Once it passes through the column it passes 
by the detector , usually a UV or fluorescence detector, which sends an 
electrical signal to the computer to generate a chromatogram. A 
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wavelength scan was performed for each drug on a Tecan NanoQuant 
Infinite M200 to determine the optimum wavelength for detection of the 
drug by HPLC.  
Figure 2.9 HPLC Chromatogram Example chromatogram for 1-Aza 
(5μM) as it appears  by HPLC at 336 nm.
2.6.5 Drug Incorporation Efficiency
To determine the incorporation efficiency of the drugs into the MNPs, the 
previously collected supernatants were subjected to HPLC. The peak 
area of the drug was compared to a standard curve performed on the 
same day to determine the concentration of drug from the supernatant. 
The concentration of drug detected in the supernatant was then 
subtracted from the theoretical drug loaded to give the concentration of 
drug incorporated. The following equation was then used to calculate the 
incorporation efficiency:
(Concentration of drug incorporated/Theoretical drug loaded) X 100 = % 
of drug incorporated.
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2.6.6 Drug release studies: 
To study the release of drug from the nanoparticles, the stored 
nanoparticle pellets were re-suspended in 1 ml of dH2O and were left for 
up to 14 days at room temperature and 37°C in the presence or absence 
of pulsed magnetisation (30s on, 10s off for 5 minutes) from the external 
Dextran magnet (Dexter Magnetic Technologies, 2501008). Pulsed 
magnetisation has previously been shown to increase cellular uptake of 
nanoparticles (Min et al., 2013) and a similar study performed with PTX-
PLGA-MNPs found the short magnetisation time of 5 minutes sufficient to 
inhibit restenosis in vivo (Chorny et al., 2010). The nanoparticles were 
centrifuged at 17000 x g after 24hrs, 48hrs, 72hrs, 7 days and 14 days in 
the various environmental conditions and the supernatants were analysed 
by HPLC for the presence of drug in the supernatant. The percentage of 
drug released at each time point was calculated as follows:
(Concentration of drug in supernatant/concentration of drug incorporated) 
X 100 = % of drug released from nanoparticle.
Total percentage drug released at each time was simply calculated as the 
percentage released at that time point plus previous time points.
2.6.7 Dynamic Light Scattering: 
DLS (Malvern Zetasizer Nano) was performed to determine the size and 
colloidal stability of the nanoparticles. Dynamic Light Scattering is a laser 
based system which sends a laser beam through a polariser to the 
sample and measuring the scatter light to yield information about 
molecules in a solution. 100μL of nanoparticles were added to 0.9 ml of 
ultrapure water and filtered through a 0.45μM disposable plastic cuvette 
for size and disposable folded capillary cuvette for zeta potential and 
covered with parafilm. The automated protocol for magnetite in water was 
followed on the Zetasizer software. 12 reads at 30 seconds each were 
performed for each sample in triplicate.
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Figure 2.10 DLS Sizing Peaks Sample DLS triplicate reading of blank 
nanoparticles.
2.6.8 TEM and FeSEM 
A 100μL of nanoparticles was pipetted onto carbon coated copper TEM 
grids. TEM images were recorded in the University of Limerick and Fe-
SEM (Hitachi S5500 FeSEM) images were recorded  in the NRF DCU.
Figure 2.11 TEM image. Representative TEM image of blank 
nanoparticles. 
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2.6.9 Statistical Analysis: 
All biochemical analysis experiments and autofluorescence experiments 
were performed in triplicate and data are presented as mean ± SEM for at 
least three independent runs. Statistical analysis was performed with 
Prism v6 software package using t-test for parametric data or a Wilcoxon 
Signed Rank test for non-parametric data.
Raman and FTIR data were analysed as described above (2.2.4) and 
statistical analysis was performed using the leave one out statistical 
method whereby one spectra from each population was left out of the 
analysis and later compared to mean spectra for percentage accuracy.
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Chapter 3
Photonic Discrimination of Vascular Stem cells, their 
myogenic progeny and healthy SMC and arteriosclerotic 
(diseased) SMCs-like cells by centrifugal microfluidics and 
label free autofluorescence
imaging.
 91
3.1.1  Introduction
The arterial blood vessel consists of three layers of cells; the outer 
adventitial layer that houses fibroblasts, connective tissue, stem cells and 
perivascular nerves; the medial middle layer that predominantly contains 
vascular smooth muscle cells (SMCs) and some resident vascular stem 
cells and the intimal inner most monolayer of cells called the endothelium. 
A hallmark of CVD is neointimal thickening of the artery due to SMC 
accumulation leading to the obstruction of blood flow that can result in a 
heart attack or stroke (Hoglund et al., 2010). The source of these SMCs 
has been controversial with either de-differentiated SMCs (Nguyen et al. 
2013., Alexander et al., 2012) or progenitor stem cell-derived SMCs (Tang 
et al., 2013; Tang et al., 2012) playing a putative role. Importantly, 
progenitor stem cells can develop into differentiated vascular smooth 
muscle cells (SMCs) and have been shown to originate from both the 
vasculature itself and/or the bone marrow (BM) (Wang, 2015). TGF-β1 1 
is an important multifunctional cytokine that regulates the promotion of 
stem cell differentiation to SMCs (Kurpinski et al., 2010). It is proposed 
that vascular stem cells become activated following injury, transition to 
SMC and subsequently dictate, in part, the vascular remodelling events 
that occur leading to vascular disease progression (Wang, 2015). Their 
role and identification within the vessel wall highlights a potential new 
diagnostic target for CVD (Majesky et al., 2011; Tang et al., 2012; Wigren 
et al., 2016). 
Label-free technologies have recently attracted significant interest for 
being both sensitive and quantitative multi-parameter analysis tools to 
examine biological systems. Several different classes of label-free 
sensors are currently being developed for bio-analytical applications that 
include plasmonic detection, photonic detection, electrical detection and 
mechanical sensors too (Qavi et al., 2009). 
 92
Every material has distinct photonic properties depending on its 
composition and morphology. The innate optical response comprises of 
scattering, absorbance and auto-fluorescence signals. The combination 
of several fluorescence and/or absorbance bands together with scattering 
bands form a specific pattern which is unique for each particular cell 
(photonic fingerprint).  (Yun & Kwok, 2017; Kinnunan et al., 2015). Label-
free optical technologies have been developed with highly efficient cell-to-
light coupling and in combination with microfluidics has been successfully 
employed to measure the real-time response of individual cells in a 
population (Nwankire et al., 2015; Jahnke et al., 2013; Yun et al., 2013). 
3.1.2 Objectives:  
The main aims of this chapter were:-
1. To determine the AF signature of individual differentiated medial 
vascular smooth muscle cells (dSMCs) isolated from the mouse 
carotid artery and differentiated medial vascular dSMCs isolated 
from the mouse aorta.
2. To determine whether differences exist between the AF signature 
of normal (healthy) medial differentiated SMCs from carotid and 
aorta and medial and neointimal cells (arteriosclerotic) from 
carotid artery following partial ligation.
3. To compare the AF signature of individual undifferentiated bone 
marrow derived mouse mesenchymal stem cells (mMSCs) and 
their respective myogenic progeny following treatment with TGF-
β1 or the Notch ligand, Jag-1 for up to 7-28 days in culture.
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3.1.3. Strategy 
The first main objective of this chapter was to determine whether 
photonics can be used as a tool to identify and discriminate healthy 
medial differentiated SMCs from diseased medial and intimal SMC-like 
cells using a partial carotid artery injury model in mice (Korshunov et al., 
2003). In order to achieve this, ligated and sham carotid arteries were 
cleaned, de-endothelialised (by gentle rubbing) and the adventitia 
separated from medial layer before SMCs were enzymatically digested 
and loaded onto PDMS chips and centrifuged into v-cup arrays for single-
cell analysis of AF signatures (see Chapter 2.3). The medial SMCs from 
carotid artery were also compared to medial cells from fresh aorta 
following similar de-endothelialisation and removal of fat and adventitia. 
In a similar manner, individual undifferentiated mesenchymal stem cells 
(mMSCs) and their myogenic progeny following induction with medial 
supplemented TGF-β1 (10ng/ml) or Jag-1 (2 μg/ml) for 7 days (see 
Chapter 2.2.5) were loaded onto PDMS chips and centrifuged into v-cup 
arrays for single-cell analysis of AF signatures (see Chapter 2.3). In order 
to confirm that any differences in the AF signatures were independent of 
the inductive stimulus and dependent on myogenic differentiation, AF 
signatures were assessed in stem cells that were treated with two 
dissimilar myogenic inductive stimuli (TGF-β1 or Jag-1) and were also 
compared to a RAMOS β-cell line. Both murine bone-marrow derived 
mesenchymal stem cells (mMSCs), multipotent embryonic adventitial 
cells (C3H-10T1/2 cells) and rat multipotent resident vascular stem cells 
(rMVSCs) derived from rat aorta were treated with TGF-β1 (10ng/ml) or 
Jag-1 (2 μg/ml) for 7 days to induce myogenic differentiation before 
individual cells were captured and analysed. 
Hence, the altered light scattering properties of vascular smooth muscle 
cells from healthy and arteriosclerotic diseased (following carotid artery 
ligation) vessels were compared to identify a novel  AF photonic signature 
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associated with intimal medial thickening (IMT). Further to this, the AF 
signatures of undifferentiated stem cells and their myogenic progeny 
were compared to assess for differences and determine whether these 
myogenic progeny shared any spectral similarity with SMC-like cells 
dissociated from remodelled (injured) carotid arteries.
In all analysis, significance testing was carried out using the Prism 
software. Statistical tests were chosen based on the normal distribution of 
the data with sets of data with normal distribution analysed by paired or 
un-paired t-tests and groups that were not normally distributed analysed 
by paired non-parametric Wilcoxon ranked t-tests.
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3.2 Results
3.2.1 Photonic Auto-Fluorescence (AF) analysis of individual 
vascular cells from diseased and healthy vessels.
Carotid arteries were excised from C57/Bl6 mice 14 days after sham or 
partial ligation as described in Chapter 2.2.4. The excised vessels were 
cleaned, sectioned and H&E stained to determine the volume of the 
lumen, medial and adventitial layers, respectively. The sections were 
further probed with anti-α-actin (SMA) and anti-Myh11 antibodies to 
determine the  contribution of α-actin and Myh11 positive cells, 
respectively to the neo-intimal layer. Carotids were prepared and stained 
by Eileen Redmond, Rochester, NY. The carotid cells, ligated and the 
matching sham, were also enzymatically digested, loaded onto 
microfluidic chips for capture, and analysed for their auto-fluorescence 
(AF) signature to broadband light, as described in Chapter 2.3. 
H&E staining shows the medial and intimal layer of the ligated vessel 
significantly increased in diameter with a concomitant decrease in the 
lumen volume compared to sham controls [Figure 3.1(a,b)]. 
Immunohistological staining with α-actin and Myh11 showed the presence 
of α-actin positive cells in the media of the aorta and uninjured sham 
vessels and Myh11 in the uninjured media of the sham vessel. The intimal 
layer of the ligated vessel had decreased Myh11 expression but intense 
α-actin expression [Figure 3.1(c)]. Single cell analysis measurements 
from sham and ligated carotids and normal aorta were recorded from 
individual cells captured on v-cups using the centrifugal Lab-on-a-Disc 
(LoaD) platform [Figure 3.1(d)]. The auto-fluorescence (AF) pattern of a 
minimum 55 cells per group were recorded at each wavelength and 
compared. The cells from the ligated injured carotid  had higher AF 
intensities across all wavelengths compared to the sham control, with the 
most significant differences in the first 3 wavelengths (465, 530 and 565 
nm± 20 nm) [Figure 3.1 (e)]. When comparing isolated differentiated SMC 
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(dSMC) from both the sham carotid and normal aorta, the AF intensities 
were much similar, as expected, with minor differences at the 530± 20 nm 
and 670± 20 nm wavelength and no difference at the 565 nm± 20 nm 
wavelength [Figure 3.1(f)]. However, there were significant differences in 
the AF intensities at 465 ± 20 nm and 630± 20 nm wavelengths, 
respectively [Figure 3.1(f)].
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Figure 3.1 (a-c) Photonic AF analysis of cells from ligated and 
corresponding control carotid arteries.  (a) H&E staining of sham and 
ligated vessels 14 days post-ligation; (b) Morphometric analysis of 
medial, intimal and adventitial layers in sham and ligated vessels and 
significance was determined using the Prism software and paired t-tests; 
(c) Myh11 and α-actin staining (red) and DAPI nuclei staining (blue) or 
cells in the adventitial, medial and intimal layer of the sham and ligated 
carotid artery and in the adventitial and medial layer of the aorta. *p<0.05.
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Figure 3.1 (d-f).  Photonic AF analysis of cells from sham and ligated 
carotid arteries and normal aorta.  (d) Digested cells from sham and 
ligated carotids and normal aorta were captured in a v-cup and the AF 
intensity of cells from each group measured across the five wavelengths 
from 465±20 nm to 670±20 nm. (e) AF profile of cells from sham and 
ligated carotids (n=55) (f) AF profile of differentiated SMC from sham and 
normal aorta (n=55).  Standard paired t-tests were carried out for all 
wavelengths except for the 565±20 nm wavelength, which was not 
normally distributed and hence a non-parametric Mann-Whitney test was 
performed. *p<0.05 was considered significant for all t-tests.  Data are the 
mean ± SEM of 55 cells/group from 2 pooled vessels, *p<0.05 vs sham.
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(d) (e)
(f)
3.2.2 Transforming growth factor beta 1 (TGF-β1) promotes 
myogenic differentiation of mesenchymal stem cell and embryonic 
C3H 10T1/2 mesenchymal stem cells towards a vascular phenotype.
Before photonic AF analysis was performed on undifferentiated stem cells 
and their myogenic progeny, the cells were directly compared for 
differences using conventional genetic, biochemical and histological 
analyses before and after myogenic differentiation [Figure 3.2]. Freshly 
isolated mRNA from aortic dSMCs and bladder dSMCs were highly 
differentiated since both preparations were highly enriched for the SMC 
differentiation marker, Myh11 transcript. In contrast, undifferentiated bone 
marrow derived mesenchymal stem cells (MSCs), multipotent C2H 10T 
1/2 stem cells and embryonic stem cells (ESCs) were devoid of Myh11 
transcript [Figure 3.2(a)].
Freshly isolated differentiated aortic dSMCs, subcultured SMCs 
(ddSMCs), mMSCs and mMSCs treated with (2ng/ml) TGF-β1 for 7 days 
were analysed by chromatin immunoprecipitation (ChiP) assays for 
enrichment of the SMC specific epigenetic mark, di-methlyation of lysine 
4 on histone 3 (H3K4me2) at the Myh11 locus (Gomez et al. 2015) and 
for the stem cell mark tri-methylation of lysine 27 on histone 2 
(H3K27me3). The aortic dSMCs were highly enriched for the H3K4me2 
mark but devoid of the H3K27me3 mark. Interestingly, the levels of 
H3K4me2 decreased when mSMCs were grown in culture and become 
‘de-differentiated” ddSMCs yet still remained enriched for the H3K4me2 
mark. The mMSCs were highly enriched for the H3K27me3 mark but with 
low abundance of the H3K4me2 mark which is typical of a stem cell. After 
treatment of the mMSCs (2ng/ml) TGF-β1 for 7 days (the minimum TGF-
β1 dose and time to elicit a significant response), the signature changed 
so that the mMSCs were now enriched for the SMC mark H3K4me2 and 
had lost some of the enrichment for the stem mark H3K27me3, further 
indicating the transition to SMC and myogenic differentiation [Figure 
3.2b]. This was work was carried out in collaboration with Dr. Roya 
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Hakimjavadi, Mariana Soledad di Luca and Denise Burtenshaw (VBT 
Lab, DCU).     
Treatment of mMSCs and C3H T101/2 cells with myogenic inductive 
media containing TGF-β1 (2ng/ml) for 48 h that had been transfected with 
a plasmid encoding the Myh11 promoter resulted in a significant increase 
in relative luciferase activity (RLU) relative to to both mock transfected 
cells and vehicle control indicative of specific Myh11-promoter 
transactivation, carried out by Gillian Casey (TCD) [Figure 3.2c]. The 
levels of CNN1 and Myh11 mRNA transcripts were also significantly 
increased following TGF- β1 (10ng/ml) treatment of both mMSCs and 
C3H 10T1/2 cells when compared to vehicle control [Figure 3.2(d, e)]. 
Parallel studies using immunocytochemistry for SMC differentiation 
markers also demonstrated a significant increase in CNN1 and Myh11+ 
cells compared to the vehicle control. This result was confirmed by 
analysing protein levels by western blot which also indicated an increase 
in CNN1 and Myh11 protein levels following TGF-β1 treatment. [Figure 
3.3]. It is noteworthy that a lower dose and treatment time was necessary 
to activate the Myh11 promotor in the mMSCs and C3H T10 1/2 cells 
compared to the mRNA and protein levels.
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Figure 3.2 TGF-β1 up-regulates SMC gene expression in stem cells 
(a) Relative Myh11 levels in aorta, bladder, mMSCs, C3H T10 ½ cells and 
mESCs; (b) Enrichment of SMC histone modification mark H3K4me2 and 
stem cell histone modification marker H3K27me3 at the Myh11 promoter 
in mouse aorta, cultured mSMCs and mMSCs in the absence or 
presence of TGF-β1; (c) RLU activity in mMSCs transfected with the 
Myh11 promotor plasmid in response to TGF-β1; (d) RLU activity in C3H 
T10 ½ cells transfected with the Myh11 promotor plasmid in response to 
TGF-β1; Data are mean ± SEM of 3 representative experiments 
performed in triplicate (e) Fold change in calponin1 expression in mMSCs 
in response to TGF-β1; (f) Fold change in calponin1 expression in C3H 
T10 ½ cells in response to TGF-β1. Data are the mean of triplicate 
samples within one experiment. Data analysis was carried out using the 
prism software and the data was tested for significance using appropriate 
t-tests with *p<0.05 considered as significant.
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Figure 3.3 TGF-β1 induced myogenic differentiation of multipotent 
stem cells (a) Representative immunocytochemical staining of mMSCs 
and C3H T10 ½ cells with DAPI (blue) and CNN1/Myh11 (green) following 
TGF-β1 (10ng/ml) treatment for 7 days; (b) Fraction of CNN1 positive 
mMSCs and C3H cells following TGF-β1 treatment in an average of at 
least 5 images per group; (c) Fraction of Myh11 positive mMSCs and 
C3H cells following TGF-β1 treatment in an average of at least 5 images 
per group in triplicate; (d) Western blot analysis of mMSCs and C3H T10 
½ cell protein levels of Myh11 and CNN1 in the presence and absence of 
TGF-β1. Data are mean ± SEM of 3 representative experiments. Data 
analysis was carried out using the prism software and the data was 
tested for significance using paired t-tests with *p<0.05 considered as 
significant. 
 103
20 H 3 K 4 r n e 2
H3K27rne3
15
10
5
0
(-) TGF-131 ( + )  TGF-131 (-) TGF-131 ( 4 )  TU-131
2.0
•
1.5
• • •
1.0
••  • • ••
0.5
• •  41
0.0
(-)Tu-pl ( + )  TGF-131 ( - )  TGF-131 ( + )  IGF-131
•  •
• •
•
20—
1 5-
10-
5-
0-
0.4
150
100
50
0
E T E  I
Mock M y t i l l
(-) TGF-P1
E T E
Mock Myhi l
(+) TGF-131
Mock M y h l  1 M o c k  M y h  1 1
(-) TGF-pl  ( + )  TG F-131
,  s r
••••• •
0.8-
0.6-
0.4-
0.2-
0.0
0.6-
OA-
0.2-
I T I.0 •
I • I n T u m e
0.8— (-) TGF-131 ( + )  IGF-131 ( - )  IGF•Pl (+) IGF-131
(-) TGF-I31 ( + )  IGF-131 ( - )  IGF-pl (+) IGF-131
a -
• •  -
ATI-t - - • ,•••"4- -  '
(-)
 T
GF
β
(+
) T
GF
β
(-)
 T
GF
β
(+
) T
GF
β
0.0
0.2
0.4
0.6
F
o
ld
 C
h
a
n
g
e
 in
 C
N
N
1
 E
x
p
re
s
s
io
n
(-)
 T
GF
β
(+
) T
GF
β
(-)
 T
GF
β
(+
) T
GF
β
0.0
0.2
0.4
0.6
0.8
F
o
ld
 C
h
a
n
g
e
 in
 M
y
h
1
1
 E
x
p
re
s
s
io
n
Ao
rta
m
SM
Cs
MS
C
MS
C+
TG
F+
β1
0
5
10
15
20
F
o
ld
 E
n
ri
c
h
m
e
n
t
H3K4me2
H3K27me3
(-)
 T
GF
β
(+
) T
GF
β
(-)
 T
GF
β
(+
) T
GF
β
0
50
100
F
o
ld
 C
h
a
n
g
e
 in
 C
N
N
1
(a)
F
o
ld
 E
n
ri
ch
m
en
t
F
o
ld
 C
h
an
g
e 
in
 C
N
N
1
mMSC C3H
R
L
U
R
L
U
(c)
(d)
(f)
*
*
* *
*
*
Aorta mSMC mMSC  mMSC 
 (+) TGFβ1
mMSC C3H
mMSC C3H
(-)             (+)               (-)             (+)
(-)              (+)              (-)              (+)
TGF-β1
mMSC
C3H
*
(e)
F
ra
ct
io
n
 o
f 
C
N
N
1+
 c
el
ls
(b)
F
ra
ct
io
n
 o
f 
M
yh
11
+  
ce
lls
TGF-β1 TGF-β1
Mock       Myh11    Mock     Myh11
(-) TGF-β1
(-) TGF-β1
(+) TGF-β1
(+) TGF-β1
Mock       Myh11    Mock     Myh11
R
el
at
iv
e 
M
yh
11
 m
R
N
A
 
mMSC C3H 10T1/2
200kDa
*
(-)              (+)              (-)              (+)
Myh11 Myh11SM1SM2
CNN1
CNN1
β-actinβ-actin
TGF-β1 (ng/ml)
(-)   (+)   0    1   3.3  10
TGF-β1 (ng/ml)
20 H 3 K 4 r n e 2
H3K27rne3
15
10
5
0
(-) TGF-131 ( + )  TGF-131 (-) TGF-131 ( 4 )  TU-131
2.0
•
1.5
• • •
1.0
••  • • ••
0.5
• •  41
0.0
(-)Tu-pl ( + )  TGF-131 ( - )  TGF-131 ( + )  IGF-131
•  •
• •
•
20—
1 5-
10-
5-
0-
0.4
150
100
50
0
E T E  I
Mock M y t i l l
(-) TGF-P1
E T E
Mock Myhi l
(+) TGF-131
Mock M y h l  1 M o c k  M y h  1 1
(-) TGF-pl  ( + )  TG F-131
,  s r
••••• •
0.8-
0.6-
0.4-
0.2-
0.0
0.6-
OA-
0.2-
I T I0.0 •
I • I n T u m e
0.8— (-) TGF-131 ( + )  IGF-131 ( - )  IGF•Pl (+) IGF-131
(-) TGF-I31 ( + )  IGF-131 ( - )  IGF-pl (+) IGF-131
a -
• •  -
ATI-t - - • ,•••"4- -  '
(-)
 TG
Fβ
(+)
 TG
Fβ
(-)
 TG
Fβ
(+)
 TG
Fβ
0.0
0.2
0.4
0.6
Fo
ld
 C
ha
ng
e 
in
 C
N
N
1 
Ex
pr
es
si
on
(-)
 TG
Fβ
(+)
 TG
Fβ
(-)
 TG
Fβ
(+)
 TG
Fβ
0.0
0.2
0.4
0.6
0.8
Fo
ld
 C
ha
ng
e 
in
 M
yh
11
 E
xp
re
ss
io
n
Ao
rta
mS
MC
s
MS
C
MS
C+
TG
F+
β1
0
5
10
15
20
Fo
ld
 E
nr
ic
hm
en
t
H3K4me2
H3K27me3
(-)
 TG
Fβ
(+)
 TG
Fβ
(-)
 TG
Fβ
(+)
 TG
Fβ
0
50
100
Fo
ld
 C
ha
ng
e 
in
 C
N
N
1
(a)
Fo
ld
 E
nr
ich
m
en
t
Fo
ld
 C
ha
ng
e i
n 
CN
N1
mMSC C3H
RL
U
RL
U
(c)
(d)
(f)
*
*
* *
*
*
Aorta mSMC mMSC  mMSC 
 (+) TGFβ1
mMSC C3H
mMSC C3H
(-)             (+)               (-)             (+)
(-)              (+)              (-)              (+)
TGF-β1
mMSC
C3H
*
(e)
Fr
ac
tio
n 
of
 C
NN
1+
 ce
lls
(b)
Fr
ac
tio
n 
of
 M
yh
11
+  
ce
lls
TGF-β1 TGF-β1
Mock       Myh11    Mock     Myh11
(-) TGF-β1
(-) TGF-β1
(+) TGF-β1
(+) TGF-β1
Mock       Myh11    Mock     Myh11
Re
lat
ive
 M
yh
11
 m
RN
A 
mMSC C3H 10T1/2
200kDa
*
(-)              (+)              (-)              (+)
Myh11 Myh11SM1SM2
CNN1
CNN1
β-actinβ-actin
TGF-β1 (ng/ml)
(-)   (+)   0    1   3.3  10
TGF-β1 (ng/ml)
20 H 3 K 4 r n e 2
H3K27rne3
15
10
5
0
(-) TGF-131 ( + ) TGF-131 (-) TGF-131 ( 4 ) TU-131
2.0
•
1.5
• • •
1.0
••  • • ••
0.5
• •  41
0.0
(-)Tu-pl ( + )  TGF-131 ( - )  TGF-131 ( + )  IGF-131
•  •
• •
•
20—
1 5-
10-
5-
0-
0.4
150
100
50
0
E T E  I
Mock M y t i l l
(-) TGF-P1
E T E
Mock Myhi l
(+) TGF-131
Mock M y h l  1 M o c k  M y h  1 1
(-) TGF-pl  ( + )  TG F-131
,  s r
••••• •
0.8-
0.6-
0.4-
0.2-
0.0
0.6-
OA-
0.2-
I  I. •
I • I n T u m e
0.8  (-) TGF-131 ( + )  IGF-131 ( - )  IGF•Pl (+) IGF-131
(-) TGF-I31 ( + )  IGF-131 ( - )  IGF-pl (+) IGF-131
a -
• •  -
ATI-t - - • ,•••"4- -  '
(-)
 TG
Fβ
(+)
 TG
Fβ
(-)
 TG
Fβ
(+)
 TG
Fβ
0.0
0.2
0.4
0.6
Fo
ld
 C
ha
ng
e 
in
 C
N
N
1 
Ex
pr
es
si
on
(-)
 TG
Fβ
(+)
 TG
Fβ
(-)
 TG
Fβ
(+)
 TG
Fβ
0.0
0.2
0.4
0.6
0.8
Fo
ld
 C
ha
ng
e 
in
 M
yh
11
 E
xp
re
ss
io
n
Ao
rta
mS
MC
s
MS
C
MS
C+
TG
F+
β1
0
5
10
15
20
Fo
ld
 E
nr
ic
hm
en
t
H3K4me2
H3K27me3
(-)
 TG
Fβ
(+)
 TG
Fβ
(-)
 TG
Fβ
(+)
 TG
Fβ
0
50
100
Fo
ld
 C
ha
ng
e 
in
 C
N
N
1
(a)
Fo
ld
 E
nr
ic
hm
en
t
Fo
ld
 C
ha
ng
e 
in
 C
NN
1
mMSC C3H
RL
U
RL
U
(c)
(d)
(f)
*
Aorta mSMC mMSC  mMSC 
 (+) TGFβ1
mMSC C3H
MSC C3H
(-) (+) (-) (+)
(-)              (+)              (-)              (+)
TGF-β1
mMSC
C3H
*
(e)
Fr
ac
tio
n 
of
 C
NN
1+
 c
el
ls
(b)
Fr
ac
tio
n 
of
 M
yh
11
+  
ce
lls
T F-β1 T F-β1
Mock       Myh11    Mock     Myh11
(-) TGF-β1
(-) TGF-β1
(+) TGF-β1
(+) TGF-β1
Mock       Myh11    Mock     Myh11
Re
la
tiv
e 
M
yh
11
 m
RN
A 
mMSC C3H 10T1/2
20 kDa
(-) (+) (-) (+)
Myh1 Myh1SM1SM2
CNN1
CNN1
β-actinβ-actin
TGF-β1 (ng/ml)
(-) (+)  0 1 3.3 10
TGF-β1 (ng/ml)
20 H 3 K 4 r n e 2
H3K27rne3
15
10
5
0
(-) TGF-131 ( + ) TGF-131 (-) TGF-131 ( 4 ) TU-131
2.0
•
1.5
• • •
1.0
••  • • ••
0.5
• •  41
0.0
(-)Tu-pl ( + )  TGF-131 ( - )  TGF-131 ( + )  IGF-131
•  •
• •
•
20—
1 5-
10-
5-
0-
0.4
150
100
50
0
E T E  I
Mock M y t i l l
(-) TGF-P1
E T E
Mock Myhi l
(+) TGF-131
Mock M y h l  1 M o c k  M y h  1 1
(-) TGF-pl  ( + )  TG F-131
,  s r
••••• •
0.8-
0.6-
0.4-
0.2-
0.0
0.6-
OA-
0.2-
I T I0.0 •
I • I n T u m e
0.8— (-) TGF-131 ( + )  IGF-131 ( - )  IGF•Pl (+) IGF-131
(-) TGF-I31 ( + )  IGF-131 ( - )  IGF-pl (+) IGF-131
a -
• •  -
ATI-t - - • ,•••"4- -  '
(-)
 T
GF
β
(+
) T
GF
β
(-)
 T
GF
β
(+
) T
GF
β
0.0
0.2
0.4
0.6
F
o
ld
 C
h
a
n
g
e
 in
 C
N
N
1
 E
x
p
re
s
s
io
n
(-)
 T
GF
β
(+
) T
GF
β
(-)
 T
GF
β
(+
) T
GF
β
0.0
0.2
0.4
0.6
0.8
F
o
ld
 C
h
a
n
g
e
 in
 M
y
h
1
1
 E
x
p
re
s
s
io
n
Ao
rta
mS
MC
s
MS
C
MS
C+
TG
F+
β1
0
5
10
15
20
Fo
ld
 E
nr
ic
hm
en
t
H3K4me2
H3K27me3
(-)
 T
GF
β
(+
) T
GF
β
(-)
 T
GF
β
(+
) T
GF
β
0
50
100
F
o
ld
 C
h
a
n
g
e
 in
 C
N
N
1
(a)
Fo
ld
 E
nr
ic
hm
en
t
Fo
ld
 C
ha
ng
e 
in
 C
N
N
1
mMSC C3H
R
LU
R
LU
(c)
(d)
(f)
*
*
* *
*
*
Aorta mSMC mMSC  mMSC 
 (+) TGFβ1
mMSC C3H
mMSC C3H
(-)              (+)               (-)             (+)
(-)              (+)              (-)              (+)
TGF-β1
mMSC
C3H
*
(e)
Fr
ac
tio
n 
of
 C
N
N
1+
 c
el
ls
(b)
Fr
ac
tio
n 
of
 M
yh
11
+  
ce
lls
TGF-β1 TGF-β1
Mock       Myh11    Mock     Myh11
(-) TGF-β1
(-) TGF-β1
(+) TGF-β1
(+) TGF-β1
Mock       Myh11    Mock     Myh11
R
el
at
iv
e 
M
yh
11
 m
R
N
A
 
mMSC C3H 10T1/2
200kDa
*
(-)              (+)              (-)              (+)
Myh11 Myh11SM1SM2
CNN1
CNN1
β-actinβ-actin
TGF-β1 (ng/ml)
(-)   (+)   0    1   3.3  10
TGF-β1 (ng/ml)
(a) (b)
(c)
(d)
3.2.3 Photonic analysis of murine progenitor stem cells
Individual undifferentiated murine bone marrow derived mesenchymal 
stem cells (mMSCs) and murine multipotent embryonic fibroblast (C3H 
T101/2) stem cells were loaded and captured in v-cup arrays using 
microfluidic chips and exposed to light at different wavelengths, (from 465 
nm - 670 nm) before the AF photon intensity at each wavelength was 
recorded and compared to background noise [Figure 3.4(a, b)]. At each 
wavelength, the photon counts of the mMSCs [Figure 3.4(a)] and C3H 
T10 ½ cells [Figure 3.4 (b)] were considerably higher than the 
background noise – confirming that this technique can detect the AF 
signature of individual undifferentiated stem cells at various wavelengths 
[Figure 3.4(a, b)]. In all cases, the data are the mean ± SEM of three 
samples and are representative of 3 similar experiments. Data analysis 
was performed using the Prism software and paired t-tests were carried 
out to test for significance where p<0.05 was considered significant.
3.2.4 Photonic analysis for the comparison of stem cells and their 
myogenic progeny
Murine mMSCs and C3H T101/2 cells were treated with 10ng/ml TGFβ1 
for 7 days to induce myogenic differentiation towards a vascular SMC 
phenotype. Dose and treatment times where extracellular protein 
changes were confirmed biochemically were chosen for AF analysis. 
These cells were then captured and analysed on the microfluidic chips for 
their AF spectra [Figure 3.5(a, b)]. When the mMSCs were treated with 
TGF-β1, their AF photon intensity increased compared to untreated 
mMSCs across all wavelengths {Figure 3.5(a)]. The most significant 
increase was observed at the 565 nm ± 20 nm wavelength [Figure 
3.5(a)]. Similarly,  C3H T10 ½ cells had a significant increase in AF 
intensity at this wavelength compared to the untreated cells, indicating 
that changes at this wavelength is the most significant when tracking 
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stem cell differentiation towards a myogenic lineage [Figure 3.5(b)].  In 
contrast, the AF intensities in response to TGF-β1 for all other 
wavelengths for this stem cell decreased [Figure 3.5(b)]. To confirm that 
the change in auto-fluorescence patterns, particular at the 565 nm ± 20 
nm was due to physical differences in the cells following TGF-β1 
stimulation and not an auto-fluorescent pattern due to the inducer itself, a 
non-vascular human B lymphocyte Ramos cell line was treated with TGF-
β1 for 7 days and the auto-fluorescent profile analysed [Figure 3.5(c)]. 
The TGF-β1 treated Ramos B cells had lower auto-fluorescence 
intensities across all wavelengths, including the 565 nm ± 20 nm, further 
supporting the notion that this wavelength is the most likely indicator for 
myogenic differentiation of stem cells in vitro.
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Figure 3.4 Photonic AF analysis of multipotent stem cells. (a) 
Representative pattern of AF photon intensity of mMSCs compared to the 
background noise; (b) Representative pattern of AF photon intensity of 
C3H T10 ½ cells compared to the background noise. Data are the mean 
± SEM of 55 cells/group from 3 independent experiments, *p<0.05 vs 
control (without TGF-β1). Paired t-tests were carried out for all samples 
with *p<0.05 considered significant.
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Figure 3.5  Photonic AF analysis discriminates undifferentiated stem 
cells from their myogenic progeny (a) capture of mMSCs ± TGF-β1 
and the AF intensity in response to broadband light. Wilcoxon t-tests was 
performed for all wavelengths bar the 465±20 nm which had a standard t-
test (b) capture of C3H ± TGFβ-1 and the AF intensity in response to 
broadband light. Standard t-tests was carried out for C3H ± TGFβ1 at the 
530±20 nm and 670±20 nm and Wilcoxon t-tests carried out for all other 
wavelengths; (c) capture of Ramos B  cells ± TGF-β1 and the AF intensity 
in response to broadband light. Data are the mean ± SEM of 55 cells/
group from 3 independent experiments, *p<0.05 vs control (without TGF-
β1). Standard t-tests were carried out for all wavelengths bar the 630±20 
nm which had the Wilcoxon t-test due to its data distribution. Data 
analysis was carried out using the prism software and *p<0.05 was 
considered as significant.
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3.2.5  Jag-1-Fc induces myogenic differentiation in stem cells. 
Undifferentiated multipotent resident rat vascular stem cells (rMVSCs) 
treated with control IgG-Fc or Jag-1-Fc (2 μg/ml) for 7 days (Chapter 
2.25) were compared for SMC marker expression and change in auto-
fluorescence [Figure 3.6]. By trial and error, 2 μg/ml of Jag-1 for 7 days 
was found to be the optimum dose and time to consistently activate SMC 
marker genes, particularly Myh11. Scant expression of CNN1 and Myh11 
was evident in the control (IgG-Fc) rMVSCs; however rMVSCs treated 
with Jag-1-Fc showed significant CNN1 and Myh11 expression [Figure 
3.6(a)].  The number of CNN1 and Myh11 positive cells was significantly 
increased following Jag-1-Fc treatment when compared to the IgG-Fc 
control cells [Figure 3.6(a)]. The levels of CNN1 and Myh11 mRNA 
transcripts were also significantly increased following treatment with 
Jag-1-Fc [Figure 3.6(b)]. In all cases, data are the mean ± SEM of three 
samples and are representative of 3 similar experiments. Data analysis 
was carried out using the prism software and paired t-tests were used to 
test for significance. *p<0.05 was considered significant.
3.2.6 Auto-fluorescence pattern of stem cells in response to an 
alternative myogenic stimulus, Jag-1.  Undifferentiated rMVSCs were 
treated with IgG-Fc or the myogenic stimulus, Jag-1-Fc for 7 days before 
cells were captured on a microfluidic v-cup array and exposed to light at 
various wavelengths 465±20 nm, 530±20 nm, 565±20 nm, 630±20 nm 
and 670±20 nm  [Figure 3.6c]. The dose and time chosen correlated to 
changes in protein expression confirmed biochemically. The AF photon 
intensity of Jag-1-Fc treated cells significantly increased at 565±20 nm. 
All other AF photon intensities significantly increased following Jag-1-Fc 
treatment with the exception at the 630±20 nm [Figure 3.6d]
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Figure 3.6  Jag-1-Fc induces SMC marker expression and changes 
in AF photon intensity. (a) representative immunocytochemical image of 
rMVSCs with DAPI (blue) and CNN1/Myh11 (green) in response to Jag-1-
Fc with the fraction of CNN1 and Myh11 positive cells calculated by the 
average of at least 5 images per treatment group. Scale bars were set to 
100μm (b) fold change in CNN1 and Myh11 mRNA expression in rMVSCs 
in response to Jag-1-Fc; Data are the mean ± SEM from 3 independent 
experiments (c) Representative phase contract image of rMVSCs treated 
with IgG-Fc and Jag-1-Fc and captured on v-cups; (d) AF photon 
intensities of control IgG-Fc and Jag-1-Fc treated rMVSCs across the 
wavelengths from 465±20 nm to 670±20 nm. Data are the mean ± SEM 
of 55 cells/group from 3 independent experiments. *p<0.05 vs control 
(without Jag-1).Data analysis was carried out using the prism software 
and the biochemical data was tested for significance using paired t-tests 
and the auto-fluorescence data was tested for significance with Wilcoxon 
t-tests. *p<0.05 considered as significant. 
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3.2.7 TGF-β1 stimulates auto-fluorescent elastin and collagen 
expression in stem cells.
Undifferentiated mMSCs and rMVSCs were treated with TGF-β1 (10ng/
ml) for 7 days to evaluate whether the enhanced AF photon intensity of 
stem cell-derived myogenic progeny at 565 ± 20 nm was due to 
increased expression of key autofluorescent molecules, elastin and 
collagen within these cells. The dose and time that demonstrated an AF 
change was naturally used to evaluate fluorophore gene expression. The 
expression of elastin, collagen type 1A1, collagen type1A2, collagen type 
3A1 and collagen type 3A2 were all increased following TGF-β1 
treatment, however not statistically significant according to Wilcoxon 
ranked t-tests due to the small sample size [Figure 3.7, 3.8]. 
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Figure 3.7 TGF-β1 stimulation of Collagen 1A and Collagen 3A mRNA 
levels in mMSCs after 7 days. (a) Change in AF photon intensities of 
mMSCs following treatment with TGF-β1 for 7 days at the 565±20 nm 
wavelength; (b) Fold change in elastin mRNA expression in mMSCs in 
response to TGF-β1; (c) Fold change in collagen1 alpha 1 mRNA 
expression in mMSCs in response to TGF-β1; (d) Fold change in 
collagen1 alpha 2 mRNA expression in mMSCs in response to TGF-β1; 
(e) Fold change in collagen3 alpha 1 mRNA expression in mMSCs in 
response to TGF-β1 1; (f) Fold change in collagen3 alpha 2 mRNA 
expression in mMSCs in response to TGF-β1. Data are the mean ± SEM 
of triplicate samples. N number  of experiments were too low for 
significance.
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Figure 3.8 TGF-β1 stimulation of elastin, Collagen 1A and Collagen 
3A mRNA levels in rMVSCs after 7 days. (a) Brightfield image of 
rMVSCs untreated and treated with (10ng/ml) TGF-β1 for 7 days; (b) Fold 
change in elastin mRNA expression in rMVSCs in response to TGF-β1; 
(c) Fold change in collagen1 alpha 1 mRNA expression in rMVSCs in 
response to TGF-β1 (d) Fold change in collagen1 alpha 2 mRNA 
expression in rMVSCs in response to TGF-β1; (e) Fold change in 
collagen3 alpha 1 mRNA expression in rMVSCs in response to TGF-β1; 
(f) Fold change in collagen3 alpha 2 mRNA expression in rMVSCs in 
response to TGF-β1. Data are the mean ± SEM of triplicate samples. N 
number  of experiments were too low for significance.
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3.2.8 Jag-1 stimulates auto-fluorescent elastin and collagen 
expression in stem cells. 
To determine if enhanced expression of collagen and elastin in response 
to TGF-β1 was specific to myogenic differentiation, rMVSCs were also 
treated with Jag-1-Fc and IgG-Fc and analysed in a similar manner. 
There was a  with a significant increase in the AF photon intensities 
across all wavelengths [Figure 3.9(a)] concomitant with an increase in 
elastin, collagen 3A1 and collagen 3A2 in rMVSCs following Jag-1-Fc 
treatment, when compared to the IgG-Fc control. Although the increases 
are evident they failed the Wilcoxon t-test most likely due to the small 
sample set. [Figure 3.9(b-d)].
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Figure 3.9 Jag-1 stimulation of AF photon intensities and elastin and 
collagen mRNA levels in rMVSCs. (a) Representative fold change in 
auto-fluorescence pattern of rMVSCs treated with IgG-Fc and Jag-1 Fc (2 
μg/ml); Data are the mean ± SEM of 3 independent experiments (b) fold 
change in elastin gene expression following treatment with IgG-Fc and 
Jag-1 Fc (2 μg/ml), (c) Fold change in collagen type 3A1 gene expression 
following treatment with IgG-Fc and Jag-1 Fc (2 μg/ml); (d) fold change in 
collagen type 3A2 gene expression following treatment with IgG-Fc and 
Jag-1 Fc (2 μg/ml). Data are the mean ± SEM of triplicate samples. N 
number  of experiments were too low for significance. *p<0.05.
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3.2.9 Prolonged treatment of undifferentiated stem cells with TGF-β1 
results in comparable AF profile to ligated cells at the 565±20 nm 
wavelength
The AF intensity profile at the 565±20 nm wavelength of mMSCs treated 
with TGF-β1 (10ng/ml) for 14 and 28 days were analysed and compared 
to undifferentiated stem cells and neointimal SMC-like cells isolated from 
ligated carotids after 14 days [Figure 3.10(a)]. Prolonged treatment of 
cells with TGF-β1 resulted in an AF photon intensity profile at the 565 ± 20 
nm wavelength that mirrored the enhanced AF signature of the neointimal 
SMC-like cells at this wavelength [Figure 3.10(a)].
3.2.10 Knockdown of collagen significantly reduces auto-
fluorescence at the 565 ± 20 nm wavelength.
Undifferentiated mMSCs were transfected with scrambled and siRNA 
duplexes specific for collagen III and elastin for 72h before the effect of 
the respective knockdown on the AF photon intensity at the 565±20 nm 
was assessed. The transfection efficiency of 98% was determined using 
a fluorescent labelled control siRNA [Figure 3.10(b)].  The effect of 
collagen III and elastin knockdown on collagen III and elastin mRNA 
expression was determined by q-RT-PCR (Figure 3.10(c)]. The mMSCs 
treated with the collagen III siRNA resulted in over 70% knockdown 
whereas the mMSCs treated with the elastin siRNA had almost complete 
knockdown [Figure 3.10(c)].  In parallel studies, mMSCs were then 
captured on the v-cup and exposed to light before the AF photon intensity 
at 565 ± 20 nm wavelength was recorded. The AF intensity of mMSCs at 
the 565 ± 20 nm wavelength was slightly reduced in cells following elastin 
knockdown, but not significantly according to Wilcoxon t-test, when 
compared to the scrambled control.  In contrast, the AF intensity of 
mMSCs at the 565 ± 20 nm wavelength was significantly reduced in 
mMSCs following collagen III knockdown, when compared to the 
scrambled control. These data suggest that collagen III may be 
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responsible for the AF photon intensity at the 565±20 nm wavelength in 
stem-cell derive myogenic progeny. 
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Figure 3.10 Collagen knockdown reduces AF photon intensity at 565 
± 20 nm wavelength in mMSCs. (a) Fold change in AF photon intensity 
at 565±20 nm of undifferentiated mMSCs and cells treated with TGF-β1 
(10ng/ml) for 14 days and 28 days and compared to cells from ligated 
vessels. Data are the mean ± SEM of 3 independent experiments. 
Significance was determined using Wilcoxon t-tests with a p<0.05 
considered significant (*). (b) representative image of mMSCs transfected 
with a fluorescent Tye-siRNA imaged after 72 hours; the scale bar was 
set to 100μm (c) Percentage knockdown of elastin and collagen in 
response to the elastin and collagen siRNAs, when compared to 
scrambled control.  Significance was tested using the Prism software with 
the standard paired t-test. Data are the mean ± SEM of triplicate samples. 
N number  of experiments were too low for significance. (d) AF photon 
intensity of mMSCs following treatment with scrambled siRNA and siRNA 
targeted against collagen III and elastin. Data are the mean ± SEM of 55 
cells/group in 3 independent experiments. Significance was tested using 
Wilcoxon ranked t-tests with a *p<0.05 considered significant. 
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3.3 Discussion & Conclusion
3.3.1. Discussion
It is widely accepted that the majority of cells composing neointimal 
lesions are smooth muscle (SMCs)-like cells (Schiele et al., 2005). After 
the emergence of evidence suggesting that native differentiated SMCs do 
not appear in the lesion (Tang et al., 2012), conflicting reports on the 
potential source of these cells have appeared in the literature. On one 
side of the debate, several investigators propose a re-programming event 
referred to as 'de-differentiation' is occurring whereby differentiated SMC 
becomes more plastic and lose differentiated SMC markers before 
appearing in the lesion (Nemenoff et al., 2011; Herring et al., 2014; 
Shankman et al., 2015; Cherepanova et al., 2016; Majesky et al., 2016; 
Chappell et al., 2016). The other side of the debate proposes that 
resident and/or circulating vascular stem cells and/or endothelial cells that 
undergo EndoMT differentiate to smooth muscle like-cells, proliferate and 
accumulate to form the lesion (Torsney et al., 2011; Hu et al., 2004; Klein 
et al., 2011; Klein 2016; Sata et al. 2002; Hoglund et al. 2010; Tang et al., 
2012; Wan et al., 2012; Shikitani et al., 2016; Kramann et al., 2015; 
Cooley et al., 2014; Yuan et al., 2017). Much of the compelling evidence 
for de-differentiation and re-programming of SMC comes from lineage 
tracing experiments where transgenic animals with a Cre recombinase 
upstream of a smooth muscle marker promotor are bred with animals with 
a Cre-LoxP specific fluorescent promotor to create an animal where every 
cell with the SMC promotor are indelibly tagged facilitating high definition 
tracking using confocal microscopy. However as stem cells may acquire 
the SMC promotor shortly after injury and themselves become tagged, 
especially if the inducing stimulus for the Cre (tamoxifen) remains high 
within tissues, the interpretation of these experiments becomes 
problematic (Reinert et al., 2012). Moreover, when lineage tracing 
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analysis is performed using transgenic mice with the Cre upstream of a 
stem cell specific promoter, nestin (Wan et al., 2012), Gli (Kramann et al., 
2015) or S100β (Cahill Lab, unpublished), the tracking suggests a 
considerable portion of the neointimal and medial SMCs are derived from 
a non-SMC source.  One major drawback with this lineage tracking 
technique is the requirement for the animals to be sacrificed for tissue 
extraction and labelling (Kretzschmar & Watt, 2012). In this context, a 
label-free technology with the potential to track the appearance of cells in 
vivo would be an excellent platform to resolve this debate.
As outlined in Chapter 1, the interaction of light with cells and tissues 
produces a scattering of light which can be recorded to generate unique 
patterns for each cell/tissue type based on their molecular differences 
(Yun & Kwok, 2017). Lab-on-a-Disc (LOAD) platforms have demonstrated 
many attractive qualities for cellular analysis and disease diagnosis 
(Godin et al., 2008). The v-cup array design and auto-fluorescence 
readings makes it possible to analyse populations of single cells within 
minutes. Taking advantage of the low cost and ease of use of this 
platform and the rapid generation of results from this technology, the aim 
of this chapter was to determine whether the LiPhos LOAD system could 
detect significant  auto-fluorescence differences between individual cells 
from healthy (medial) and diseased (neointimal and medial) vessels and 
furthermore, whether similar spectral signatures of individual cells from 
diseased vessels were evident following myogenic differentiation of 
undifferentiated stem cells.
Here, for the first time, we utilise auto-fluorescence patterns to compare 
healthy differentiated SMCs and diseased arteriosclerotic SMCs and 
stem cells and their vascular progeny.
Sham and ligated carotid arteries were isolated from mice, fixed, 
sectioned and H&E stained before the intimal and medial volumes 
assessed. The ligated model had significantly larger media and intima. 
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The sham carotid displayed α-actin and Myh11 staining whereas the 
ligated vessel had plenty of the immature α-actin marker and very little of 
the mature Myh11 marker. The auto-fluorescence patterns were 
significantly different for the sham and ligated models with the ligated 
model exhibiting a higher intensity of auto-fluorescence spanning all 
wavelengths. The differences between the patterns were most prominent 
at the 475±20 nm, 530±20 nm and 565±20 nm wavelengths. Interestingly, 
when medial SMCs from sham carotid arteries were compared with aortic 
SMCs, there was only a slight variation in the signature observed and 
they had the same auto-fluorescent intensity at the 565±20 nm 
wavelength. Some amount of variation is to be expected as the 
differentiated SMCs are derived from two distinct embryological origins 
(neuroectoderm vs mesoderm) (Cheung et al., 2012). The results 
demonstrate that auto-fluorescence can be used as a photonic platform 
to discriminate healthy and diseased vessels label-free. Single cell 
analysis of the cell populations from ligated vessels showed significant 
spectral differences to cells from the medial layer of the normal carotid 
and aorta. As the neointima is composed of primarily SMC-like cells 
(Schiele et al., 2005) and the medial layer of the vasculature is made of 
differentiated SMCs (Karrer et al., 1961), this tool can also distinguish 
neointimal SMC-like cells from native differentiated SMCs. This is not the 
first study to discriminate healthy and diseased vascular vessels based 
on auto-fluorescence. Skin auto-fluorescence (SAF) readings have been 
well characterised in the literature with many reports correlating higher 
SAF readings in patients with a cardiovascular related issues than in a 
healthy individual (Noordzig et al., 2012; Dekker et al., 2013; Wong et al., 
2014). However, it is the first study, to our knowledge, that discriminates 
cells isolated directly from diseased and healthy carotids based on their 
auto-fluorescence patterns.
In an attempt to provide insight to the source of SMC-like cells in the 
neointima using such auto-fluorescent patterns, the next aim of this 
chapter was to characterise patterns for stem cells and their myogenic 
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progeny and compare those patterns to that of the neointimal SMC-like 
cells.
To do this, TGF-β1 and Jag-1 were used as drivers of myogenic 
differentiation. TGF-β1 is known to activate a heteromeric complex of two 
serine/threonine kinase receptors [the type IITGF-β receptor (TβRII) and 
the type I receptor, ALK5], that results in phosphorylation-dependent 
activation of Smads 2 and 3 that subsequently complex with Smad4 and 
translocate to the nucleus where they stimulate myogenic gene 
expression (Massague et al., 2005). Similarly, Jag-1 binds to specific 
Notch receptors on the plasma membrane that, once cleaved, act as 
transcriptional activators of myogenic differentiation (Morrow et al., 2008), 
including activation of the SMA promoter (Noseda et al., 2006). 
In this study, mMSCs and C3H T101/2 cells treated with TGF-β1 (5-10ng/
ml) for 7 days resulted in a shift in epigenetic modification, promotor 
transactivation, gene expression and protein marker expression towards 
a SMC phenotype. Importantly, mMSCs treated with TGF-β1 exhibited a 
higher intensity of auto-fluorescence across all wavelengths. C3H T101/2 
cells treated with TGF-β1 only exhibited greater auto-fluorescence 
intensity at the 565±20 nm which suggests the change in auto-
fluorescence at that particular wavelength may relate to myogenic 
differentiation. 
To evaluate whether the change in auto-fluorescence is due to myogenic 
differentiation as opposed to a direct effect of TGF-β1, Ramos B cells 
were treated in parallel in the same manner and exhibited lower auto-
fluorescence across all wavelengths, demonstrating that the auto-
fluorescent effect seen with TGF-β1 is due to a change in the cell 
phenotype and not an auto-fluorescent effect of the molecule itself. 
Secondly, an alternative myogenic stimulus Jag-1-Fc was used to 
evaluate the changes in auto-fluorescence of rMVSCs before and after 
treatment. Immunocytochemical and gene expression analysis were 
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performed to confirm the differentiation of rMVSCs to an SMC-like 
phenotype before cells were captured on the v-cup array. The auto-
fluorescent pattern of rMVSCs with and without the myogenic stimulus 
mimicked that of the mMSCs in the presence and absence of TGF-β1, 
further demonstrating that an increase in auto-fluorescence at 565±20 nm 
in particular occurs concomitant with myogenic differentiation. Moreover, 
these data suggest that stem cells undergoing myogenic differentiation 
could also contribute to the increase in intensity of auto-fluorescence of 
the ligated vessel cells at the 565±20 nm wavelength.
Previous studies have evaluated the change in auto-fluorescence 
patterns in response to stem cell differentiation using two photon excited 
fluorescence microscopy for human mesenchymal stem cells and their 
osteogenic and adipogenic progeny. These studies report a decrease in 
auto-fluorescence following differentiation to both progeny, however the 
studies are limited to the 460 nm and 525 nm emission wavelengths 
(Quinn et al., 2013; Rice et al., 2007; 2010). Multiphoton scanning laser 
microscopy has also been utilised to evaluate the change in auto-
fluorescence of mESCs during spontaneous differentiation and the auto-
fluorescence profile increased at the 457 nm emission wavelength 
(Squirrel et al., 2012) and the 520 nm wavelength (Thimm et al., 2015). In 
a comparable study, mESCs induced to differentiate to neural stem cells 
using retanoic acid were analysed for changes in auto-fluorescence. 
Again, auto-fluorescence intensities increased at 457 nm (emission) 
following differentiation using multiphoton laser scanning microscopy; 
however changes at other wavelengths were not investigated (Squirrel et 
al., 2012). 
Much of the data reported to date is limited to the 460±10 nm and 525 nm 
wavelengths as photonic intensities at those wavelengths have been 
attributed to auto-fluorescent molecules nicotine adenine dinucleotide 
(NADH/NAPDH) and flavins, respectively (Bartolome et al., 2015; Quinn 
et al., 2013; Rice et al., 2007; 2010). As the ratio of NADH/NADPH and 
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flavins dictate cellular energy and metabolism, alterations in the levels of 
the molecules can drive the pathogenesis of many diseases such as 
cancer, neurodegeneration and diabetes. Hence these changes are 
easily detected label free (Blacker et al., 2014). However, there are many 
other auto-fluorescent molecules in the cell that may drive detectable 
changes in auto-fluorescence, such as retinol, folic acid, pyridoxine, 
lipofuscin, tryptophan, melanin, collagen and elastin (Gosnel et al., 2016). 
In fact, in one study using multiphoton laser scanning microscopy, 
researchers detected an increase in auto-fluorescence during mESC 
differentiation with a concomitant increase of collagen and elastin at 
520±35 nm, which suggests other molecules also contribute to auto-
fluorescence at that wavelength (Thimm et al., 2015).
In this study, treatment for 7 days with TGF-β1 and Jag-1, yielded a 
dramatic spectral change, particularly at the 565±20 nm wavelength. 
Further treatment of the cells with TGF-β1 continued to increase the auto-
fluorescence at 565±20 nm to comparable levels of the ligated SMC-like 
cells. One reason suggested for the high level of auto-fluorescence 
associated with the samples in this study could be due to the elastin and 
collagen content of the extracellular matrix of SMCs (Bank et al. 1996, 
Naryanan et al. 1976, Wanjare et al. 2015). Neointimal SMC-like cells 
have been shown to produce collagen and elastin following injury (Wang 
et al., 1998; Krishnan et al., 2016; Pahk et al., 2017) and elastin and 
collagen have been previously shown to exhibit auto-fluorescence 
(Richards-Kortum and Sevick-Muraca, 1996; Masters and So, 1999; 
Agarwal et al., 2001; Gosnel et al., 2016). Moreover, stem cells 
undergoing myogenic differentiation produce collagen and elastin 
(Swaminathan et al., 2014; Li et al., 2016; Thimm et al., 2015). Of course, 
de-differentiated smooth muscle cells have also been historically 
implicated in the high rate of collagen and elastin production in disease. 
Subcultured primary aortic rat and rabbit SMC-like cells exhibit enhanced 
collagen production in vitro (Sjolund et al., 1986; Ang et al., 1990; Okada 
et al., 1990) and in vivo (Hachani et al., 2011). However, none of these 
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studies address the possibility that the 'de-differentiated SMCs' could 
actually be stem-cell derived SMCs. Recent evidence suggest that this 
indeed may be the case since indelibly marked SMCs from Myh11 Cre-
LoxP transgenic mice are lost as SMC are cultured in vitro (Yuan et al., 
2017). Moreover, during vascular development, SMCs also exhibit very 
high rates of synthesis of extracellular matrix components including 
collagen, elastin which is due to myogenic differentiation from early 
vascular progenitors (Owens et al., 2004). In fact, to the best of our 
knowledge,  there have been no definitive experiments proving that de-
differentiated SMCs, and not stem cell-derived SMCs, produce collagen 
and elastin.
To evaluate whether elastin and collagen could be responsible for the 
high levels of auto-fluorescence in myogenic progeny samples and the 
neointimal SMC-like cell sample, gene expression analysis for elastin, 
collagen type I and collagen type III was carried out for mMSCs and 
rMVSCs following myogenic differentiation. Targeted siRNA knockdown of 
those genes was also analysed for the effect on the auto-fluorescence 
profile at the 565±20 nm wavelength. The elastin and collagen content of 
mMSCs and rMVSCs increased in response to TGF-β1 and Jag-1-Fc 
supporting previous reports that stem cell derived SMCs produce 
collagen and elastin (Swaminathan et al., 2014; Li et al., 2016). Targeted 
siRNA knockdown of the collagen III gene showed a depletion in the auto-
fluorescence levels at the 565±20 nm wavelength, further indicating that 
collagen contributes to auto-fluorescence at that wavelength. This 
correlates with the mESC study mentioned above that also noted an 
increase in auto-fluorescence in conjunction with an increase in collagen 
at a nearby wavelength (Thimm et al., 2015). It is interesting to note that 
collagen type III is associated with the high 565±20 nm auto-fluorescence 
signature of myogenic progeny in vitro and the ligated SMC-like cells 
following vascular injury (Wang et al., 1998; Krishnan et al., 2016; Pahk et 
al., 2017).  Moreover, collagen III has been specifically implicated with 
restenotic plaques in human arterial models, while collagen I is 
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associated with atherosclerosis but reduces during re-stenosis (Krishnan 
et al., 2016).  Furthermore, Collagen type III levels increase in stented 
coronary arteries versus un-stented (Vladimirskaya et al., 2017) and 
deposition of collagen type III has been identified along with neointimal 
SMC-like cells in a rat carotid model (Pahk et al., 2017). 
Collectively, the data presented in this study clearly demonstrate that 
differentiated SMCs are different to the medial and neointimal SMC. This 
can be seen clearly from the decreased immunohistochemical staining of 
neointimal SMC-like cells that lose Myh11 expression and the 
autofluorescence signature of neointimal SMC-like cell that exhibit higher 
autofluorescence intensities, in particular, at 565±20 nm. This study also 
demonstrates that stem cells can be distinguished from dSMCs 
biochemically based on their gene and protein expression, epigenetically 
based on their histone modifications and further by their auto-
fluorescence profiles. The stem-cell derived myogenic progeny can also 
be distinguished from undifferentiated stem cells biochemically and 
epigenetically as they exhibit increased SMC marker gene and protein 
expression but also acquire the SMC specific histone modification 
H3K4me2 at the Myh11 promoter. Stem-cell derived myogenic progeny 
can also be discriminated based on their auto-fluorescence profiles with 
myogenic progeny characterised by higher auto-fluorescence particularly 
at the 565±20 nm. Although myogenic progeny increase their expression 
of SMC markers and acquire the SMC epigenetic modifications, the SMC 
marker levels and epigenetic H3K4me2 enrichment levels are much lower 
than the differentiated dSMC which further suggests that stem cell 
derived SMCs are different to dSMCs. In fact, at an epigenetic level, stem 
cell-derived SMCs mimic vascular smooth muscle cells in culture which 
are referred to as 'de-differentiated SMCs', supporting the findings by 
Tang et al., (2012) which suggest they are the same cell (Tang et al., 
2012). Moreover, myogenic progeny reach dSMC auto-fluorescent levels 
after 7 days but exceed those levels over longer periods of time. Longer 
treatment with TGF-β1 actually drives the auto-fluorescence levels to the 
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neointimal SMC-like cell profile. Based on these biochemical, epigenetic 
and AF photonic similarities, this study therefore clearly supports the 
concept that the source of the SMC-like cells present in the neointima 
may be derived from a stem cell source. 
3.3.2 Conclusion
Regardless of the cause for the change in auto-fluorescence patterns of 
individual cells from sham (healthy) and ligated (arteriosclerotic) carotid 
arteries this chapter clearly demonstrates the ability of the microfluidic v-
cup array and auto-fluorescence studies to fundamentally discriminate 
between cells from healthy and diseased (arteriosclerotic) vessels, 
undifferentiated stem cells and their myogenic progeny. While this novel 
platform is attractive, as it is cheap and easy to use, it lacks the specificity 
to identify the exact cellular and/or molecular differences relating to the 
differences in auto-fluorescence signatures.
To address this question in more detail, Chapter 4 outlines the more 
sensitive vibrational spectroscopic photonic platforms, Raman and FTIR, 
in discriminating undifferentiated stem cells from their myogenic and 
osteogenic progeny and also compares their spectral signatures to that of 
the proposed 'de-differentiated SMC’ in culture.
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Chapter 4 
Photonic Discrimination of vascular stem cells, their 
myogenic progeny and de-differentiated smooth muscle 
cells by Raman spectroscopy and Fourier Transform IR
4.1.1 Introduction
Among the various imaging platforms available to interrogate closely 
related cell populations and discriminate cell-dependent changes in 
vessel structure due to arteriosclerosis, label-free techniques such as 
vibrational spectroscopy have shown great promise (Cheng & Xie, 2016). 
Vibrational spectroscopy is a subset of spectroscopy which analyses 
vibrations within a molecule (or material), which are characteristic of the 
molecular structure and, in polyatomic molecules, give rise to a 
spectroscopic "fingerprint" of that molecule. The spectrum of vibrational 
energies can thus be employed to characterise a molecular structure, or 
changes to it due to the local environment or external factors (e.g. 
radiation, chemical agents). Vibrational energies fall within the mid - 
Infrared (IR) region of the electromagnetic spectrum and are commonly 
probed through IR absorption spectroscopy (Miller, 1982). Raman 
spectroscopy is a complementary technique whereby incident radiation 
couples with the oscillating polarisation of the molecule and thus 
generates or annihilates a vibrational quantum, similarly resulting in a 
vibrational spectrum (Byrne et al., 2016). The differing underlying 
mechanisms give rise to a complementarity of the two techniques, such 
that vibrations of asymmetric, polar bonds tend to be strong in IR spectra, 
whereas Raman is particularly suitable as a probe of symmetric, non-
polar groups. Moreover, FTIR monitors the absorption of IR radiation 
whereas Raman scattering can be employed in the UV, visible or near-IR 
regions of the spectrum and thus offers intrinsically higher spatial 
resolution for cellular and sub-cellular mapping or profiling. The limit of 
resolution is determined classically by the wavelength (<1μm for Raman, 
~5-10μM for IR) (Efeoglu et al., 2016). Therefore, the longer wavelength 
of mid infrared radiation, coupled with the use of multidetector arrays in 
the Fourier Transform mode, render IR techniques more suitable for 
mapping larger cell populations or tissue sections (Byrne et al., 2016).
To follow on from Chapter 3, the current study was undertaken to 
establish whether vibrational spectroscopy could be implemented as a 
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novel photonic platform to more specifically discriminate undifferentiated 
bone marrow-derived stem cells from their myogenic progeny following 
differentiation in vitro and further whether these cell populations could be 
discriminated from de-differentiated ‘synthetic’ SMCs and stem cell-
derived osteogenic progeny. 
4.1.2. Objectives:  
The main aims of this chapter were:-
4. To first validate the use of vibrational spectroscopy (Raman and 
FTIR) to discriminate undifferentiated bone marrow-derived 
mesenchymal stem cells (bm-MSCs) from their osteogenic 
progeny in vitro.
5. To discriminate undifferentiated mesenchymal stem cells (bm-
MSCs), their myogenic progeny (St-SMCs) and de-differentiated 
smooth muscle cells (ddSMCs) in culture by FTIR as a rapid 
label-free screening tool.
6. To specifically characterise and discriminate undifferentiated stem 
cells (bm-MSCs), their myogenic progeny (St-SMCs) and de-
differentiated smooth muscle cells (ddSMCs) by Raman 
spectroscopy to compare and contrast molecular differences 
between these cell populations.
7. To determine whether Raman and FTIR can discriminate 
myogenic progeny from osteogenic progeny in vitro when derived 
from the same undifferentiated stem cell population.
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4.1.3. Strategy
The main objective of this chapter was to analyse undifferentiated MSCs, 
their myogenic and osteogenic progeny and ‘de-differentiated’ 
subcultured SMCs by FTIR and Raman spectroscopy to evaluate whether 
these distinct cell populations can be discriminated based on their 
spectral properties. To achieve this, rat MSCs were cultured with TGF-β1 
(10ng/ml) for 14 days to induce myogenic differentiation or 21 days with 
osteogenic media to induced osteogenic differentiation. Rat aortic SMCs 
were enzymatically digested and sub-cultured to the point that they 
become highly proliferative and lose their contractile Myh11 marker and 
are termed ‘de-differentiated' (ddSMCs). The ddSMCs,  undifferentiated 
stem cells (MSCs) and their myogenic progeny (St-SMCs) were then 
seeded onto calcium fluoride discs and both FTIR of individual cell 
populations and Raman spectra of individual nuclei were recorded for 
each population. The spectra were also transformed using the principle 
component algorithm to plots of their principle components as a 
classification system for each cell type so that the system can also be 
used to classify unidentified cells.
Data analysis for the biochemical data was carried out using the Prism 
software and paired t-tests for parametric data and Wilcoxon ranked t-
tests for non-parametric data. 
Spectral pre-processing was carried out using MatLab. FTIR spectra 
were corrected using a scatter free standard matrigel spectrum previously 
characterised and background scattering was removed using the 
Resonant MIE correction algorithm. Similarly, Raman spectra were 
baseline corrected and subjected to cosmic ray and MIE scattering 
removal using the extended multiplicative signal correction algorithm. 
Spectra were finally smoothed using Savitzky-Golay filter (k = 3; w = 7) to 
reduce noise.
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FTIR and Raman spectra were then analysed by the unsupervised 
multivariate analysis techniques, principle component analysis and linear 
discriminant analysis, to plot the spectra based on their variances 
(principle components) and group classes based on their PC scores.
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4.2. Results
4.2.1.  Validation that Raman and FTIR spectra provide biochemical 
information about a cell 
A sample population of CD44+ bm-MSCs was analysed by both FTIR and 
Raman spectroscopy, and the raw spectra recorded, processed and the 
mean spectrum presented [Figure 4.1]. The FTIR bands are labelled with 
assignments of typical biochemical origin. In the "high wavenumber 
region", >2500 cm-1, the distinctive vibrations of N-H, C-H and O-H of 
lipids and proteins can be found, whereas in the "fingerprint region", 
<2000 cm-1, the features are typically more complex combinations, 
including the Amide I (1650 cm-1) and Amide II (1520 cm-1) modes of 
proteins, nucleic acid phosphate stretching modes at 1070 cm-1 and 1250 
cm-1 and lipidic derived features at 1310 cm-1 and 1750 cm-1. A more 
detailed list of band assignments is provided in Table 4.1.  Mean Raman 
spectra for bm-MSC nuclei were also recorded and analysed following 
cosmic ray removal and EMSC correction and the prominent peaks in 
bm-MSCs are annotated and presented [Figure 4.1(b), Table 4.2]. It 
should be noted that, although complementary techniques, the features in 
the respective spectra of FTIR and Raman have similar origin. Thus, the 
Raman spectrum of the nucleus exhibits similarly prominent signatures 
associated with proteins and lipids across the fingerprint region, as well 
as large peaks related to DNA and RNA at 785 cm-1.
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Figure 4.1(a). FTIR cell spectra. Representative mean FTIR spectra 
recorded for bm-MSCs following Resonant Mie (RMieS) correction with 
classification of relevant peaks and their known association to proteins, 
nucleic acid and lipids are described in the adjacent Table 4.1.
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Table 4.1
Figure 4.1(b). Raman cell spectra.  Raw (110, top) and processed (55, 
bottom) and mean Raman spectra for bm-MSCs (black) following cosmic 
ray removal and EMSC correction and their known association to 
proteins, nucleic acid and lipids are described in the adjacent Table 4.2. 
Also highlighted are nine commonly referenced wavenumber bands 
within the fingerprint region that can be generally attributed to: proteins, 
nucleic acids; carbohydrates and lipids.
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Table 4.2
4.2.2. FTIR and Raman spectroscopy both discriminate bone-
marrow derived mesenchymal stem cells from their osteogenic 
progeny in vitro
Osteogenic differentiation of bm-MSC (St-Osteo) was first validated by 
phase contrast microscopy of gross morphological differences before and 
after differentiation. St-Osteo cells were morphologically distinct from bm-
MSC and exhibited a more osteoblast phenotype with a pronounced, 
large spherical nucleus [Figure 4.2a(ii-iii)]. Alizarin red staining confirmed 
the presence of calcium deposits in St-Osteo when compared to bm-MSC 
[Figure 4.2a (iv-v)], providing evidence for bm-MSC multipotency in vitro. 
Osteogenic differentiation of bm-MSC to St-Osteo was analysed by FTIR 
spectroscopy and a spectrally integrated IR map of a representative 
population of bm-MSC is presented [Figure 4.2a(vi)]. There were notable 
differences in the St-Osteo mean spectra across the high wavenumber 
(2000-3500 cm-1) and fingerprint (1000-1800 cm-1) regions [Figure 4.2b], 
in particular, a strong feature at ~1037 cm-1 that overlapped the nucleic 
acid phosphate backbone band at ~1070 cm-1 that is commonly assigned 
to carbonate groups in apatite (Awonusi et al., 2007). There were also 
notable differences at 2964 cm-1 (corresponding to CH3 asymmetric 
stretching of lipids and proteins) where St-Osteo cells had a greater peak 
intensity. The loading of the discriminating PC1 demonstrated 
pronounced increases in the feature at 1037 cm-1 for St-Osteo and a 
reduction of the strong Amide I and Amide III features at 1220-1280 cm-1 
[Figure 4.2b]. PCA identified all significant changes across the FTIR 
spectroscopic datasets and the scatter plots generated clearly 
discriminated both groups from each other [Figure 4.2c].
Raman spectra of individual cell nuclei from bm-MSC and St-Osteo were 
also recorded and the mean spectra are superimposed to reveal clear 
differences [Figure 4.2d]. The most pronounced was the peak at 960 
cm-1, clearly indicating the presence of phosphates associated with 
mineralisation within the St-Osteo cells [Figure 4.2d] (McManus et al., 
2012).  Prominent bands at 1030 cm-1 and 1070 cm-1 associated with 
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phosphate and carbonate groups respectively, were also evident although 
they were very much weaker compared to the prominent 960 cm-1 
feature. Several other peaks were observed that clearly separated bm-
MSC from their osteogenic progeny and relate to nucleic acid (DNA/RNA) 
at 788 cm-1, 1338 cm-1, 1490 cm-1, and 1585 cm-1 as well as lipids at 
1379 cm-1 [Figure 2d]. PCA identified significant changes across the 
spectrum and the scatter plots generated clearly discriminated both 
groups from each other [Figure 4.2e].
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Figure 4.2. Vibrational spectroscopic analysis o f bm-
MSCs and their osteogenic progeny. (a)(i) Representative 
immunocytochemical image of CD44+ bm-MSC in culture, (ii-iii) phase 
contrast images and (iv, v) alizarin red staining of bm-MSCs before and 
after osteogenic differentiation with osteogenic inductive media for 21 d, 
(vi) representative FTIR heat map of bm-MSCs. (b) Mean FTIR spectra 
and loading plot of the first principal component and (c) PCA score plot of 
the bm-MSCs (black) and the St-Osteo (green) cell groups before and 
after osteogenic differentiation. (d) Mean Raman spectra and loading plot 
of the first principle component following PCA of the processed bm-MSC 
and St-Osteo datasets and (e) PCA score plot of bm-MSCs and St-Osteo 
before and after osteogenic differentiation.
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4.2.3. FTIR and Raman spectroscopy discriminates bone-marrow 
derived mesenchymal stem cells from their myogenic progeny in 
vitro
Myogenic differentiation following treatment of bm-MSC with TGF-β1 was 
confirmed by determining the enrichment of a synonymous SMC 
epigenetic histone mark at the Myh11 promoter, Myh11 promoter 
transactivation, SMC differentiation marker transcript levels (Myh11, 
CNN1) and immunocytochemical detection of the number of Myh11 and 
CNN1 posi t ive cel ls, respect ively [Figure 4.3] . Chromatin 
immunoprecipitation (ChIP) analysis of freshly isolated rat aortic SMCs 
confirmed the enrichment of the specific SMC epigenetic mark, di-
methylation of lysine 4 on histone H3 (H3K4me2) at the Myh11 locus 
(Gomez et al., 2015) concomitant with a lack of enrichment of the tri-
methylation of lysine 27 on histone H3 (H3K27me3) mark which is 
consistent with a general repression of developmental genes (Van der 
Muelen et al., 2015) [Figure 4.3a]. In contrast, bm-MSC were enriched for 
the H3K27me3 mark at the same locus [Figure 4.3a]. 
Treatment of bm-MSC with TGF-β1 (2ng/ml) for 7 d (optimum dose and 
time for histone modification in this study) increased the level of 
enrichment of the H3K4me2 mark with a reciprocal diminution of the 
H3K27me3 mark to levels that were comparable to H3K4me2 and 
H3K27me3 levels in sub-cultured de-differentiated rat SMCs (ddSMCs) 
[Figure 4.3a]. This was work was carried out in collaboration with Dr. 
Roya Hakimjavadi, Mariana Soledad di Luca and Denise Burtenshaw 
(VBT Lab, DCU). TGF-β1 treatment also significantly induced Myh11 
promoter transactivation [Figure 4.3b] after 2 d concomitant with 
enhanced Myh11 mRNA levels [Figure 4.3c]. Luciferase readings were 
carried out by Gillian Casey (TCD).
Furthermore, treatment of bm-MSCs with TGF-β1 (2ng/ml) for 14 d 
resulted in a marked increase in the number of Myh11+ and CNN1+ 
positive cells, when compared to vehicle control [Figure 4.3d]. Similarly, 
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treatment of bm-MSC with Jag-1-Fc resulted in a significant increase in 
Myh11 and CNN1 mRNA levels after 48 h [Figure 4.3e] concomitant with 
a dramatic increase in the number of smooth muscle cell α-actin (SMA+) 
and CNN1+ positive cells after 7 d [Figure 4.3f]. As with the mMSCs and 
C3H T10 1/2 cells in chapter 3, doses and times were chosen by a trial 
and error approach whereby promotor activity required less TGF-β1 and 
time for sufficient activation than protein expression. The rat bm-MSCs 
also required additional time to yield consistent protein changes. Spectra 
were recorded at the time where protein changes were biochemically 
confirmed.
FTIR maps and mean spectra were recorded for bm-MSC and their 
myogenic progeny [Figure 4.3g]. In both cases, there were significant 
peak intensity increases in myogenic progeny in the high wavenumber 
region, >2500 cm-1, in particular, between 2800 cm-1 and 3000 cm-1 
[Figure 4.3g] which is associated with acyl chain stretching vibrations 
from fatty acids of lipids (Movasaghi & Rehman, 2007). There were also 
significant spectral differences in bands in the C-H stretching region 
associated with absorbance from lipids (3050-2800 cm-1), the amide I and 
II region associated with protein absorbance (1700-1500 cm-1), and in the 
lower wavenumber region associated with nucleic acids (1300-1000 cm-1) 
[Figure 4.3g]. Notably, PCA of the FTIR spectroscopic data demonstrated 
that bm-MSCs could be clearly separated from their myogenic progeny 
according to the first principal component (PC1) [Figure 4.3h]. Moreover, 
3-way multivariate statistical analysis revealed that bm-MSC could be 
clearly discriminated from their myogenic progeny, independent of the 
inductive stimulus to generate the progeny [Figure 4.3h].
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Figure 4.3. FTIR spectroscopic analysis of bm-MSCs and their 
m y o g e n i c p r o g e n y . ( a ) R e p r e s e n t a t i v e C h r o m a t i n 
Immunoprecipitation(ChIP) analysis of H3K4me2 and H4K27me3 
enrichment at the Myh11 locus in freshly isolated differentiated aortic 
SMCs, sub-cultured ddSMCs and bm-MSCs before and after myogenic 
differentiation with TGF-β1 (2ng/ml) for 7 d. Data are the mean ± SEM of 
three samples and are representative of 3 similar experiments (b) Myh11 
promoter transactivation and (c) Myh11 mRNA expression levels in bm-
MSCs before and after myogenic differentiation with TGF-β1 (2ng/ml) for 
2 d. Data are the mean ± SEM of three experiments (d) Representative 
immunocytochemical analysis of the number of Myh11+ and CNN1+  bm-
MSCs before and after myogenic differentiation with TGF-β1 (2ng/ml) for 
7 d, (e) n and Myh11 mRNA levels before and after myogenic 
differentiation with Jag-1 (2 μg/ml) for 2 d and (f) representative 
immunocytochemical analysis of the number of SMA+ and CNN1+ before 
and after myogenic differentiation with Jag-1 (100ng/ml) for 5 d. (g) Mean 
FTIR spectra and (h) Scatter plot of the first principal component after 
PCA for bm-MSCs before and after myogenic differentiation with TGF-β1 
(2ng/ml) and Jag-1 (2 μg/ml) for 14 d. Data analysis (a)-(e) was carried 
out using the Prism software and paired t-tests and *p<0.05 considered 
significant.
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4.2.4. FTIR spectroscopic comparisons between de-differentiated 
SMC, MSCs and stem cell derived SMC progeny.
Dissociated rat aortic SMCs were isolated and grown in culture to the 
point where they became highly proliferative and lost their SMC MHC 
marker (approximately passage 4), and were therefore deemed ‘de-
differentiated' SMCs (ddSMCs). Morphological analysis of the ddSMCs 
exhibited strong cytoplasmic refractivity, an oval nucleus and rich 
cytoplasm and overlapped when confluent, forming typical SMC 'peak-to-
valley' growth, as previously reported [Figure 4.4a] [31]. The two major 
morphological phenotypes were spindle shaped [Figure 4.4a(i), a(ii)] and 
epithelioid [Figure 4.4a(iii)]. Both phenotypes expressed SMA and Myh11 
[Figure 4.4a (iv), (v)], but without the distinctive Myh11 myofilament 
arrangement within the cytoplasm [Figure 4.4a (v)]. In contrast, the 
majority of myogenic progeny [St-SMC-TGF-β1] were spindle-like cells 
without a strong cytoplasmic refractivity [Figure 4.4a(vi)]. Moreover, the 
levels of Myh11 mRNA in ddSMC were significantly reduced when 
compared to that of freshly isolated rat aortic SMCs and were comparable 
to the levels present in stem cell-derived myogenic progeny [St-SMC-
TGF-β1] [Figure 4.4b].
FTIR maps and mean spectra were recorded and analysed for ddSMCs 
and compared to both undifferentiated bm-MSCs and their myogenic (St-
SMC-TGF-β1) and osteogenic progeny (St-Osteo), respectively [Figure 
4.4c], before PCA analysis of the spectroscopic datasets was performed 
[Figure 4.4d]. Prominent peaks were observed for ddSMCs across the 
high wavenumber (2000-3500 cm-1) and fingerprint (1000-1800 cm-1) 
regions of the spectrum. In particular, the main spectral characteristics for 
ddSMCs were bands at ~1540 cm-1 and 1650 cm-1 (amide I and II, 
respectively), ~1060 cm-1, 1225cm-1 and 1460 cm−1 (C-C and C-H 
bending) and ~2850 cm-1 - 2960 cm-1 and 3325cm-1. The peak at 
~1225cm-1, associated with phosphate stretching modes, was noticeably 
reduced in both ddSMC and St-Osteo cells, when compared 
undifferentiated bm-MSC and their myogenic progeny [Figure 4.4c], 
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respectively, as were the peaks at 1380 cm-1 and 1660 cm-1 (associated 
with amide I and II proteins) and 2850-2960 cm-1 (associated with 
distinctive vibrations of N-H, C-H and O-H of lipids and proteins) [Figure 
4.4c].  In contrast, the ddSMC had a more prominent peak at the ~1036 
cm-1 and ddSMC and St-Osteo cells at ~ 3296 cm-1 that are associated 
with proteins [Table 4.1] [Figure 4.4c].
4.2.5. Raman spectroscopic comparisons between de-differentiated 
SMC, MSCs and stem cell derived SMC progeny.
All four cell populations were separated by multivariate statistical analysis 
of Raman spectra using a 4-way PCA scatterplot [Figure 4.4e, f, Table 
4.4] with the most notable differences apparent for the St-Osteo spectra. 
Peak intensities were higher at the 785-788 cm-1 and 1585cm-1 
correlating to nucleic acids, 960 cm-1 corresponding to its strong 
phosphate peak and the 1375cm-1 associated with proteoglycans 
(Gamsjaeger et al., 2014). Many other prominent wavenumbers in the 
loadings for the first two principal components are also highlighted and 
the wavenumber associations are discussed below.
Using 4-way multivariate statistical analysis, there was a significant 
separation of the four populations by FTIR [Figure 4.4d, Table 4.3] as it 
successfully discriminated ddSMCs, undifferentiated bm-MSCs and their 
myogenic (St-SMC(TGF-β1)) or osteogenic (St-Osteo) progeny. 
Moreover, using PCA/LDA, FTIR could discriminate between 
undifferentiated bm-MSCs from both their myogenic and osteogenic 
progeny (St-Osteo) with significant confidence even when these daughter 
cells originated from the same undifferentiated bm-MSC stem cell 
population [Table 4.3].
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Figure 4.4. Vibrational spectroscopic analysis of bm-MSCs and their 
osteogenic and myogenic progeny and de-differentiated SMCs. (a)(i-
iii) Representative phase contrast images of freshly isolated aortic SMCs 
and immunocytochemical analysis of (iv) SMA and (v) Myh11 expression 
in ddSMCs in culture (passage 4) and (vi) phase contrast of St-SMCs 
following TGF-β1 induced myogenic differentiation. (b) Myh11 mRNA 
levels in fresh aortic tissue, ddSMCs and St-SMCs (TGF-β1). Data 
analysis was performed using unpaired t-tests in the Prism software with 
*p<0.05 considered significant. (c) Mean FTIR spectra and (d) a 4-way 
scatter plot of the first two principal components after PCA of bm-MSCs , 
ddSMCs, St-SMCs (TGF-β1) and St-Osteo. (e) Mean Raman spectra and 
(f) a 4-way scatter plot of the first two principal components after PCA for 
bm-MSCs, ddSMCs, St-SMCs (TGF-β1) and St-Osteo. *p<0.05 
considered significant.
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Table 4.3. Confusion matrix for PCA-LDA of FTIR spectral data showing 
the percentage classification for each cell type. Values on the diagonal 
represent those correctly identified, off-diagonal values represent those 
incorrectly identified. 
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When the Raman spectra for bm-MSC and their myogenic progeny (St-
SMC-TGF-β1) were compared [Figure 4.5a], there was a clear separation 
across both of the first two components [Figure 4.5b].  Analysis of the 
prominent spectral features in both PC1 and PC2 for these cells revealed 
significant spectral differences relating to nucleic acid (DNA/RNA) at 788 
cm-1, 1090 cm-1, 1262 cm-1, 1338 cm-1, 1373 cm-1, 1490 cm-1 and 1581 
cm-1;   proteins at 1004 cm-1, 1053 cm-1 and 1614-1619 cm-1;  and  lipids 
at 1262 cm-1, 1300 cm-1, 1379 cm-1, 1439-1454 cm-1 and 1650 cm-1-1695 
cm-1, respectively [Figure 4.5a].
When the Raman spectra for ddSMC were compared to bm-MSC [Figure 
4.5c], there was a clear separation across only the first component 
[Figure 4.5d], and the loading for only this component is shown [Figure 
4.5c]. Many of the spectral differences recorded for bm-MSC versus St-
SMCs (TGF-β1) were also observed when ddSMC were compared bm-
MSC [Figure 4.5c]. In addition to sharing these peaks, more peaks were 
observed in PC1 that relate to nucleic acid at 813 cm-1 and 1420 cm-1; 
proteins at 1031 cm-1; and lipids at 1220-1250 cm-1, 1420 cm-1 and 1554 
cm-1.
In contrast, when the Raman spectra of ddSMC were compared to St-
SMC (TGF-β1), there were significant similarities between both spectra 
with sharp bands at the 1004 cm-1, 1262 cm-1, 1319 cm-1, 1585cm-1 and 
1662 cm-1 [Figure 4.5e]. Some differences were observed at 788 cm-1, 
1319 cm-1 and 1585 cm-1, corresponding to nucleic acid content, 
indicative of differences between the DNA/RNA content of the St-SMCs 
(TGF-β1) and the ddSMCs [Figure 4.5e].  Further differences were 
observed in the region of 1262 cm-1 attributable to the nucleic acid 
guanine and amide III and at 1619 cm-1 attributable to tyrosine or 
tryptophan [Figure 4.5e]. Raman spectra of ddSMCs were further 
compared to St-Osteo and revealed significant differences in the spectra 
of these two populations, consistent primarily with the onset of 
mineralization. Finally, PCA analysis of Raman spectra could not directly 
 145
separate the St-SMCs (TGF-β1) and ddSMC groups with 100% accuracy 
[Figure 4.5f]. 
However, classification of both cell populations was achieved using a 
combination of PCA and LDA when applied to each of the four 
experimental groups. The ddSMC were classified correctly with 89.7% 
sensitivity and the St-SMC (TGF-β1) correctly with a 92.7% sensitivity on 
a leave-one-out cross validation method (Table 4.4).
Using PCA/LDA, Raman spectroscopy discriminated undifferentiated bm-
MSCs from both their myogenic (St-SMC-TGF-β1) and osteogenic (St-
Osteo) progeny with significant confidence even when these daughter 
cells originated from the same undifferentiated bm-MSC stem cell 
population [Table 4.4]. 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Figure 4.5. (a) Raman spectroscopic analysis of bm-MSCs, 
myogenic progeny and ddSMCs. Mean Raman spectra and the 
loadings corresponding to the first two principal components for bm-MSC 
and the St-SMCs-TGF-β1 following myogenic differentiation. Significant 
peaks in the loadings of PC1 and PC2 are highlighted and (b) 
corresponding scatter plot for the first two principle components for bm-
MSC and the St-SMCs-TGF-β1. Mean Raman spectra and the loadings of 
the first principle component and corresponding scatter plots for (c, d) 
bm-MSC versus ddSMCs and (e, f) ddSMCs versus St-SMC. For (c) and 
(d), only the first loadings are shown, corresponding only to PC1, since 
separation is found in this component alone.
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Table 4.4. Confusion matrix for PCA-LDA of Raman spectral data 
showing the percentage classification for each cell type. Values on the 
diagonal represent those correctly identified, off-diagonal values 
represent those incorrectly identified.
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4.3 Discussion & Conclusion
4.3.1. Discussion
Vibrational spectroscopy has shown great promise in functional analysis 
of single cells and in label-free detection of diseases (Cheng & Xie, 
2016). Raman micro-spectroscopy is normally performed in a point to 
point mapping mode, and thus is considerably slower than FTIR in 
imaging mode. Nevertheless, its higher spatial and spectral resolution 
favours it for cellular and sub-cellular analysis, rather than large scale 
screening of cell population [Byrne et al., 2016; Bryne et al., 2010]. 
Multivariate statistical techniques such as Principal Components Analysis 
(PCA) and Discriminant Analysis (DA) have significantly contributed to the 
development of diagnostic algorithms based on the information recovered 
in Raman and FTIR spectral signatures. However, before vibrational 
spectroscopy can be fully implemented as a diagnostic platform, cross-
validation with known immunohistochemical platforms for biomarker 
detection is required (Sule-Suso et al., 2014). In this context, the current 
study has established for the first time that vibrational spectroscopy can 
discriminate undifferentiated stem cells from their myogenic and 
osteogenic progeny in vitro following validation using conventional 
genetic, biochemical and histological analyses. The further aim was to 
compare stem cell derived myogenic progeny to de-differentiated SMCs 
in culture.
While several studies have confirmed the accuracy of Raman 
spectroscopy in various biological tissues such as the cervical lesions, 
gastric tissues, colon, thyroid, larynx, skin, bladder amongst others 
(Cheng & Xie, 2016), data on the interrogation of vascular tissue for early 
signs of disease have been limited (Motz et al., 2006). The accumulation 
of neointimal SMC-like cells within the vessel wall leading to the 
obstruction of blood flow represents a major hallmark of CVD (Bennett et 
al., 2016). Recent lineage tracing studies in mice and biomarker 
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identification in human vessels have provided compelling evidence that 
stem cell-derived myogenic progeny (either directly or via endothelial-
mesenchymal-transition) in addition to de-differentiated SMCs may be 
responsible for neointimal formation (Yuan et al., 2017; Kramann et al., 
2016; Chappell et al., 2016; Torsney et al., 2006). Hence the ability to 
discriminate de-differentiated SMC from undifferentiated stem cells and 
their myogenic and osteogenic progeny within the vessel wall and map 
their respective accumulation over time using label-free platforms 
represents an attractive diagnostic platform for vascular proliferative 
disease. 
The potential of FTIR and Raman to screen cell populations and 
discriminate undifferentiated stem cells from their differentiated progeny 
was first established using an osteogenic progeny model. This was used 
as it is a highly validated method with the added benefit that 
atherosclerotic plaques are often calcified. In particular, analysis of the 
FTIR spectra clearly indicated the onset of mineralization via the 
emergence of the feature at 1037 cm-1 which is associated with 
carbonate groups in apatite (Awonusi et al., 2007). Interrogation of 
individual cell nuclei by Raman spectroscopy further distinguished a 
discriminant alteration in phosphate content in situ due to the pronounced 
peak at 960 cm-1 (McManus et al., 2012) that facilitated identification of 
these cells from each other by PCA.
TGF-β1 and Jag-1 have been previously reported in neointimal lesions 
and to drive myogenic differentiation (Gridley 2010; Kurpinski et al., 2010; 
Li et al., 2006; Wang 2015; Morrow et al., 2008). In this study, both of 
these stimuli promoted myogenic differentiation of bm-MSCs in vitro by 
inducing specific epigenetic changes at the Myh11 promoter leading to 
Myh11 promoter transactivation, increased expression of transcript for 
SMC differentiation markers (Myh11 and CNN1) concomitant with a 
significant increase in the number of Myh11+, SMA+ and CNN1+ positive 
cells.  Interrogation of de-differentiated SMCs (ddSMCs), undifferentiated 
bm-MSC and their myogenic (St-SMCs) and osteogenic progeny (St-
 150
Osteo) by FTIR revealed significant differences in their respective 
spectral signatures. Notably, the spectra associated with cellular 
phospholipid content of myogenic progeny decreased when compared to 
undifferentiated bm-MSC whereas there was a marked increase in levels 
of -CH2 symmetric and -CH and -CH3 asymmetric stretching associated 
with proteins and lipids.  This was in contrast to osteogenic differentiation 
where there was a notable marked decrease in levels of –CH2 symmetric 
and -CH and -CH3 asymmetric stretching.  Furthermore, the similarity in 
the pattern of FTIR spectral changes for both TGF-β1 and Jag-1 
myogenic progeny when compared to undifferentiated bm-MSC suggests 
that these differences are independent of the inductive stimulus and were 
specifically associated with a myogenic inductive stimulus and response. 
As stem cell-derived myogenic progeny and de-differentiated SMC were 
also separated by PCA analysis of their corresponding FTIR spectra, 
these data collectively suggest that FTIR is a reliable platform to screen 
and map undifferentiated stem cell populations from their myogenic 
progeny. Indeed, because of the limit of resolution, the longer wavelength 
of mid infrared radiation, coupled with the use of multidetector arrays in 
the Fourier Transform mode, render IR techniques very suitable for 
mapping larger cell populations or tissue sections (Byrne et al. 2016). 
Raman spectroscopy of individual cell nuclei from undifferentiated bm-
MSC, their myogenic progeny (St-SMC-TGF-β1) and ddSMCs further 
defined discrete spectral shifts in these cell populations and quantitatively 
provided reliable estimates of in situ protein, nucleic acids and lipid 
content of bm-MSCs before and after myogenic and osteogenic 
differentiation. Nine distinct wavenumber bands within the fingerprint 
region 600-1800 cm-1 were recorded that correspond to broad 
biochemical groupings (Kerr et al., 2016; Movasaghi & Rehman., 2007). 
Analysis of the spectra revealed significant differences that facilitated 
further discrimination of these cell populations by PCA. Notably, when 
compared to ddSMC, undifferentiated bm-MSC had higher peaks at 
785-788 cm-1 and 1585cm-1 which are attributable to nucleic acid content. 
Similar spectral differences were also observed at 785-788 cm-1 for St-
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SMC. This is not surprising, as stem cells are known to have a higher 
nucleic acid content than differentiated cells (Chan et al., 2009; Notingher 
et al., 2004). The peak at 1262 cm-1 that corresponds to nucleic acid and 
lipid content has also been associated with collagen (Buschman et al., 
2001) and was found in this study to be higher in the ddSMC when 
compared to bm-MSC. Other notable differences for St-SMC appear at 
1319 cm-1 and 1341 cm-1 and are associated with lipids, nucleic acids 
and proteins in addition to a higher peak at 1585cm-1 which corresponds 
to nucleic acids. 
Importantly, there was a clear separation observed across the first 
principle component for bm-MSCs and St-SMCs and for bm-MSC and 
ddSMCs by FTIR suggesting that these cell populations are clearly 
distinct. However, interrogation by Raman across the first principle 
components failed to separate the st-SMC and ddSMC populations with 
100% accuracy. This is not unexpected since FTIR datasets are from 
whole cell spectra while Raman spectra were generated exclusively from 
the cell nucleus. The spectral differences within the cytoplasm may be 
more pronounced as these cells begin to fate towards a myogenic lineage 
but still retain significant differences within their cytoplasmic content. 
Nevertheless, the stem cell-derived SMCs mimic the ddSMCs when 
compared by Raman analysis of  their respective nuclei. This is mirrored 
epigenetically as the bm-MSCs have remarkably similar histone 
modifications at they Myh11 promoter to the ddSMCs. Moreover, neither 
cells are as enriched for the H3K4me2 mark as the differentiated SMCs. 
Therefore, the results in this study suggest that stem cell-derived progeny 
and ddSMCs share similar epigenetic and photonic signatures, 
respectively, to  imply that these two cell populations may be derived from 
the same source. This supports recent studies that demonstrate medial 
Sox10+ resident vascular stem cells predominate in culture and expand at 
a faster rate than differentiated cells that were indelibly marked using 
Myh11 CreLoxP transgenic mice (Yuan et al., 2017). Taken together, 
these data strongly suggest that  'de-differentiated SMCs' may in fact be 
 152
stem cell-derived myogenic progeny (Tang et al., 2012; Yuan et al., 
2017). 
Although PCA analysis did not separate the St-SMCs (TGF-β1) and 
ddSMC groups with 100% accuracy, classification of both cell lines was 
eventually achieved using a combination of PCA and LDA suggesting that 
there are also important differences, despite these similarities.
The main limitation of these studies is that they are confined to cell 
culture models. Vibrational spectroscopy for ex vivo analysis of various 
tissues affected by vascular diseases, including atherosclerotic plaque, 
vessel wall remodelling and endothelial dysfunction has been performed 
(Marcez et al., 2015; Buschman et al., 2001). The Raman spectral 
differences in remodelled vessels following IMT originated mainly from 
the protein features within the main bands at 1660 cm-1 (amide I), 1244 
cm-1 (amide III), and at 1004 cm-1 (phenylalanine). In the spectrum of 
normal intimal SMCs, major bands due to amide I (1656 cm-1), amide II 
(1556 cm-1), and CH bending (1457 cm-1) vibrations of the proteins 
collagen and elastin have also been reported (Motz et al., 2006; Marcez 
et al., 2015; Peres et al., 2011). In the spectrum of the intima of non-
calcified atherosclerotic plaque, major bands due to both proteins and 
lipids are also observed. The lipid bands at 1734 cm-1, 1468 cm-1, 1171 
cm-1 and 1058 cm-1 were assigned to the C = O (ester) stretch, CH2 bend, 
C--O (ester) stretch and C--O stretch, respectively (Motz et al., 2006).
Our current study suggests that St-SMCs exhibit similar enhanced 
spectral intensities at peaks at 1004 cm-1 1451 cm-1 and 1662 cm-1 when 
compared to bm-MSCs and ddSMCs respectively, suggesting that these 
peak intensities might represent a specific photonic signature for stem 
cell-derived myogenic progeny that could be exploited using diagnostic 
platforms. This is interesting as the peaks at 1451 cm-1 and 1662 cm-1 
have been previously associated with collagen and elastin (Peres et al., 
2011, Abubaker et al., 2007; and Buscman et al., 2001). This strongly 
correlates with results from Chapter 3 where the AF photon intensity of 
mMSCs- and rMVSCs-derived myogenic progeny at 530 ± 20 nm 
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wavelength significantly increased concomitant with an increase in 
collagen content. Moreover this photonic signature was attenuated when 
collagen was reduced following siRNA knockdown. 
Furthermore, as vascular lesions are often calcified (Bennett et al., 2016), 
the ability to discriminate between St-Osteo and St-SMCs is also an 
advantage. Our data suggests that both FTIR and Raman can detect 
differences between myogenic and osteogenic progeny even when they 
are derived from the same undifferentiated stem cell.  
4.3.2. Conclusion
Our studies reveal for the first time that FTIR detects specific alterations 
in the cellular profile of nucleic acid, protein and lipid content of bm-MSC 
when they progress towards a distinct myogenic phenotype in vitro. 
Moreover, Raman further distinguished a discriminant alteration in the 
nuclear spectra for nucleic acid, protein and lipid profiles of these cells. 
These data highlight the significant screening potential of FTIR and the 
more analytical potential of Raman at discriminating undifferentiated stem 
cells from de-differentiated SMCs and stem cell-derived osteogenic and 
myogenic progeny. Notably, the feasibility of using prototype devices 
including a laser-scanning fibre endoscope (SFE) to interrogate vascular 
structure in real-time in vivo and detect the early signs of disease has 
been validated (Motz et al., 2006; Savastano et al., 2017).
In conclusion, vibrational spectroscopy was successfully applied to the 
study of bm-MSCs before and after myogenic differentiation in vitro to 
identify discrete spectral characteristics that could facilitate localisation 
and detection of myogenic differentiation of resident vascular stem cell 
populations in vivo. The ability to assess the accumulation of stem cell-
derived progeny using label free platforms in situ or the shedding of these 
progeny into the blood during disease progression may facilitate 
interrogation of these phenotypes by their discrete spectroscopic 
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signatures using liquid biopsies and microfluidic platforms, such as the 
lab-on-a-disc platform as described in Chapter 3.
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Chapter 5
The Development of a Novel Drug and Delivery Platform 
Using Bare Metal Stents  
5.1.1 Introduction
The findings presented so far in this study have provided further evidence 
that neointimal SMC-like cells may be derived from a stem cell source 
(Chapter 3, Chapter 4, Tang et al., 2012, Kramann et al., 2015; Wan et 
al., 2012). In humans, neointima formation typically follows stent 
deployment post balloon angioplasty (Dangas et al., 2002). Varying rates 
of revascularisation following stent deployment (up to 10-17.2% of 
cases), have been reported in the literature (Terstein et al. 2012). 
Paclitaxel (Taxol™) and rapamycin (Sirolimus™) are the most commonly 
used drugs to coat stents to prevent ISR (Ma et al., 2011). Paclitaxel and 
rapamycin are anti-mitotic drugs typically used to treat tumour growth. 
However, there is emerging evidence of 'cancer stem cells' present in 
tumours that drive chemo-resistance due to the presence of adenosine 
triphosphate binding cassette transporters which shield stem cells from 
these drugs (Moitra et al., 2011). The evidence presented in this thesis 
(Chapter 3 and 4) using photonic platforms to analyse cells 
spectroscopically strongly indicate that stem cell-derived myogenic 
progeny, de-differentiated ddSMCs in culture and medial/neointimal cells 
in vivo following vascular injury all possess similar photonic signatures 
and suggest that these cells populations may be derived from an 
undifferentiated stem source. Lineage tracing experiments using stem cell 
promoters to drive Cre-LoxP reporter genes and indelibly mark stem cells 
have provided further compelling evidence of the presence of stem cell-
derived myogenic progeny within vascular lesions during disease 
progression, at least in murine models (Chapter 3, Chapter 4, Kramann et 
al., 2015; Wan et al., 2012; Cahill et al., unpublished). Therefore, one 
contributing factor to the unacceptably high rate of ISR following 
deployment of DES is most likely the inherent resistance of resident 
vascular stem cells to these drugs (Moitra et al., 2011). An alternative 
drug strategy that targets stem cells and the generation of myogenic 
progeny might prove a better  solution to this problem. 
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Previous studies utilising DES coated with a GSK3β inhibitor 
demonstrated a marked reduction (~47%) in the incidence of rabbit 
carotid artery lesions following stenting when compared to the routinely 
used rapamycin (Sirolimus™) coated DES (Ma et al. 2010). The multi-
functional serine-threonine kinase GSK3β is important for its role in 
arterial development, disease and vascular cell signalling. It has also 
been characterised to positively regulate Notch in drosophila, embryonic 
fibroblasts (Foltz et al. 2002), rat smooth muscle cells (Guha et al. 2011), 
mouse fibroblasts and human embryonic kidney cells (Espinosa et al. 
2003; Jin et al. 2009). It has also been shown to regulate SMC markers in 
vascular SMCs (Zhou et al., 2016). As our group (Morrow et al., 2009, 
Redmond et al., 2014) and others (Sakata et al. 2004; Gridley et al. 2010; 
Caolo et al. 2011) have shown that exaggerated Notch signalling is 
associated with neointimal progression in vivo through its role in 
controlling myogenic differentiation and cell growth (Doi et al. 2006; 
Kurpinski et al. 2010, Mooney et al. 2015; High et al. 2007; Chang et al. 
2011; Tang et al. 2012), Notch presents as a potentially important 
therapeutic target for combatting stem cell driven ISR.
Another important deficiency with current DES strategies is the natural 
depletion of targeted drug payloads off stents over time (Halkin et al., 
2004). To ensure the continuous attenuation of smooth muscle-like cell 
accumulation within the stented regions of vessels, nanotechnology has 
been evaluated and shown great promise for drug-delivery platforms. 
Lipids and polymers from 10 nm-1000 nm in size have been employed to 
bind or encapsulate drugs  or anti-sense duplexes to target stents in vivo. 
(Danenberg et al. 2002; Cohen-Sela et al. 2006; Ma et al. 2010; Polyak et 
al. 2016; Vosen et al. 2016). One of the most notable studies published to 
date reported a 98% inhibition of smooth muscle cell accumulation at the 
site of injury using paclitaxel loaded magnetic nanoparticles (MNP’s) 
directed towards the stent using an external magnetic field (Chorny et al., 
2010). Using magnetic nanotechnology, the stent was loaded with greater 
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specificity than non-magnetised nanoparticles and resulted in a 63% 
reduction of neointimal formation (Chorny et al. 2010). Hence,  we chose 
this is the ideal technology to target GSK3β inhibitors routinely and 
specifically towards vascular stents.
5.1.2. Objectives:  
The main aims of this chapter were:-
1. To identify a pharmacological inhibitor for targeting resident vascular 
stem cells.
2. To evaluate the effect of GSK3β inhibition on Notch signalling of 
multipotent resident vascular stem cells in vitro.
3. To evaluate the effect of GSK3β inhibition on myogenic differentiation 
of multipotent resident vascular stem cells in vitro.
4. To fabricate novel GSK3βi-loaded magnetic nanoparticles as the 
basis for a next generation therapeutic platform for drug eluting 
stents.
5. To determine the functionality of the GSK3βi-loaded magnetic 
nanoparticles in attenuating myogenic differentiation.
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5.1.3. Strategy
To achieve these aims, resident MVSCs were isolated from Sprague-
Dawley rats as described in Chapter 2.2.2 and were characterised by 
immunocytochemistry to confirm that they expressed stem cell markers 
(Sox10, Nestin) but were negative for a smooth muscle marker, Myh11. 
The rMVSCs were then treated with three different pharmacological 
inhibitors of GSK/GSK3β and analysed for their effect on cell growth by 
counting the number of DAPI nuclei and GSK3β inhibition by western blot 
using antibodies specific for inactive GSK3β phosphorylation at ser9. The 
rMVSCs were also treated with Jag-1 (2 μg/ml) for 7 days to induce 
myogenic differentiation through the Notch pathway and analysed by 
immunocytochemistry and q-RT-PCR for SMC differentiation marker 
expression (Myh11 and CNN1). The effect of the GSK3β inhibitors on this 
pathway were evaluated as free drugs first before the most potent 
inhibitor was subsequently incorporated into novel polymer coated MNPs 
by the oil in water emulsification method as described in Chapter 2.6.1 
and the success of the formulation was determined by the functionality of 
the incorporated inhibitor on myogenic differentiation. Although the size of 
the nanoparticles were >100nm and therefore should be considered as 
sub micron particles, the magnetic particles in this study will be annotated 
‘MNPs’ in line with similar reports in the literature (Chorney et al., 2010). 
The ability of the fluorescent labelled MNP’s to target bare-metal stents 
was finally assessed in vitro under magnetic conditions.
Data analysis was carried out using paired t-tests pairing each treatment 
group with its respective control. The non-parametric Wilcoxon ranked t-
test was used for sample data sets that did not follow Gaussian 
distribution.
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5.2 Results
5.2.1 Characterisation of rMVSCs with Stem Cell Markers
Multipotent resident vascular stem cells (MVSCs) were isolated from the 
rat aorta and characterised to confirm a pure culture. The rMVSCs 
stained positively for the neural stem cell markers Nestin and Sox10 and 
negatively for the SMC marker, Myh11 [Figure 5.1]. A blue fluorescent 
stain, 4’, 6-diamidino-2-phenylindole (DAPI) was used for nuclear 
staining. The rMVSCs in this study are Nestin+ and Sox10+ and Myh11—.
5.2.2 Effect of GSKβ Inhibitors on Cell Growth
Three pharmacological inhibitors were chosen to assess the direct effect 
of GSK3β inhibition on Notch activation of myogenic differentiation of 
rMVSCs using the specific Notch ligand, Jag-1. The effect of varying 
doses of each inhibitor were also analysed for their effects on rMVSC 
growth [Figure 5.2-4]. The DMSO vehicle (<0.05%) had no significant 
effect on the rMVSC growth in all these studies. Varying doses of 
SB216763 (SB) 10μM-70μM were added to rMVSCs and cells were DAPI 
stained before nuclei were counted [Figure 5.2].  Prior studies established 
a linear relationship between the numbers of cells plated and the number 
of DAPI nuclei per high power frame (hpf).  There was no significant 
effect of SB216763 on rMVSC cell number. The same experimental 
approach was applied using varying doses of Bio 1μM-10μM and doses 
as low as 7μM showed inhibitory effects on rMVSC cell growth [Figure 
5.3]. Finally, the same cells were treated with varying doses of 
10μM-50μM 1-Aza and no significant effect was observed before 
treatment with the highest 50μM dose [Figure 5.4]. Based on the images 
and statistical analysis, appropriate doses were identified as 5μM and 
20μM for Bio and 1-Aza respectively. There was no significant effect of 
SB216763 on rMVSC growth with the chosen doses, however previous 
 161
studies using AlamarBlue for cell proliferation capacity and the Annexin-
FITC/PI apoptosis assay for mMSCs and mSMCs identified 35μM as the 
IC50 for those cells. Therefore, 35μM was the chosen dose for treatments 
in these experiments. These inhibitor concentrations were used for all 
subsequent experiments. The average of 5 images for each sample were 
compared, plotted and analysed using the Prism software. One way 
anova was carried out unless otherwise stated using the Prism software 
and p<0.05 was considered significant.
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Figure 5.1 Characterisation of rMVSCs. (a) brightfield image of 
rMVSCs with elongated stem cell morphology and (b-f) representative 
immunocytochemical images of rMVSCs in culture stained with anti-
nestin and anti-sox10 antibodies. Data are representative of at least 5 
images per antibody from 3 independent experiments. Scale bars, 
100μm.
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Figure 5.2 Dose response of  rMVSCs to SB216763. rMVSCs treated 
with varying doses of SB216763 for 7 days and DAPI stained before cell 
counting (a-e). The average of 5 images for each sample were compared, 
plotted and analysed using the Prism software (f). Data are 
representative of at least 5 images per treatment in 3 independent 
experiments. One way anova was carried out using the Prism software 
and p<0.05 was considered significant. Scale bars, 100μm.
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Figure 5.3 Dose response of rMVSCs to Bio. rMVSCs treated with 
varying doses of Bio for 7 days and DAPI stained before cell counting (a-
e). The average of 5 images for each sample were compared, plotted and 
analysed using the Prism software  (f). Data are representative of at least 
5 images per treatment in 3 independent experiments. One way anova 
was carried out using the Prism software and *p<0.0001 was considered 
significant (*). Scale bars, 100μm.
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  Figure 5.4 Dose response of  rMVSCs to 1-Aza. rMVSCs treated with 
varying doses of 1-Aza for 7 days and DAPI stained before cell counting 
(a-e). The average of 5 images for each sample were compared, plotted 
and analysed using the Prism software  (f). Data are representative of at 
least 5 images per treatment in 3 independent experiments. T-tests were 
carried out using the Prism software and p<0.05 was considered 
significant (*). Scale bars, 100μm.
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5.2.3 Determine the best GSKβ Inhibitor for Inactivation of GSKβ
GSK3β is a serine/tyrosine kinase that requires prior phosphorylation to 
become inactive. If GSK3β is phosphorylated at the serine end, the 
constitutively active enzyme becomes inactive. If the inactivated GSK3β 
becomes phosphorylated at the tyrosine end it returns to its naturally 
active state. To determine the best inhibitor to inactivate GSK3β, protein 
lysates from rMVSCs treated with each of the inhibitors for 24 h were 
compared by western blot and stained for GSK3β(ser9). Beta actin 
staining corrected for equal loading of protein [Figure 5.5a,b]. The total 
amount of GSK3β was slightly higher in GSK3βi samples than the 
untreated control but not significantly so [Figure 5.5.c]. Finally, SB and 1-
Aza were the only inhibitors to show an increase in GSK3β(ser9) 
expression indicating an inactivation of GSK3β in response to these 
inhibitors. Bio on the other hand had similar enzyme inhibition properties 
as the non-treated control [Figure 5.5.a. and 5.5.d]. SB and 1-Aza were 
therefore identified as the best pharmacological inhibitors to inactivate 
GSK3β enzyme activity. Western blot bands were quantified using the gel 
analysis software in Image J. Gel peaks for GSK3β and GSK3β(ser9) 
were normalised to the β-actin control. Wilcoxon ranked t-tests were 
performed for each inhibitor versus the control for GSK3β(ser9) and a p 
value of 0.25 was assigned to each sample which is not considered 
statistically significant. 
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Figure 5.5. Effect of GSK3β on the inactivation of GSK3β (a) Western 
blot analysis of rMVSCs treated with 3 pharmacological inhibitors for 24 
hours to evaluate GSK3β for total GSK3β and inactive GSK3βser9. (b) 
Densitometry analysis of β-Actin peaks expressed as fold over untreated 
control. (c) Densitometry of total GSKβ peaks normalised to β-actin 
expressed as fold over control. (d) Densitometry of GSK3β(ser9) peaks 
normalised to β-actin expressed as fold over control. Data are 
representative of 3 similar experiments. N number was too low to 
determine significance of the data.
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5.2.4 Notch signalling drives myogenic differentiation of rMVSCs
rMVSCs treated with 2 μg/ml of Jag-1 for 7 days (previously confirmed as 
the best dose and time for myogenic differentiation of rMVSCs by a trial 
and error approach) were evaluated for myogenic differentiation markers 
Myh11 and CNN1 at the gene and protein level. The mRNA of rMVSCs 
treated with 2 μg/ml of Jag-1 for 7 days had a significant increase in 
expression for Myh11 and CNN1 [Figure 5.6.a and Figure 5.6.b]. This 
increase was concomitant with an increase in Notch target genes Hey1 
and HeyL. Data is representative data of a minimum of 3 similar 
experiments. Significance testing was carried out using Wilcoxon ranked 
t-tests in the Prism software. P<0.05 was denoted *, p<0.01 was denoted 
**, p<0.005 was denoted *** and p<0.0001 was denoted ****, all of which 
are considered statistically significant.
In parallel studies, rMVSCs were treated with 2 μg/ml of Jag-1 for 7 days 
(CNN1) and 14 days (Myh11) and immunocytochemically stained for 
CNN1 and Myh11 [Figure 5.6.e]. The average of 5 images for each 
sample were compared, plotted and analysed using the Prism software. 
The number of CNN1 and Myh11 positive cells significantly increased 
following Jag-1 treatment according to Wilcoxon ranked t-tests in the 
Prism software [Figure 5.6.f]. Jag-1 promoted Notch mediated myogenic 
differentiation of rMVSCs.
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Figure 5.6 Jagged1 stimulates Notch mediated SMC differentiation 
of rMVSCs. a) Representative CNN1 gene expression in response to 
Jag-1 (2 μg/ml) treatment for 7 days; b) Representative Myh11 gene 
expression in response to Jag-1 (2 μg/ml) treatment for 7 days; c) 
Representative fold change in gene expression of Notch target gene 
Hey1 in response to Jag-1 (2 μg/ml) treatment for 48 hours; d) 
Representative fold change in Notch target gene HeyL expression in 
r e s p o n s e t o j a g g e d 1 f o r 4 8 h o u r s ; e ) R e p r e s e n t a t i v e 
immunocytochemistry images of rMVSCs +/- Jag-1 (2 μg/ml) with DAPI 
nuclei (blue) and CNN1 or Myh11 (green) staining after 7days and 14 
days treatment respectively; (f) Fraction of CNN1 and Myh11 positive 
cells after treatment with Jag-1 for 7 and 14 days respectively as 
analysed by ImageJ. All data are the mean of triplicate readings from at 
least triplicate experiments. Wilcoxon ranked t-tests were carried out with 
*p<0.05; **p<0.005; ***p<0.001 all considered significant. Scale bars, 
100μm. 
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5.2.5 Inhibition of GSK3β blocks Notch mediated myogenic 
differentiation of rMVSCs
The rMVSCs treated with 2 μg/ml Jag-1 and the IC50 of each GSK3β 
inhibitor were assessed for changes in gene expression for Myh11 and 
CNN1 [Figure 5.7a and 5.7b]. 1-Aza was the only inhibitor shown to 
inhibit the Jag-1 mediated Myh11 [Figure 7.a]. 1-Aza and Bio significantly 
reduced Jag-1 driven CNN1 expression, where SB216763 had little effect 
[Figure 5.7.b]. 1-Aza was therefore chosen as the best inhibitor to block 
Notch mediated myogenic differentiation of rMVSCs. The levels of Notch 
target genes Hey1 and HeyL were then evaluated following Jag-1 
treatment and Jag-1 treatment in the presence of 1-Aza [Figure 5.7.c and 
Figure 5.7.d]. Jag-1 stimulated Hey1 and HeyL expression and 1-Aza 
attenuated this expression, indicating that 1-Aza blocks myogenic 
differentiation in rMVSCs through inhibition of Notch. Data is 
representative data of a minimum of 3 similar experiments and presented 
as compared to the Fc control.
Parallel immunocytochemistry studies were carried out and 1-Aza was 
shown to significantly reduce the number of Jag-1 stimulated Myh11 and 
CNN1 positive cells [Figure 5.7.e and Figure 5.7.f]. This data provides 
evidence that 1-Aza is a suitable inhibitor of Notch mediated myogenic 
differentiation of stem cells and could potentially be a novel therapeutic 
target for stem cell mediated in-stent restenosis. The average of 5 images 
for each sample were compared, plotted and analysed using the Prism 
software. 
With the attenuation of myogenic differentiation by 1-Aza confirmed, auto-
fluorescence readings at the 565±20 nm for IgG-Fc, Jag-1Fc and Jag-1Fc 
in the presence of 1-Aza were compared [Figure 5.8]. In contrast to the 
biochemical tests, 1-Aza did not attenuate the myogenic progeny photon 
counts value [Figure 5.8.a]. As it was suggested in chapter 3 that 
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Collagen 3 is the protein responsible for high auto-fluorescence in 
myogenic progeny and neointimal cells, Col3 mRNA expression in 
rMVSCs was evaluated in response to Jag-1 ± 1-Aza and it was found 
that 1-Aza did not have an effect on the Jag-1 induction of collagen 3 
[Figure 5.8.b]. As the auto-fluorescence readings at the 565 nm± 20 nm 
wavelength are apparently reliant on collagen 3 and 1-Aza does not seem 
to block collagen 3, this unfortunately is not a reliable method to analyse 
1-Aza inhibition of rMVSC myogenic differentiation.
Significance testing for all experiments in this section was carried out 
using Wilcoxon ranked t-tests compared to the Fc control, p<0.05 
denoted * was considered statistically significant. 
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Figure 5.7. Effect of GSK3β inhibitors on Notch mediated myogenic 
differentiation. (a) Representative fold change in Myh11 gene 
expression in response to rMVSCs treated with IgG-Fc, Jag-1 Fc, Jag-1 
Fc + SB216763, 1-Aza or Bio for 7 days; (b) Representative fold change 
in CNN1 gene expression in response to rMVSCs treated with IGG-Fc, 
Jag-1 Fc, Jag-1 Fc + SB216763, 1-Aza or Bio for 7 days; (c) Fold change 
in Notch target gene Hey1 gene expression in response to IgG-Fc, Jag-1 
Fc, Jag-1 Fc with 1-Aza for 48 hours; (d) Fold change in Notch target 
gene HeyL gene expression in response to IgG-Fc, Jag-1 Fc, Jag-1 Fc 
with 1-Aza for 48 hours; (e) Representative images of rMVSCs treated 
with IGG-Fc, Jag-1 Fc, Jag-1 Fc with 1-Aza stained with DAPI (blue) and 
CNN1 or Myh11 (green) for 7 and 14 days respectively. Scale bars, 
100μm. All data are the mean of triplicate readings from at least triplicate 
experiments. *p<0.05 considered significant.
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Figure 5.8. Photon count analysis of 1-Aza inhibition of myogenic 
differentiation. (a) Representative fold over background photon counts 
for rMVSCs treated with IgG-Fc; Jag-1-Fc and Jag-1-Fc + 1-Aza. (b) 
Representative collagen 3 mRNA expression for rMVSCs in response to 
Jag-1 and Jag-1 + 1-Aza. Data analysis was performed for using 
Wilcoxon ranked t-tests comparing treatment groups with control groups. 
Data are the mean ± SEM of 55 cells per group from duplicate 
experiments, *p<0.05.
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5.2.6 Polymer coated MNPs are round and relatively uniform in size. 
FeSEM images at 12X and 20X demonstrate the round shape of the 
polymer-coated magnetic nanoparticles and the differences in sizes 
depend on the number of MNPs incorporated into the PLGA shell [Figure 
5.9a, b]. At 300X, the polymer can be seen to be blurring and this can be 
a result from the shrinking of the polymer when exposed to the electron 
beam [Figure 5.9c]. 
High power TEM images show the grouping of the small 10 nm MNPs 
together to form a larger nanoparticle that would be encapsulated by the 
polymer for functionalisation [Figure 5.9.d].
 175
Figure 5.9 FeSEM and TEM images of polymer coated MNPs. (a) 
FeSEM image of PLGA/PVA coated Fe3O4-NPs s at 12X. (b) FeSEM 
image of PLGA/PVA coated Fe3O4-NPs at 20X. (c) FeSEM image of 
PLGA/PVA coated Fe3O4-NPs at 300X. (d) TEM image of PLGA/PVA 
coated Fe3O4-NPs at 100KX. 
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(a) (b)
(c) (d)
5.2.7 Characterisation of 1-Aza-loaded MNPs
The size of 1-Aza loaded MNPs is similar to blank-MNPs and measure at 
232±2.97 nm and 214±4.3 nm respectively [Figure 5.10 a (blank), b (1-
Aza-MNP) and c]. The zeta potential of nanoparticles refers to the 
electrostatic potential of the nanoparticle or as it is commonly known, the 
stability of the nanoparticle. Nanoparticles with a zeta potential of less 
than -30mV are thought to have better dispersion stability (Zhang et al., 
2008). The zeta potential of the representative 1-Aza-PLGA-MNPs 
[Figure 5.10.d] was -24.1±6.9mV. This is slightly higher than the optimum 
zeta potential however the negative charge should still electrostatically 
repulse nanoparticles to prevent aggregation (Zhang et al., 2008). 
The incorporation efficiency of 1-Aza into the PLGA-MNPs was 
determined by evaluating the concentration of 1-Aza in supernatants by 
HPLC directly following 1Aza-MNP generation. The concentration of 1-
Aza in the supernatants was subtracted from the concentration of 1-Aza 
introduced to the nanoparticles and a percentage of 1-Aza incorporated 
was determined [Figure 5.10e]. On average, 96±2.4% of 1-Aza was 
incorporated into PLGA-MNPs. The release of 1-Aza from the 
nanoparticle in the presence and absence of an external magnetic field 
was again determined by the concentration of 1-Aza in the supernatants 
by HPLC. Every 24 hours following magnetisation, the 1-Aza-MNPs were 
centrifuged at 170000 x g for 1 hour and the supernatants were collected 
and analysed [Figure 5.10.f]. When exposed to a uniform magnetic field, 
1-Aza was released at a faster and more stable rate than in the non-
magnetic conditions. The percentage release of 1-Aza compared to the 
percentage of 1-Aza incorporated was 3.4±1.56% in the presence of an 
external magnetic field and 1±0.53% in the absence of an external 
magnetic field. 1-Aza was released up to 72 hours and typically no more 
was released at this time point. 
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Figure 5.10. Characterisation of 1-Aza loaded polymer coated 
Fe3O4-NPs. (a) DLS size measurements of blank-NPs; (b) DLS size 
measurements of 1-Aza-NPs; (c) direct comparison of sizing of blank- or 
1-Aza-NPs; (d) zeta potential of blank-NPs; (e) Percentage of 
incorporation of 1-Aza into nanoparticle as analysed by HPLC; (f) The 
percent of total release of 1-Aza from nanoparticles with respect to time in 
the presence and absence of an external magnetic field as analysed by 
HPLC. All data are the mean ± SEM from a minimum of 3 independent 
experiments.
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5.2.8 Functionality of 1-Aza-MNPs
To determine whether 1-Aza loaded into PLGA-MNPs retained their anti-
myogenic effect, rMVSCs treated with Fc and Jag in the presence of 
blank PLGA-MNPs and 1-Aza loaded PLGA-MNPs were compared for 
their CNN1 mRNA expression [Figure 5.11.a]. Jag-1 Fc stimulated CNN1 
mRNA expression compared to the IgG-Fc control in the presence of 
blank MNPs. This effect was attenuated in the presence of 1-Aza-PLGA-
MNPs in the presence of a uniform magnetic field indicating 1-Aza retains 
its function even when incorporated into a PLGA-MNP. The attenuation of 
CNN1 mRNA expression in response to Jag-1 Fc is dependent on the 
dose of 1-Aza-PLGA-MNPs with the more fold dilutions of the 1-Aza-
PLGA-MNPs leading to a reduction in attenuation response [Figure 
5.11.b]. Data is representative of at least 3 experiments and statistical 
analysis was carried out in the form of paired t-tests in Prism with *p<0.05 
significant.
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Figure 5.11. Functionality of 1-Aza following incorporation into 
PLGA-MNPs. (a) CNN1 mRNA expression of rMVSCs when treated with 
Fc and Jag in the presence of blank nanoparticles and 1-Aza loaded 
nanoparticles for 7 days. Significance was determined by t-tests 
compared to Fc BNP control. Data is the mean ± SEM of triplicate 
readings from 3 independent experiments (b) The percentage response 
of rMVSCs treated with varying dilutions of 1-Aza-NPs in terms of CNN1 
mRNA expression. Statistical analysis was carried out in the form of 
Wilcoxon ranked t-tests with *p<0.05 considered significant.
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5.2.9 Magnetic nanoparticles require an external magnetic field to be 
targeted to stents
To determine whether an external magnetic field is required to target 
MNPs to stents, fluorescent-tagged PLGA coated MNPs were targeted to 
bare metal stents in the presence and absence of a magnetic field in vitro 
[Figure 5.12.a]. Trace amounts of fluorescent-tagged MNPs were found in 
the absence of a magnetic field compared to high levels in the presence 
of a magnetic field. AlexaFlour tagged IgG (488) were then incorporated 
into PLGA-MNPs and targeted to the stent in the presence of a magnetic 
field to confirm the binding of various agent-loaded PLGA-MNPs. The 
IgG-loaded PLGA-MNPs were present on the stent following magnetic 
field application [Figure 5.12.b].
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Figure 5.12. Targeting of nanoparticles to stents. (a) Targeting and 
binding of fluorescent-tagged PLGA coated nanoparticles to bare metal 
stents in the presence and absence of an external magnetic field; (b) 
Targeting and binding of alexafluor-488 IgG nanoparticles to bare metal 
stents in the presence of an external magnetic field.
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5.3 Discussion & Conclusion
5.3.1. Discussion
Vascular disease presents as an obstruction (stenosis) of key blood 
vessels (coronary, carotid) due to the presence of a vascular lesion. 
Treatment options include percutaneous transluminal coronary 
angioplasty (PTCA) and the insertion of a stent – a metal mesh tube – 
into the obstructed vessel to keep the artery open. However, the vessel 
can become re-occluded due to neointimal formation that forms as a 
result of accumulation of vSMCs within the stented area. The introduction 
of the 1st generation DES has resulted in a paradigm shift for the 
treatment of ISR with significant improvement in therapeutic outcomes. 
However, while polymer-coated DES have significantly reduced the 
incident of in-stent restenosis, current DESs treatment regimes lack the 
fundamental capacity for (i) adjustment of the drug dose and release 
kinetics and the (ii) ability to replenish the stent with a new drug on 
depletion. This limitation can be overcome by a strategy combining 
magnetic targeting via a uniform field-induced magnetisation effect and a 
biocompatible magnetic nanoparticle (MNP) formulation designed for 
efficient entrapment and delivery of specific drugs.  
There is now considerable evidence for the presence of stem cell-derived 
progeny within neointimal lesions and they are likely to be a contributing 
factor to the accumulation of SMC-like cells leading to in-restenosis (ISR) 
(Torsney et al., 2011; Hu et al., 2004; Klein 2016; Sata et al., 2002; 
Hoglund et al., 2010; Tang et al., 2013; Majesky et al., 2010; Kurpinski et 
al., 2010). There are two main reasons for the recurring failure of DES. 
The first is the lack of specificity of the anti-mitotic drugs taxol (paclitaxel) 
and sirolimus  to target the correct source of the SMC-like cells (Moitra et 
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al., 2011). Indeed, if anything, these dugs may exacerbate the problem 
since sirolimus induces progenitor cell migration and myogenic 
differentiation via CXCR4 and epidermal growth factor receptor/
extracellular signal–regulated kinase/β-catenin signal pathways, thus 
implicating a novel mechanism of restenosis formation after sirolimus-
eluting stent treatment (Wong et al., 2013). More importantly, the levels of 
these drugs are depleted over time with significant amounts released as 
early as 14 days after stent placement (Halkin et al., 2004). 
The final aim of this work was to pharmacologically inhibit resident 
vascular stem cell myogenic differentiation in vitro and incorporate this 
targeted therapy into novel magnetic nanoparticles as a delivery platform 
for therapeutic delivery to bare-metal vascular stents in vivo. 
Using a series of GSK3β inhibitors and targeted siRNA duplexes, the 
putative role of inhibiting GSK3β activity and myogenic differentiation of 
stem cells was assessed before Fe3O4 PLGA-PVA nanoparticles were 
fabricated, functionalised with GSK3β inhibitors and assessed for activity 
and binding to a bare-metal stent under a magnetic field in vitro. 
Resident MVSCs are present in the medial layer of adult arteries and 
differentiate into SMC-like cells in vitro and in murine injury models in vivo 
(Tang et al. 2013, Yuan et al., 2017). Following isolation and cell culture 
MVSCs from rat aorta were characterised as Myh11-, Nestin+ and Sox10+ 
as previously reported (Tang et al., 2013, Kennedy et al., 2014a, Kennedy 
et al., 2014b; Huang et al., 2015). 
Two ATP-competitive inhibitors of GSK3α/β, SB216763 (SB) and Bio, and 
one cell permeable selective inhibitor of GSK3β, 1-Aza (1-Aza), were 
compared for their effect on MVSC cell growth after 7 days. The effects of 
varying doses of each inhibitor was analysed by counting cell  nuclei and 
the IC50 for each was chosen for future experiments. Bio was the only 
inhibitor that seemed to have a significant effect on rMVSC cell growth at 
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low doses. The inhibitors were then compared for their inactivation of 
GSK3β as determined by the phosphorylation of the serine 9 residue of 
GSK3β. SB216763 and 1-Aza were found to have the best inactivation 
response of GSK3β whereas Bio had the least response. 
Notch signalling has been previously associated with neointimal formation 
(Sakata et al. 2004; Gridley, 2010; Caolo et al. 2011, Morrow et al., 2009; 
Redmond et al., 2015). It has also been shown to  promote myogenic 
differentiation of various stem cells (Doi et al. 2006; Kurpinski et al. 2010; 
Mooney et al. 2015; Chang et al. 2011; Tang et al., 2012). For these 
reasons, the effect of each inhibitor on Notch mediated myogenic 
differentiation was compared. Jag-1 significantly increased the levels of 
CNN1 and Myh11 mRNA levels and immunocytochemical protein levels 
compared to the IgG-Fc control in rMVSCs. The increase in myogenic 
markers was concomitant with an increase in Notch target gene 
expression of Hey1 and HeyL. When rMVSCs were treated with Jag-1 in 
the absence or presence of each inhibitor, SB216763 and 1-Aza 
significantly attenuated the Myh11 mRNA response whereas Bio did not 
have this effect. On the other hand, 1-Aza and Bio had a significant effect 
on the CNN1 mRNA response, where SB216763 did not. As 1-Aza did 
not have a significant effect on rMVSC cell growth but successfully 
inactivated GSK3β (as evidenced by an increase in the inactive GSK3β-
ser9 levels) and subsequently attenuated the Jag-1 induction of myogenic 
markers Myh11 and CNN1, this inhibitor was chosen as the drug of 
choice for future experiments by incorporating it into PLGA-coated MNPs. 
Reduced GSK3β levels has been associated with stem cell self renewal 
and pluripotency in the literature (Wray et al., 2011; Sato et al., 2011; 
Kirby et al., 2012) so the results are not entirely surprising. Inhibition of 
GSK3β has also been shown to attenuate cardiomyocyte differentiation of 
mesenchymal stem cells (Cho et al., 2009) and adipocyte differentiation 
of adipose derived stem cells (Zaragosi et al., 2008). The results 
presented herein, and with supporting evidence in the literature, propose 
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GSK3β inhibitors such as 1-Aza to be an ideal pharmacological inhibitor 
of stem cell differentiation.
To determine whether the inhibition of myogenic differentiation by 1-Aza 
was associated with the Notch signalling pathway, rMVSCs were treated 
with Jag-1 in the absence or presence of 1-Aza  before Notch target gene 
Hey1 and HeyL mRNA expression and SMC differentiation marker 
expression was assessed. 1-Aza  significantly reduced  Jag-1 stimulation 
of Notch target gene expression concomitant with reduction in SMC 
markers suggesting that GSK3β may modulate Notch control of myogenic 
differentiation in vitro. Other well known associated pathways to GSK3β 
are of course the β-catenin/Wnt pathway and the sonic hedgehog (Shh) 
pathway (Komiya et al., 2008; Guha et al., 2011). As mentioned in 
chapter 1, GSK3β is responsible for tightly regulating the Wnt/β-catenin 
pathway during embryogenesis (Komiya et al., 2008). There is also 
evidence of cross-talk between Wnt and Notch signalling (Espinosa et al., 
2003; Rodilla et al., 2008) which provides a possible mechanism of 
control of GSK3β over Notch signalling, however this was not addressed 
in this study. Similarly, previous studies have demonstrated that the 
hedgehog signalling pathway positively regulates Notch signalling in 
vSMCs (Morrow et al., 2009; Guha et al., 2011) and embryonic stem cells 
(Kim et al., 2013). Conversely, pharmacological inhibition of GSK3β and 
targeted siRNA knockdown of GSK3β was shown to attenuate Gli1 
mRNA expression in C3H T10 1/2 cells and mMSCs (see supplemental 
Figure 1). This suggests that GSK3β may also regulate Notch signalling 
through sonic hedgehog signalling. This is supported by a previous report 
in our lab that demonstrated targeted siRNA knockdown of GSK3β 
inhibited Patched1 (Ptch1) expression and sonic hedgehog signalling in 
rat vascular smooth muscle cells (Guha et al., 2011). Moreover, it is 
supported by previous reports that show decreased sonic hedgehog 
signalling in GSK3β null embryos (Nelson et al., 2011). 
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On the other hand, inhibition of GSK3β had little effect on the jag 
stimulation of collagen 3. As outlined in Chapter 3, elastin and collagen1 
and collagen3 mRNA increases across three stem cell platforms with two 
different myogenic stimuli. This is concomitant with an increase in AF at 
the 565 nm± 20 nm wavelength which can be blocked with a collagen 3 
siRNA. Jag-1 has been shown to increase collagen3 mRNA and AF. In 
this chapter, the addition of 1-Aza has attenuated Jag-1 stimulated 
myogenic differentiation. However, the addition of 1-Aza to Jag-1 treated 
cells had no effect on the collagen 3 transcript or AF profile at the 565 nm
± 20 nm. Therefore, notch driven collagen 3 up-regulation must occur in a 
pathway independent of GSK3β. The role of GSK3β in collagen 3 
signalling is not currently understood in the literature.
The use of nanoparticles as a drug delivery system is becoming 
increasingly popular. In particular, magnetic nanoparticles have shown 
great promise for drug delivery due to their small controllable size and 
easily functionalised structure. There are also further advantages such as 
prolongation of the half-life of drugs in circulation and specific targeting to 
the site of interest for more efficient drug use with limiting side effects 
(Singh et al., 2011). There has been much success in targeting drugs to 
tumours in cancer models using nanoparticles and magnetic 
nanoparticles (Muhammod et al., 2017). However, there is still concern 
about the toxic effect of magnetic nanoparticles such as the build up of 
magnetic nanoparticles and bi-products in organs, the risk of an 
inflammatory response to the particles and the possibility of aggregation 
that might result in stenosis within the circulatory system. Therefore, 
novel drug-loaded magnetic nanopart icles require r igorous 
characterisation before considering in vivo studies (Markides et al., 2012).
In this chapter, 1-Aza loaded PLGA-MNPs were successfully fabricated 
and characterised. They were round, reproducible and relatively uniform 
in size and stable. The incorporation efficiency of 1-Aza into the PLGA-
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MNP was very high and the rate of release of the drug from the 
nanoparticle steady in the presence of a uniform magnetic field.
The most similar study published to date was carried out by Chorny et al., 
who fabricated paclitaxel (PTX) loaded PLGA-MNPs by a similar method 
and successfully targeted the MNPs to rat carotid arteries to attenuate in-
stent restenosis (ISR) (See Table 6.1; Chorny et al., 2010). The PTX-
PLGA-MNPs were similar in size, if slightly larger, which suggests the 1-
Aza-PLGA-MNPs to be small enough for rat carotid models and thus 
human arterial models. The zeta potential of the PTX-PLGA-MNPs was 
lower than the MNPs in this study which would mean they are more likely 
to aggregate. Nevertheless, this was not an issue when the PTX-PLGA-
MNPs were introduced in vivo and therefore aggregation would not be 
expected with the MNPs produced in this study. The incorporation 
efficiency of PTX into the PLGA-MNPs was significantly lower than that of 
the 1-Aza-PLGA-MNPs, this could be due to the method of fabrication of 
the nanoparticle. Chorny and colleagues fabricated the nanoparticles 
based on a single emulsion evaporation method whereas the 
nanoparticles described here were formulated using a double emulsion 
method. Paclitaxel is also a hydrophobic drug which may have been 
dissolved in the solvent during the solvent evaporation phase (Chorny et 
al., 2010). The release of paclitaxel from the PTX-PLGA-MNPs was 
significantly higher than from the 1-Aza-PLGA-MNPs. Release kinetics for 
the PTX-PLGA-MNPs were performed in octanol and 1-heptane (1:1) and 
while the solvent may be the ideal sink conditions to release PTX from 
PLGA-MNPs, it does not mimic the pH and aqueous environment of the 
body, therefore a direct comparison with the drug release from the 1-Aza-
PLGA-MNPs would be unfair (Chorny et al., 2010). The low release of 1-
Aza from the PLGA-MNPs was surprising. 
One possible reason for the low level of release of drug is that PLGA has 
been shown to form covalent bonds with amine containing drugs (Lanao 
et al., 2013) which may increase the retention of drugs such as 1-Aza 
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within the nanoparticle. However, the low release did not effect the 
functional property of the 1-Aza-PLGA-MNP. Indeed, 1-Aza remained 
functional after release from the PLGA-MNPs and attenuated myogenic 
differentiation of rMVSCs in a comparable manner to free drug. The levels 
of CNN1 mRNA expression was evaluated following Jag-1 stimulation of 
rMVSCs in the absence or presence of varying dilutions of 1-Aza-loaded 
MNPs. The anti-myogenic effect of the 1-Aza loaded PLGA-MNPs was 
assessed following 8 fold dilutions (which corresponded to a 
concentration of 2.5μM 1-Aza), after which the attenuation of CNN1 
response reduced before no anti-myogenic effect was observed at a 32-
fold dilution. 
Table 5.1 Comparison of the PLGA-MNP and 1-Aza-PLGA-MNP in this 
study to the published PTX-PLGA-MNPs fabricated by Chorny et al., 
(2010).
Finally, as the overall objective of this chapter and future work is to target 
the 1-Aza loaded PLGA-MNPs to stents to attenuate restenosis, the 
ability to target this type of nanoparticle formulation to stents was 
evaluated in vitro. PLGA-MNPs were fabricated as before but this time 
functionalised with fluorescently tagged PLGA, fluorescent tagged siRNA 
or a fluorescent tagged IgG. The tagged PLGA-MNPs were then targeted 
to the stent in the presence and absence of a magnetic field to determine 
the ability of a magnetic field to target PLGA-MNPs towards the stent. 
Similarly, the siRNA-PLGA-MNPs and IgG-PLGA-MNPs were targeted to 
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1-Aza-PLGA-MNP Chorny PTX-PLGA-MNP
Size (nm) 232±2.97 nm 263±7 nm
Zeta Potential (mV) -24.1±6.9mV -12±2mV
Drug encapsulation 
Efficiency
96±2.4% 30%
Percentage drug release 3.4±1.56% 72%
the stent using an external magnetic field and specific binding to the stent 
was observed [Figure 5.5.4]. This is consistent with the findings by 
Chorny et al. (2010) who noted a 4- to 10- fold higher binding efficiency of 
PTX-PLGA-MNPs in vivo with the use of an external magnetic field 
(Chorny et al., 2010).
The results presented in this chapter have been limited to an in vitro 
model however previous reports in vivo studies have demonstrated the 
ability of GSK3β inhibitors to attenuate ISR in rabbit models and PLGA-
MNPs have been shown to specifically target bare-metal stents and 
inhibit restenosis in rat carotid models (Ma et al., 2014; Chorny et al., 
2010). The GSK3β inhibitor of choice was shown to reproducibly 
attenuate Notch mediated myogenic differentiation and the GSK3βi-
loaded-PLGA-MNPs remained functional and were further shown to have 
similar properties to published PTX-PLGA-MNP (Chorny et al., 2010). 
Together these studies suggest that targeting of the 1-Aza-PLGA-MNPs 
to bare-metal stents in vivo is possible and would likely attenuate 
restenosis due to inhibiting myogenic differentiation in response to injury.
5.3.2. Conclusion
The aims and objectives of this chapter were achieved. A successful 
inhibitor of GSK3β was characterised and selected and further 
demonstrated its ability to inhibit myogenic differentiation of rMVSCs in 
vitro. This inhibitor was efficiently incorporated into appropriately sized, 
relatively stable, PLGA-MNPs and the released 1-Aza retained its anti-
myogenic function. Finally, the formulations of PLGA-MNPs and loaded-
PLGA-MNPs showed specific binding to stents, in vitro, in the presence of 
an external magnetic field suggesting them as the ideal drug delivery 
system for vascular stent targeting. 
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Chapter 6
 
Final Discussion
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CVD remains the leading cause of death world-wide (WHO, 2017). The 
most common form of heart disease is atherosclerosis which in response 
to various risk factors culminates in a build up of cholesterol, lipids, 
smooth muscle-like cells and inflammatory cells within a intimal lesion 
(Insull et al., 2009). The current treatment option for this disease involves 
balloon angioplasty and subsequent deployment of a drug-eluting 
vascular stent (White et al., 2005), typically loaded with paclitaxel 
(Taxol™) or rapamycin (Sirolimus™) (Jeremias et al., 2008). Despite the 
presence of such DES, the phenomenon of ISR may still prevail (Dangas 
et al., 2002). ISR is characterised by a (neo)intimal thickening of the 
vessel wall due to the accumulation of a high proportion of smooth 
muscle-like cells (Schiele et al., 2005). One key question in vascular 
biology that remains controversial is the potential source of these 
neointimal cells. Are they derived from differentiated SMC through a re-
programming event (de-differentiated) or or are they stem cell-derived 
myogenic progeny from circulating or resident stem/endothelial cells 
(Tang et al., 2012). Moreover, what therapeutic strategy best targets 
these cells using DES platforms? The overall aims of this thesis are to 
address these compelling questions using both photonic platforms to 
discriminate vascular phenotypes and novel functionalised magnetic 
nanoparticles loaded on vascular stents to specifically target these cells. 
6.1 Photonics can be used as a label free platform to characterise 
and identify cells.
To establish whether healthy differentiated SMCs from aorta and carotid 
arteries could be discriminated from arteriosclerotic neointimal SMC-like 
cells following carotid injury using photonics, cells from each population 
were enzymatically isolated from murine tissue, captured on a microfluidic 
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device and exposed to broadband light. The auto-fluorescence of 
vascular tissue has been studied since the late 1980's. Reports in the 
literature compare auto-fluorescence differences in atherosclerotic versus 
healthy human arteries and attribute them to collagen, elastin, lipids and 
calcium deposits (Fitzmaurice et al., 1989). The use of auto-fluorescence 
to diagnose vascular diseases has more recently been reported mainly 
using skin auto-fluorescence (Noordzig et al., 2012; Dekker et al., 2013; 
Wong et al., 2014). Information on the auto-fluorescence of vascular cells 
is limited. Although, there are studies evaluating the changes in auto-
fluorescence of  undifferentiated stem cells undergoing differentiation but 
only at 460 nm and 525 nm emission wavelengths (Quinn et al., 2013; 
Rice et al., 2007; 2010; Thimm et al., 2015; Squirrel et al., 2012), there is 
a significant lack of information about the autofluorescence signatures for 
undifferentiated stem cells undergoing myogenic differentiation.
As differences in AF has been noted before in the literature for healthy 
and diseased arteries (Fitzmaurice et al., 1989) it is not surprising that 
individual medial and neointimal SMC-like cells from arteriosclerotic 
(ligated) vessels exhibited much higher AF signatures across all 
wavelengths than the healthy medial SMCs. These SMC-like cells have 
been widely reported to be of a more immature, stem-like/de-
differentiated phenotype (Schwartz et al., 1998).
Lineage tracing analysis and epigenetic profiling of neointimal cells have 
since provided compelling evidence for the involvement of stem cell-
derived progeny (Torsney et al., 2011; Hu et al., 2004; Klein et al., 2011; 
Klein 2016; Sata et al. 2002; Hoglund et al. 2010; Tang et al., 2012; Wan 
et al., 2012; Shikitani et al., 2016; Kramann et al., 2015; Cooley et al., 
2014; Yuan et al., 2017), in addition to ‘re-programmed’ differentiated 
SMCs (Nemenoff et al., 2011; Herring et al., 2014; Shankman et al., 
2015; Cherepanova et al., 2016; Majesky et al., 2016; Chappell et al., 
2016; Gomez et al., 2015) as well as SMC derived from endothelial-
mesenchymal transition (EndMT)(Cooley et al., 2014; Yuan et al., 2017) 
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in progressing neointimal formation in murine models or arteriosclerotic 
disease.  An important caveat for all of these studies is that stem cells 
may acquire SMC promoters as they undergo myogenic differentiation 
while SMCs may acquire specific stem cell promoters as they de-
differentiate/re-programme. The use of a time dependent switch is an 
essential pre-requisite for appropriately designed lineage tracing 
experiments. Inducible models were developed using cell-specific 
promoters modified to include a regulatory element that controls Cre 
expression only when activated by specific exogenous inducing 
molecules (e.g, tamoxifen, Tm). As a consequence, Cre will recombine 
the DNA in target cells that express the marker gene only during the 
administration of the inducing Tm molecule, thus opening a transient 
window in which the cells can be labelled. Upon withdrawal of the 
inducing molecule, no additional cells can undergo genetic 
recombination, even if they express the cell-specific promoter. In many of 
these landmark lineage tracing studies, Tm was given prior to injury to 
mark cells and then withdrawn for up to a week. It was then assumed 
only cells expressing the cell-specific promoter and all their progeny are 
marked and tracked in vivo. However, a recent study using an in vivo 
bioassay to directly assess the length of time that a given dose of Tm can 
induce Cre-loxP recombination has seriously questioned this assumption. 
These studies elegantly demonstrated that a significant number of cells 
are marked long after Tm is stopped, potentially confounding the 
interpretation of time-sensitive studies using Tm-dependent models to 
track differentiated cells (Reinert et al,, 2012).  
In this context, the AF profile of mMSCs, mC3H cells and rMVSCs 
following myogenic differentiation with TGF-β1 and Jag-1 was assessed 
to determine whether multipotent stem cells could acquire a neointimal 
SMC-like AF photonic signature following differentiation. The benefit of 
using a microfluidic and auto-fluorescence platform over lineage tracing 
and epigenetic markers is that it is label free, cheap, easy to use and 
cells can be analysed singularly or as a population. Following 
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confirmation of myogenic differentiation using various biochemical and 
epigenetic markers, including epigenetic data confirming mMSCs acquire 
the SMC histone H3K4me2 di-methylation mark at the Myh11 promoter. 
the stem cell-derived progeny shared the greatest photonic similarity with 
the neointimal cells from ligated vessels, particularly at the 565 ± 20 nm 
wavelength. In particular, when mMSCs were treated with myogenic 
inductive media for up to 28 days, the AF profile at the 565 ± 20 nm 
wavelength resembled that of neointimal SMC-like cells.
One of the main drawbacks of this technique is the limited information 
generated from assessing auto-fluorescence patterns alone. In an effort 
to identify the molecule(s) involved in exhibiting the high AF signature at 
565 ± 20 nm in neointimal SMC-like cells and stem cell-derived myogenic 
progeny, the role of auto-fluorescent matrix proteins, elastin and collagen 
were investigated (Richards-Kortum and Sevick-Muraca, 1996; Masters 
and So, 1999; Agarwal et al., 2001). Indeed, neointimal SMC-like cells 
exhibit high levels of collagen and elastin (Merrilees et al., 2011; Xu & Shi 
et al., 2014). Elastin and collagen were also up-regulated in myogenic 
progeny from mMSCs and rMVSCs regardless of the inductive stimulus 
(TGF-β1 or Jag-1). This result is in agreement with other studies that have 
shown that stem cell-derived myogenic progeny produce collagen and 
elastin (Swaminathan et al., 2014; Li et al., 2016). In order to determine 
whether this increased collagen and/or elastin expression contributed to 
the high AF signature observed at the 565 ± 20 nm, the AF profile at this 
wavelength was assessed following collagen and elastin knockdown 
using specific targeted siRNA duplexes. Elastin knockdown reduced, but 
not significantly, the AF signature at this wavelength. In contrast, collagen 
knockdown significantly reduced the AF signature at 565 ± 20 nm. This 
suggests that collagen is responsible in part for the increase in AF at 565 
± 20 nm during myogenic differentiation. Collectively, these photonic data 
support the concept that stem cell-derived progeny may contribute to 
SMC-like cells that accumulate at the site of injury to form a (neo)intima.  
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This AF profiling of cells is also dependent on microfluidic capture of cells 
thereby rendering it more suitable for interrogating cells within fluid 
biopsies. Indeed, it is known that tumours shed circulating cells and 
microfluidics can be adapted as a “liquid biopsy” that enables tumour 
characterisation by minimally invasive means. Multiple studies have 
described how molecular information about parent tumours can be 
extracted from these cellular components (Perakis and Speicher, 2017). 
In this context, microvesicles are shed from vascular lesions (Bobryshev 
et al., 2013) and it is not inconceivable that vascular lesions may also 
shed circulating cells as the neointima enlarges.
Importantly, these data were generated using rodent models of vascular 
injury and multipotent stem cells in vitro. While widely used in vascular 
research, the mechanism(s) for injury, pathogenesis of the disease and 
overall structure of the artery (no intima) are significantly different to 
human outcomes (Shanks et al., 2009). It will therefore be necessary to 
assess whether similar AF signature differences are evident between 
cells from human arteriosclerotic vessels and human stem cell-derived 
myogenic progeny.  Finally, as one further disadvantage of assessing AF 
signatures is the specific identity of the discriminant molecules, vibrational 
spectroscopic methods were employed for a more rigorous approach at 
discriminating stem cells from their myogenic progeny and further to 
compare these cells with ‘de-differentiated’ SMCs in vitro. 
Vibrational spectroscopy has shown great promise as a diagnostic tool to 
characterise changes in cell phenotype. Much of the work to date has 
focused on cancer models which include in vitro, ex vivo and in vivo 
studies on prostate, cervical, uteri, skin, breast, colon, oesophagus, 
bladder, oral mucosal cancers with the aim of generating a reliable 
diagnostic platform to reduce false negatives obtained from conventional 
diagnostic techniques (Butler et al., 2016; Vardaki et al., 2016; Crow et 
al., 2005; Baker et al., 2014). The same has been applied to diagnosing 
bone diseases such as osteoporosis, with the added benefit that it does 
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not require prior sample prep such as homogenisation or de-calcification 
of the sample. Similarly, Raman and FTIR have bene applied to kidney 
and gallstones for label-free detection of the stones. In particularly, they 
hydroxyapatite band of the kidney stone makes detection reliable and 
easy. Finally in terms of diagnosis, some research has been carried out 
comparing atherosclerotic and healthy tissue in vivo (mice) and ex vivo 
carotids (human) (Krafft et al., 2009). Although the results of these 
studies are very promising, a few issues are currently preventing this 
technology becoming clinically translated. The first being that the data 
processing of the acquired spectra can be tricky (Smith et al., 2016). 
Background signals and scattering require removal from spectral datasets 
and normalisation of the data to a reference spectrum is usually required. 
Background subtraction and normalisation are applied through 
computational algorithms such as  the Extended Multiplicative Scatter 
Correction protocol, which requires software and training (Byrne et al., 
2016). The next issue is the difference in tissue thickness and density, 
this can cause issues with IR and Raman signals and can result in longer 
acquisition times for spectra which can be detrimental to biological 
specimen (Byrne et al., 2016; Smith et al., 2016). Finally, for ex vivo 
analysis in relation to pathological tissue, expensive substrates such as 
CaF2 are necessary to reduce background signals for reliable spectra. 
The substrates may be too expensive for clinical feasibility. Even with the 
current limitations, the foundation exists for a spectral based diagnostic 
platform for disease (Byrne et al., 2016).
In this context, the application of vibrational spectroscopy to characterise 
stem cells from their myogenic and osteogenic progeny was assessed 
and the spectral data obtained can be used as a biomarker for the 
accumulation of myogenic progeny in the neointima in future studies. 
There are already reports in the literature using vibrational spectroscopy 
to characterise stem cells and their progeny such as hESCs and 
cardiomyocytes and neural stem cells from glial cells (Smith et al., 2016) 
and therefore the technique was adapted for stem cells, myogenic 
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progeny and also 'de-differentiated' SMCs to characterise differences 
between the cells at a molecular level.
To test whether vibrational spectroscopic methods could discriminate 
undifferentiated stem cells from their differentiated progeny, rMSCs were 
initially differentiated to osteocytes and analysed by FTIR and Raman. 
These techniques have previously been shown to discriminate 
undifferentiated stem cells from their osteogenic progeny and provided a 
standard to be compared against (McManus et al., 2012). Principle 
component analysis with linear discriminant analysis (PCA-LDA) of FTIR 
and Raman spectra generated for rMSCs and their osteogenic progeny 
facilitated successful discrimination of both cell populations.
With both platforms validated, rMSCs were treated with TGF-β1 and 
Jag-1 to induce myogenic differentiation. This was validated 
biochemically, including epigenetic data confirming rMSCs acquire the 
SMC histone H3K4me2 di-methylation mark at the Myh11 promoter. 
Subcultured rSMCs (ddSMCs) exhibiting a ‘de-differentiated’ phenotype 
were compared with undifferentiated rMSCs and their myogenic progeny. 
PCA-LDA of FTIR spectra from individual cell populations demonstrated 
significant overlap between the undifferentiated rMSC and the ddSMC 
spectra, indicating there were stem cell-like cells within the de-
differentiated  population. De-differentiated SMCs and stem cell derived 
SMCs were fully discriminated 100% of the time using FTIR. This 
suggests that FTIR could be used as a useful tool to identify the SMC-like 
cell in the neointimal lesion as it can specifically identify and discriminate 
de-differentiated ddSMCs and stem cell derived SMCs.
The more sensitive Raman analysis successfully discriminated individual 
nuclei of undifferentiated rMSCs from ddSMCs 100% of the time. There 
was significant overlap however, in the spectra and PCA plot between the 
ddSMCs and stem cell-derived progeny indicating that ddSMCs and stem 
cell-derived myogenic progeny are notably similar at the nuclear level. 
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This result was very interesting, but not altogether surprising. In particular 
the epigenetic data from stem cell-derived SMCs have a remarkably 
similar profile to SMCs in culture, typically referred to as 'de-differentiated' 
SMCs, in both mice and rats [Figure 6.1 (a), (b)]. The presence of either 
stem cell derived SMCs or 'de-differentiated' SMCs are accepted as being 
the contributing cell to neointimal lesions, and the autofluorescence 
profile in this study demonstrated the likeness of stem cell myogenic 
progeny with the neointimal SMC-like cells [Figure 6.1 (c). Finally, high 
resolution spectral recordings of the nucleus of stem cell derived progeny 
and de-differentiated SMCs generated overlapping spectra that when 
subjected to Principle Component Analysis could not be uniquely 
discriminated from one another with 100% accuracy [Figure 6.1 (d)].
It has previously been demonstrated that the sudden high proliferative 
capacity of ‘de-differentiated’ ddSMC in culture is due in part to the 
expansion of the naturally highly proliferative small subpopulation of stem 
cells in the culture that eventually take over the population yielding stem 
cell derived progeny (Tang et al., 2012; 2013, Yuan et al., 2017). This 
phenomenon was also observed in this study when freshly isolated 
differentiated SMCs became a rapidly proliferating population over four 
passages with decreased Myh11 gene expression. It is known that 
Sox10+ resident medial multipotent vascular stem cells (MVSCs) are 
present in SMC cultures and more than likely dominated the culture 
(Kennedy et al., 2014a, Kennedy et al., 2014b). It is therefore possible 
that the stem cell-derived progeny and the so called ‘de-differentiated’ 
SMCs are actually the same type of cells (myogenic progeny) but from 
different stem cell origins i.e. bone marrow derived mesenchymal stem 
cells versus resident multipotent vascular stem cells
In summary of this data, stem cell-derived progeny are likely to contribute 
to the SMC-like cells in the neointima. Moreover, at an epigenetic and 
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molecular level, stem cell-derived SMCs and 'de-differentiated' SMCs in 
culture are essentially and photonically the same cell.
Figure 6.1 Summary of photonic and vibrational spectroscopy 
analysis of SMC-like cells. (a) Fold enrichment of SMC dimethylation 
marker H3K4Me2 and stem cell methylation marker H3K27me3 in mice 
cell models (b) rat cell models; (c) Representative autofluorescence 
profiles of mMSCs with TGF-β1 and neointimal SMC-like cells; (d) PCA 
score plot of de-differentiated SMCs and stem cell derived SMCs (TGF-
β1). Data analysis as described in previous chapters. Arrows point to 
similar fold enrichment values.
A primary limitation of the current study is that the stem cell populations 
were of rodent origin, heterogeneous in nature and expanded in culture 
media that is different from protocols required for pre-clinical and clinical 
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studies. Moreover, spectral measurements were taken with cell cultures, 
or ex vivo rather than being obtained from an intact vessel in situ. 
Culturing the progeny of a single CFU or phenotype-isolated single 
clonogenic human stem cell would give rise to a more homogenous “true” 
human MSC population that could serve to provide similar results and 
further validate vibrational spectroscopic for clinical applications. 
Nevertheless, the presence of resident multipotent vascular stem cells 
and their myogenic capacity has been reported  in human cells (Tang et 
al., 2012, 2013).
Vibrational spectroscopy was successfully applied to the study of 
undifferentiated MSCs before and after myogenic differentiation in vitro to 
identify discrete spectral characteristics that could facilitate localisation 
and detection of myogenic differentiation of resident vascular stem cell 
populations in vivo. The vasculature is unique in that it has a well-defined 
spatial geography of cells either side and within the internal (IEL) and 
external elastic lamina (EEL) that could facilitate acquisition of label-free 
analysis of cell spectra with relative confidence. The initial step in the 
development of arteriosclerotic disease is IMT and neointimal formation 
that facilitates the build-up of LDL (low density lipoprotein) particles within 
the intimal layer of the vessel wall (Sun et al, 2000; Subbotin et al., 2016). 
Interrogation of early atherosclerotic vessels in situ using vibrational 
spectroscopy could discriminate the presence of stem cell-derived 
progeny not readily available in current diagnostic imaging techniques 
such as IVUS, MRI, and angiography (Tarkin et al., 2017). Indeed, 
significant progress has already been made towards in vivo application of 
vibrational spectroscopy. Raman spectroscopy in particular, as an optical 
probe, lends itself naturally to endoscopic application and has recently 
been deployed for intra-operative guidance of brain surgery (Jermyn et 
al., 2015) and endoscopic gastrointestinal procedures (Wang et al., 
2015). A smart Raman needle probe has also been developed and tested 
for potential in vivo and ex vivo use, capable of measuring Raman 
molecular tissue signals in <1-2 seconds down a hypodermic needle (Day 
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et al., 2013). Because of its high sensitivity to water, there have been 
relatively fewer in vivo applications of IR spectroscopy, although the 
recent emergence of high brightness, tunable Quantum Cascade Lasers 
has opened the door towards their development (Michel et al., 2013). 
This suggests that, with further development, FTIR could provide initial 
selection of cells for interrogation before quantitative chemical and 
morphological evaluation by Raman discriminates these cells within 
vascular lesions in situ, such as the presence of stem cell derived 
myogenic or osteogenic progeny so that more targeted therapies against 
these discrete phenotypes can be introduced. Finally, circulating vascular 
cells and progenitor cells shed from the vessel wall during IMT and 
disease progression could be retrieved from blood and interrogated using 
vibrational spectroscopy for clinical evaluation to provide a more definitive 
tool for early diagnosis (Perakis et al., 2017). The ability to assess the 
accumulation of stem cell-derived progeny using label free platforms in 
situ or the shedding of these progeny into the blood during disease 
progression may further facilitate interrogation of these phenotypes by 
their discrete spectroscopic signatures using liquid biopsies and 
microfluidic platforms. 
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6.2 GSK3β inhibitors can be incorporated into PLGA-MNPs as a 
novel therapeutic platform for drug eluting stents.
To address the issue of SMC-like cell accumulation during in-stent 
restenosis (ISR), and given the likelihood of a contribution from stem cell-
derived myogenic progeny to the lesion, a novel inhibitor of myogenic 
differentiation was incorporated into PLGA-MNPs and investigated for its 
ability to bind to bare metal stents under magnetic conditions and  control 
myogenic differentiation of undifferentiated stem cells.
Stents coated with a GSK3β inhibitor have previously shown success in 
reducing neointimal lesions in animal models of ISR (Ma et al., 2010). 
However, the GSK3β inhibitor was primarily evaluated for its 're-
endothelialisation' potential rather than its effect on myogenic 
differentiation (Ma et al., 2010). GSK3β has been reported to be involved 
in the progression of vascular diseases in many other studies. Deletion 
and pharmacological inhibition of GSK3β has improved vessel diameter 
and atherogenesis in mice (Woulfe et al., 2010; Bowes et al., 2009) and 
pigs (Potz et al., 2016) and elevated levels of GSK3β have been found in 
atherosclerotic plaques and in the neointima following carotid ligation in 
rats (Wang et al., 2013; Guha et al., 2011). GSK3β inhibition has been 
well characterised in terms of maintaining pluripotency of stem cells 
(Wray et al., 2011; Sato et al., 2011; Kirby et al., 2012) and even 
increasing embryonic stem cell resistance to differentiation (Wray et al., 
2011). However, there is very little reported in the literature about the role 
of GSK3β in stem cell differentiation models. Of the available reports in 
the literature, conflicting results have been presented. For example, 
inhibition of GSK3β has been shown to enhance neuronal differentiation 
of neural stem cells (Maurer et al., 2007) and somatic stem cells 
(Dastjerdi et al., 2012), promote epithelial transition of colorectal cancer 
stem cells (Costabile et al., 2017), induce endothelial differentiation from 
iPSCs and mESCs (Kitajima et al., 2016) and promote cancer stem cell 
tumour differentiation (Korur et al., 2009). However it has also been 
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shown to attenuate cardiomyocyte differentiation of MSCs (Cho et al., 
2009) adipocyte differentiation from adipose stem cells (Zaragosi et al., 
2008) and reduced GSK3β levels have been associated with inhibition of 
embryonic stem cell differentiation to neurons and skeletal muscle (Bain 
et al., 2016). 
The majority of the studies implicating the inactivation of GSKβ in stem 
cell differentiation are associated with enhanced Wnt/β-Catenin signalling 
(Maurer et al., 2007; Dastjerdi et al., 2012) which is an essential process 
in embryogenesis (Komiya et al., 2008) however it is usually switched off 
in adult systems (Ring et al., 2014). GSKβ has been demonstrated to be 
the indirect mediator between Wnt/β-catenin signalling and another highly 
conserved signalling pathway, hedgehog (Ring et al., 2014). Supportive 
reports in our lab have shown GSKβ inhibition attenuated hedgehog 
signalling (ptch1 levels) in vascular SMCs (Guha et al., 2011). GSK 
inhibition also attenuated hedgehog signalling in MSCs and C3H T10 1/2 
stem cells (Supplemental Figure 1). GSKβ has also been associated with 
Wnt and Notch signalling (Espinosa et al., 2003; Ring et al., 2014). Notch 
signalling is commonly associated with vascular disease models (Liedner 
et al., 2001; Li et al., 2009; Morrow et al., 2009; Redmond et al., 2014; 
Caolo et al., 2011) and myogenic differentiation of various stem cells such 
as MSCs (Doi et al., 2006; Mooney at al., 2015), hESCs (Kurpinski et al., 
2010), neural crest stem cells (High et al., 2007) and multipotent vascular 
stem cells (Tang et al., 2010). GSKβ has been shown to regulate Notch 
through phosphorylation of the Notch intracellular domain and inhibition of 
GSKβ results in an attenuation of Notch target gene transcription (Foltz et 
al., 2002; Guha et al., 2011). In this study, Notch activation was chosen 
as the driver of myogenic differentiation to evaluate the effect of GSKβ on 
Notch mediated myogenic differentiation.
Three pharmacological inhibitors of GSK3β were evaluated for their 
inhibitory effect on myogenic differentiation. Cultured undifferentiated 
rMVSCs were treated with the Notch ligand, Jag-1 to induce myogenic 
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differentiation. Jag-1 induced myogenic differentiation of undifferentiated 
resident stem cells (MVSCs) was confirmed before rMVSCs were treated 
with Jag-1 in the absence or presence of each GSK3β inhibitor. The most 
specific inhibitor for GSK3β, 1-Aza (1-Aza), was also the most effective at 
attenuating Jag-1 induced myogenic differentiation. To determine whether 
the effect of 1-Aza on myogenic differentiation was due to regulation of 
Notch signalling, Jag-1 induced Notch target gene expression was 
evaluated in the absence or presence of 1-Aza.  The GSK3β inhibitor 
significantly inhibited Jag-1 induced Notch target gene expression 
concomitant with a reduction in myogenic differentiation. The results 
clearly show that Notch drives myogenic differentiation and GSK3β has a 
role in this pathway that can be manipulated therapeutically to block this 
process. The results in this work supports several studies reporting that 
GSK3β positively regulates Notch signalling (Ruel et al., 1993; Foltz et 
al., 2002; Guha et al., 2011). 
Finally, a current issue with all DES is the problem with depletion of drugs 
over time (Halkin et al., 2004). Researchers are beginning to utilise 
nanoparticles to deliver drugs and agents to stents (Danenberg et al., 
2002; 2003; Cohen-Sela et al., 2006; Chan et al., 2011). The small size of 
nanoparticles make them ideal for systemic drug delivery (Siafaka et al., 
2016). More recently, magnetic nanoparticles have been employed for 
drug delivery in cancer and vascular models as they have the added 
benefit that they can be manipulated using an external magnetic field for 
specific targeting which therefore reduces systemic drug exposure and 
less drug is required for a therapeutic effect (Tietze et al., 2015; et al., 
2010; Vosen et al., 2016; Chorny et al., 2011). 
With this in mind, 1-Aza was encapsulated with PLGA-MNPs using the 
double oil in water emulsion method (McCall et al., 2013). Using an 
adaptation of this method (see Chapter 2.6.1),  1-Aza-PLGA-MNPs were 
formulated and characterised based on their size, stability, drug release 
kinetics and stent targeting. The 1-Aza-PLGA-MNPs were sized at 
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approximately 232±2.97 nm and were relatively round in size and small 
enough to be transported around human arteries (Dodge et al., 1992). 
The zeta potential of -24.1mV for the 1-Aza-PLGA -MNPs was albeit less 
than the -30mV recommended (Clogston & Patri, 2011) which would 
suggest that they have the potential to aggregate. However, in a similar 
study where PTX-PLGA-MNPs were generated and introduced in vivo, 
the zeta potential was 12mV, the researchers did not report any 
aggregation or coagulation of the nanoparticles and they still maintained 
the ability to reduce restenosis in vivo (Chorny et al., 2010). Therefore, 
aggregation of the 1-Aza-PLGA-MNPs would not be expected when 
subjected to in vivo studies. A very high incorporation efficiency, 
approximately 96±2.4%, was found for 1-Aza in the PLGA-MNPs with low 
levels of drug released after 72 hours.  Release studies were carried out 
for up to 14 days with no additional release. The high incorporation 
efficiency and low release of 1-Aza from the PLGA-MNPs is possibly due 
to covalent bonds forming between the polymer and amine groups of 1-
Aza (Lanao et al., 2013) causing retention of the drug within the PLGA-
MNP. However, even with the low release rates and short duration times 
for 1-Aza, the released 1-Aza remained functional and attenuated Notch 
mediated myogenic differentiation. 
To track targeting of this formulation of nanoparticles to the bare-metal 
stent in vitro,  FITC labelled PLGA-MNPs were generated and the 
presence of an external magnetic field was critical for targeting the 
nanoparticles to the bare metal stent. This supports a similar in vivo study 
where PTX-PLGA-MNPs were found to bind the stent in rat carotid 
arteries with four- to ten- fold more specificity in the presence of an 
external magnetic field (Chorny et al., 2010). 
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6.3 Future Work
Using three novel diagnostic photonic platforms to interrogate normal 
(healthy) and arteriosclerotic (diseased) cells, in addition to 
undifferentiated stem cells and their myogenic and osteogenic progeny in 
vitro, the major findings from this study contribute significantly to the 
ongoing debate about the source of the SMC-like cells that populate 
neointimal lesions and moreover,  present a clinically translatable strategy 
to specifically target the source of these cells in vivo using novel magnetic 
nanoparticles to deliver targeted therapies against these cells.
The main limitation of this work is the lack of in vivo studies. The 
microfluidic photonic platform contained some ex vivo work when 
comparing the healthy differentiated SMCs from the carotid artery and 
aorta with the arteriosclerotic cells from ligated carotid vessel. In addition, 
the stem cells before and after myogenic differentiation were from cell 
culture models in vitro. The vibrational spectroscopy approach to 
characterising and identifying stem cells, myogenic progeny and de-
differentiated SMCs, while powerful was limited to cell culture models and 
may display different spectral characteristics for human cells in vivo. 
Moreover, microfluidic platforms using liquid biopsy samples from healthy 
and diseased vessels could form the basis for AF, FTIR and Raman 
interrogation and profiling of cells, these studies. This would be a more 
feasible diagnostic platform using this photonic approach as patient 
vessels cannot be isolated and digested as outlined in this study. This 
approach has already been described for blood samples in liver assays 
(Nwankire et al., 2015) and adapted with Raman spectroscopy in urine 
samples for bacterial detection for urinary tract infections (Shroder et al., 
2015). 
The AF platform described in this study used non-specified broadband 
light which yielded a low resolution. To gain more information about the 
samples in future and to achieve higher resolution, ‘narrow band imaging’ 
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could be employed whereby narrow band filters, particularly for the 565 ± 
20 nm wavelength, can focus the illumination for more precise analysis of 
the autofluorescence of these cells (Filip et al., 2011). Alternatively, the 
increasingly popular multi-photon microscopy could be used for a more 
focused excitation bandwidth through the simultaneous absorption of two 
photons emitted by a laser source. Multi-photon microscopy has many 
benefits over broadband AF microscopy such as the ability to optically 
section a sample with little photodamage or out of focus bleaching (Tauer, 
2002) so therefore would be the next logical step in the development of 
this particular technology. Furthermore, in addition to the concentration of 
fluorophores and fluorescent intensity, fluorescence lifetime analysis has 
been utilised in the literature to describe the molecular environment of the 
cell and in particular differentiate the contributing fluorophores. As 
previously mentioned, the metabolic state of cells can be assessed by 
analysing the fluorescent lifetime of the fluorophore NADH as it loses its 
fluorescence when it becomes oxidised, whereas FAD exhibits AF when it 
is oxidised and loses it when it is reduced. The ratio between the two 
fluorophore AF levels indicates protein binding, phosphorylation and 
glycolysis within a cell. In a similar manner, fluorescent lifetime imaging 
microscopy (FLIM) could be applied to this study to gain more information 
about the contributing fluorophores to the AF levels detected (Becker, 
2015).
FTIR and Raman spectroscopy have been widely reported for ex-vivo 
characterisation of tumours and tissues (Verdaki et al., 2016; Ooi et al., 
2008; Backhaus et al., 2010). In some cases, vibrational spectroscopy 
was found to be a more reliable approach to cancer diagnosis than typical 
histology (Njoroge et al.,  2006; El-Tawil et al., 2008). Therefore, the next 
step in this study would be to isolate normal and diseased cells using 
microfluidic platforms and obtain specific spectra from these tissue 
samples before the platform is miniaturised to interrogate cells in situ to 
become a minimally invasive diagnostic platform for CVD. Alternatively, 
as an in vivo approach, miniaturised Raman or FTIR fibre optic probes 
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could be developed on a catheter based system for guidance to the site 
of a suspected vascular occlusion (Motz et al., 2006; Savastano et al., 
2017). Vibrational spectra can be recorded using this technology to yield 
the discrete information within the vascular vessels and in conjunction 
with this, colour maps can be generated based on the chemical and 
structural information within the vessel by Raman or FTIR mapping. 
Using this technology, the structural information and molecular 
composition of an obstruction could be simultaneously identified with high 
speed and specificity (Coman & Leopold, 2017).
The analysis of GSK3β control of Notch mediated myogenic 
differentiation and subsequent targeting of GSK3β inhibitor loaded 
nanoparticles to the cells was also an in vitro study.  There are concerns 
for the toxicity of magnetic nanoparticles for cells and tissues in vivo, 
such as the build up of MNPs and by products in organs, aggregation of 
particles to cause a stenosis or interference with cell-cell interactions 
(Markides et al., 2012). These concerns were addressed in this in vitro 
study however and the less toxic iron oxide was chosen as the 
nanoparticle and the aggregation potential (zeta potential) of the 
nanoparticle formulation was assessed and compared to a previous in 
vivo model and was found to be favourable to the previous published 
work (Chorny et al., 2010). Therefore, the 1-Aza-PLGA-MNPs are ready 
to progress to in vivo studies.
A recently reported platform that may prove useful before applying this 
therapy in vivo would be the use of a mock vascular phantom (Colombo 
et al., 2013). This mock vascular phantom fabricated using Sylgard™ 
supports both stent deployment and cell growth within the stented region 
when connected to a cell culture chamber where in vivo hemodynamic 
conditions of pulsatile flow and circumferential strain are fully 
incorporated (Colombo et al., 2013). This technology could be adapted by 
seeding rMVSCs to the mock vascular phantom containing a stent coated 
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with Jag-1 followed by the addition of 1-Aza-PLGA-MNPs and guidance 
of the nanoparticles to the cells on the stent (as described in Figure 6.2)
Figure 6.2 Mock vascular phantom system. Figure 6.2 depicts a 
suggested future experiment where a stent is inserted into a mock 
vascular phantom that is hooked up to a cell culture chamber. rMVSCs 
can be added to the system followed by the 1-Aza-PLGA-MNPs and 
guided the stent using an external magnetic field. 
Should this experiment be successful, the technology should be 
considered for in vivo studies, perhaps starting in rat carotid models 
following the success of neointimal reduction following PTX-PLGA-MNP 
targeting (Chorny et al., 2010).
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6.4 Final Conclusion
The overall aims and objectives of this thesis were to apply a photonic 
platform to discriminate individual cells from healthy and diseased 
(arteriosclerotic) vessels ex vivo and to compare their profiles to de-
differentiated SMCs, undifferentiated stem cells and their myogenic and 
osteogenic progeny in vitro. Specific vibrational spectroscopy techniques 
were further used to compare ddSMCs and undifferentiated stem cells 
from their myogenic and osteogenic progeny at a molecular level. Finally, 
a novel therapeutic platform was developed using functionalised MNP’s 
to specifically target stem cell-derived progeny in a localised, 
replenishable manner to a bare-metal stents in vitro. 
Significant data has been presented that demonstrates the feasibility of 
photonic methods such as the microfluidic-AF platform and vibrational 
spectroscopy to identify and discriminate differentiated cells from 
undifferentiated stem cells and their myogenic and osteogenic progeny. 
The findings also support the putative role of stem cell-derived SMCs and 
their contribution to the neointimal formation(Tang et al., 2012; Kramann 
et al., 2015) and that so termed 'de-differentiated SMCs' are possibly 
stem cell-derived progeny in culture (Tang et al., 2012; Yuan et al., 2017). 
This study also agrees with reports that GSK3β positively regulates Notch 
mediated myogenic differentiation (Foltz et al., 2002; Guha et al., 2011) 
and that this process can be manipulated pharmacologically. Finally, a 
method to incorporate the inhibitor into a novel delivery system has been 
evaluated and described to hopefully aid researchers working with similar 
technology in this field and others.
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Appendix A
List of Materials
Cell culture
Material Product Code Company
1-Azakenpaullone A3734 Sigma-Aldrich, Arklow, 
Ireland
2-Mercaptoethanol M7522 Sigma-Aldrich, Arklow, 
Ireland
B27 supplement 17504-044 Gibco/Bio-sciences, Dun 
Laoghaire
Bio B1686 Sigma-Aldrich, Arklow, 
Ireland
C3H T10 1/2 Cells ATCC-CCL-226 ATCC, Middlesex, UK
Chick Embryo Extract Seralab CE-650-J Seralab, West Sussex, UK
Col1A1 SiRNA sc-44044 Santa-Cruz Biotechnology, 
Heidelberg, Germany
Col3A1 siRNA sc-43063 Santa-Cruz Biotechnology, 
Heidelberg, Germany
Collagenase Type 1A C9891 Sigma-Aldrich, Arklow, 
Ireland
DMEM D5796 Sigma-Aldrich, Arklow, 
Ireland
DMEM ATCC-30-2002 ATCC, Middlesex, UK
Elastase Type III E0127 Sigma-Aldrich, Arklow, 
Ireland
Elastin siRNA sc-43361 Santa-Cruz Biotechnology, 
Heidelberg, Germany
EMEM ATCC-30-2003 ATCC, Middlesex, UK
FBS F9665 Sigma-Aldrich, Arklow, 
Ireland
FBS ATCC-SCRR-30-2020 ATCC, Middlesex, UK
Hanks Balanced Salt 
Solution
H6649 Sigma-Aldrich, Arklow, 
Ireland
IgG-Fc 110-HG-100 R&D, Abingdon, UK
Jagged-1-Fc 599-JG-100 R&D, Abingdon, UK
Luciferase Assay System E1500 Promega, Madison, WI
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Photonics
Cell Characterisation
Antibodies and Reagents (ICC and Western Blot)
Mesencult Proliferation Kit 
with Mesenpure
5512 StemCell Technologies, 
Cambridge, UK
Mirus TransIT-X2 MIR 6003 MSC, Mulhuddart, Ireland
Mouse Mesenchymal Stem 
Cells
S1502-01 Gibco/Bio-sciences, Dun 
Laoghaire
Myh11 Reporter Plasmid MPRM16957-PG02 GeneCopoeia, Maryland, 
USA
N2 Supplement A13707-01 Gibco/Bio-sciences, Dun 
Laoghaire
Opti-MEM 1 Reduced 
Serum Media
11058021 Biosciences, Dun 
Laoghaire, Ireland
Penicillin/streptomycin P4333 Sigma-Aldrich, Arklow, 
Ireland
Protein G 21193 MSC, Mulhuddart, Ireland
Rat Mesenchymal Stem 
Cells
S1601-01 Gibco/Bio-sciences, Dun 
Laoghaire
Renilla Reporter Plasmid E2231 Promega, Madison, WI
Retanoic Acid R2625 Sigma-Aldrich, Arklow, 
Ireland
rmFGF 3139-FB-025 R&D/Biotechne
SB-216763 S3442 Sigma-Aldrich, Arklow, 
Ireland
Soybean Trypsin Inhibitor 
in MEM
10109886001 Roche, Dublin, Ireland
StemPro Osteogenesis 
Medium
A1007201 Thermo-fisher, Paisley, UKTGF-­‐β1 7666-MB-05 R&D, Abingdon, UK
Product Code CompanyMaterial
Material Product Code Company
PDMS Sylgard 184 Dow Corning, GmbH, 
Germany
TrypleE Select 12563029 Thermo-fisher, Paisley, UK
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Material Product Code Company
anti-beta actin 2228 Sigma-Aldrich, Arklow, 
Ireland
anti-calponin 1 ab46794 Abcam, Cambridge, UK
anti-CD44 ab24504 Abcam, Cambridge, UK
anti-nestin ab11306 Abcam, Cambridge, UK
anti-SM-MHC (Myh11) sc-79079 Santa-Cruz Biotechnology, 
Heidelberg, Germany
anti-sox10 MAB2864 R&D, Abingdon, UK
APS A3678 Sigma-Aldrich, Arklow, 
Ireland
BCA Assay 23225 Thermo Fisher, Paisley, UK
Bis Acrylamide A3699 Sigma-Aldrich, Arklow, 
Ireland
BSA A4503-50g Sigma-Aldrich, Arklow, 
Ireland
Collagen Probe Gift TCD
DAPI D9542-5 mg Sigma-Aldrich, Arklow, 
Ireland
donkey anti-goat 
alexafluor488
A-11055 Bio-sciences, Dun 
Laoghaire, Ireland
Dynamag PCR Magnet 492025 Bio-sciences, Dun 
Laoghaire, Ireland
goat anti-mouse 
alexafluor488
A11030 Bio-sciences, Dun 
Laoghaire, Ireland
goat anti-rabbit 
alexafluor488
A11008 Bio-sciences, Dun 
Laoghaire, Ireland
GSK-3β XP® 5676S Cell Signalling, Leiden, 
Netherlands
H3K27me3 mAb 9733S Cell Signalling, Leiden, 
Netherlands
H3K4me2 mAb 9725S Cell Signalling, Leiden, 
Netherlands
Laemlli Buffer 161-0747 Fannin & Co, Dublin, 
Ireland
MAGnify™ Chromatin 
Immunoprecipitation 
System
492024 Bio-sciences, Dun 
Laoghaire, Irelandphospho-­‐GSK3β-­‐(ser9) 9336S Cell Signalling, Leiden, 
Netherlands
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Real Time q PCR Reagents
Phosstop 4906845001 Roche, Dublin, Ireland
Ponceau S Solution P7170 Sigma-Aldrich, Arklow, 
Ireland
Protease Inhibitor Cocktail P8340 Sigma-Aldrich, Arklow, 
Ireland
Protein G Dynabeads Bio-sciences, Dun 
Laoghaire, Ireland
RIPA Buffer R0278 Sigma-Aldrich, Arklow, 
Ireland
SDS L3771 Sigma-Aldrich, Arklow, 
Ireland
TEMED T9281 Sigma-Aldrich, Arklow, 
Ireland
TMB T0565 Sigma-Aldrich, Arklow, 
Ireland
Triton X-100 X-100 Sigma-Aldrich, Arklow, 
Ireland
Trizma Base T1503 Sigma-Aldrich, Arklow, 
Ireland
Product Code CompanyMaterial
Material Product Code Company
PrimeTime Calponin1 
forward
IDT Technologies, Leuven, 
Belgium
PrimeTime Calponin1 
reverse
IDT Technologies, Leuven, 
Belgium
PrimeTime Hey1 IDT Technologies, Leuven, 
Belgium
PrimeTime HeyL IDT Technologies, Leuven, 
Belgium
PrimeTime mHPRT 
Forward 
IDT Technologies, Leuven, 
Belgium
PrimeTime mHPRT 
Reverse
IDT Technologies, Leuven, 
Belgium
PrimeTime Myh11 forward IDT Technologies, Leuven, 
Belgium
PrimeTime Myh11 reverse IDT Technologies, Leuven, 
Belgium
Quantitect Col1A1_1 
Primer Assay
QT01055572 Qiagen, Hilden, Germany
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Nanoparticle Formulation & Analysis
Quantitect Col1A1_2 
Primer Assay
QT02325736 Qiagen, Hilden, Germany
Quantitect Col3A1_1 
Primer Assay
QT01055516 Qiagen, Hilden, Germany
Quantitect Col3A1_2 
Primer Assay
QT02331301 Qiagen, Hilden, Germany
Quantitect Elastin Primer 
Assay
QT01070482 Qiagen, Hilden, Germany
Quantitect mHPRT Primer 
Assay
QT00166768 Qiagen, Hilden, Germany
Reliaprep RNA Miniprep 
spin columns
Z6012
Rotor-Gene SYBR® Green 
RT-PCR Kit 
204174 Qiagen, Hilden, Germany
Sensifast SYBR no-rox Bio-72005 MSC, Mulhuddart, Ireland
Product Code CompanyMaterial
Material Product Code Company
poly(lactic-co-glycolic acid) 
(PLGA)
P2066 Sigma-Aldrich, Arklow, 
Ireland
dichloromethane 650463 Sigma-Aldrich, Arklow, 
Ireland
Iron(II)(III) Oxide in solution 700312 Sigma-Aldrich, Arklow, 
Ireland
Poly(vinyl)alcohol (PVA) 363138 Sigma-Aldrich, Arklow, 
Ireland
Supelco Discovery C18 
Column
568523-U Sigma-Aldrich, Arklow, 
Ireland
Acetonitrile 34851 Sigma-Aldrich, Arklow, 
Ireland
Dextran Magnet 2501008 Dexter Magnetic 
Technologies, IL, USA
 249
Appendix B
Supplementary Figure 1
Supplemental Figure 1: Effect of GSK3β inhibitor on hedgehog 
signalling in stem cells. (a) Representative Gli1 and Gli2 mRNA 
expression in response to rShh (0.5 μg/ml), rShh + Cycoplamine (15μM) 
(c), Bio (5μM) alone and rShh+Bio for 24hrs in C3H T10 1/2 cells. (b) 
Representative Gli1 and Gli2 mRNA expression in response to rShh (0.5 
μg/ml), rShh + Cycoplamine (15μM) (c), Bio (5μM) alone and rShh+Bio 
for 24hrs in mMSCs. (c) Gli1 mRNA expression in mC3H T10 1/2 and 
mMSCs in response to rShh + scrambled siRNA and rShh + GSK3β 
siRNA.
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